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A B S T R A C T
Background
Mass drug administration (MDA), defined as the empiric administration of a therapeutic antimalarial regimen to an entire population at
the same time, has been a historic component of many malaria control and elimination programmes, but is not currently recommended.
With renewed interest in MDA and its role in malaria elimination, this review aims to summarize the findings from existing research
studies and program experiences of MDA strategies for reducing malaria burden and transmission.
Objectives
To assess the impact of antimalarial MDA on population asexual parasitaemia prevalence, parasitaemia incidence, gametocytaemia
prevalence, anaemia prevalence, mortality and MDA-associated adverse events.
Search methods
We searched the Cochrane Infectious Disease Group Specialized Register, the Cochrane Central Register of Controlled Trials (CEN-
TRAL), MEDLINE+, EMBASE, to February 2013. We also searched CABS Abstracts, LILACS, reference lists, and recent conference
proceedings.
Selection criteria
Cluster-randomized trials and non-randomized controlled studies comparing therapeutic MDA versus placebo or no MDA, and
uncontrolled before-and-after studies comparingpost-MDA to baseline datawere selected. Studies administering intermittent preventive
treatment (IPT) to sub-populations (for example, pregnant women, children or infants) were excluded.
Data collection and analysis
Two authors independently reviewed studies for inclusion, extracted data and assessed risk of bias. Studies were stratified by study
design and then subgrouped by endemicity, by co-administration of 8-aminoquinoline plus schizonticide drugs and by plasmodium
species. The quality of evidence was assessed using the GRADE approach.
1Mass drug administration for malaria (Review)
Copyright © 2013 The Authors. The Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Main results
Two cluster-randomized trials, eight non-randomized controlled studies and 22 uncontrolled before-and-after studies are included
in this review. Twenty-two studies (29 comparisons) compared MDA to placebo or no intervention of which two comparisons were
conducted in areas of low endemicity (≤5%), 12 in areas of moderate endemicity (6-39%) and 15 in areas of high endemicity (≥
40%). Ten studies evaluated MDA plus other vector control measures. The studies used a wide variety of MDA regimens incorporating
different drugs, dosages, timings and numbers of MDA rounds. Many of the studies are now more than 30 years old.
Areas of low endemicity (≤5%)
Within the first month post-MDA, a single uncontrolled before-and-after study conducted in 1955 on a small Taiwanese island
reported a much lower prevalence of parasitaemia following a single course of chloroquine compared to baseline (1 study, very low
quality evidence). This lower parasite prevalence was still present after more than 12 months (one study, very low quality evidence). In
addition, one cluster-randomized trial evaluating MDA in a low endemic setting reported zero episodes of parasitaemia at baseline,
and throughout five months of follow-up in both the control and intervention arms (one study, very low quality evidence).
Areas of moderate endemicity (6-39%)
Within the first month post-MDA, the prevalence of parasitaemia was much lower in three non-randomized controlled studies from
Kenya and India in the 1950s (RR 0.03, 95% CI 0.01 to 0.08, three studies, moderate quality evidence), and in three uncontrolled
before-and-after studies conducted between 1954 and 1961 (RR 0.29, 95% CI 0.17 to 0.48, three studies,low quality evidence).
The longest follow-up in these settings was four to six months. At this time point, the prevalence of parasitaemia remained substantially
lower than controls in the two non-randomized controlled studies (RR 0.18, 95% CI 0.10 to 0.33, two studies, low quality evidence).
In contrast, the two uncontrolled before-and-after studies found mixed results: one found no difference and one found a substantially
higher prevalence compared to baseline (not pooled, two studies, very low quality evidence).
Areas of high endemicity (≥40%)
Within the first month post-MDA, the single cluster-randomized trial from the Gambia in 1999 found no significant difference in
parasite prevalence (one study, low quality evidence). However, prevalence was much lower during the MDA programmes in three non-
randomized controlled studies conducted in the 1960s and 1970s (RR 0.17, 95% CI 0.11 to 0.27, three studies, moderate quality
evidence), and within one month ofMDA in four uncontrolled before-and-after studies (RR 0.37, 95%CI 0.28 to 0.49, four studies,low
quality evidence).
Four trials reported changes in prevalence beyond three months. In the Gambia, the single cluster-randomized trial found no difference
at five months (one trial, moderate quality evidence). The three uncontrolled before-and-after studies had mixed findings with large
studies from Palestine and Cambodia showing sustained reductions at four months and 12 months, respectively, and a small study from
Malaysia showing no difference after four to six months of follow-up (three studies,low quality evidence).
8-aminoquinolines
We found no studies directly comparing MDA regimens that included 8-aminoquinolines with regimens that did not. In a crude
subgroup analysis with a limited number of studies, we were unable to detect any evidence of additional benefit of primaquine in
moderate- and high-transmission settings.
Plasmodium species
In studies that reported species-specific outcomes, the same interventions resulted in a larger impact onPlasmodium falciparum compared
to P. vivax.
Authors’ conclusions
MDA appears to reduce substantially the initial risk of malaria parasitaemia. However, few studies showed sustained impact beyond six
months post-MDA, and those that did were conducted on small islands or in highland settings.
To assess whether there is an impact of MDA on malaria transmission in the longer term requires more quasi experimental studies
with the intention of elimination, especially in low- and moderate-transmission settings. These studies need to address any long-term
outcomes, any potential barriers for community uptake, and contribution to the development of drug resistance.
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P L A I N L A N G U A G E S U M M A R Y
Administration of antimalarial drugs to whole populations
Malaria is the most important mosquito-borne disease caused by a parasite, accounting for an estimated 660,000 deaths annually.
Fortunately, malaria is both preventable and treatable. Several malaria control tools currently exist, and new and innovative approaches
are continually under development.
The administration of drugs against malaria to whole populations, termedmass drug administration (MDA), was a component of many
malaria elimination programmes in the 1950s, and is once again attracting interest as a malaria elimination tool. As a consequence, it
is important to review the currently available literature in order to assess the potential for this strategy to reduce malaria burden and
transmission, and to identify gaps in our understanding.
This review assessed the impact of MDA on several malaria-specific outcome measures. Thirty-two studies were included in this review,
from sites in Asia, Africa, Europe and the Americas.
The review found that although MDA can reduce the initial risk of malaria-specific outcomes, these reductions are often not sustained.
However, a few studies conducted on small islands or in highland areas did show sustained impact more than six months after MDA.
Adverse events were inadequately addressed in most studies. Notable severe drug reactions, including haemolysis, haemoglobinuria,
severe anaemia and death, were reported with 8-aminoquinoline plus schizonticide drug co-administration, while severe skin reactions
were reported with sulphadoxine-pyrimethamine plus artesunate plus primaquine.
Assessing the true impact ofMDAprogrammes can be a challenge due to the heterogeneity of the studymethods employed.Nonetheless,
this review can help guide future antimalarial MDA interventions and their evaluation.
B A C K G R O U N D
Description of the condition
Malaria causes an estimated 219 million clinical episodes and
660,000 deaths annually, primarily among young children in sub-
Saharan Africa (WHO 2012). Four main species of the malaria
parasite infect humans: Plasmodium falciparum, P. vivax, P. ovale,
and P. malariae. P. falciparum and P. vivax cause the majority of
infections, with P. falciparum responsible for most cases of severe
and potentially fatal malaria.
Malaria is both preventable and treatable. Prevention efforts have
focused on vector control strategies to reduce adult mosquito pop-
ulations and human-mosquito contact, and to eradicate mosquito
breeding grounds. These strategies include the use of insecticide
treated nets (ITNs), indoor residual spraying (IRS), larviciding,
and environmental management. In addition, treatment strategies
in endemic areas frequently combine case management, and the
diagnosis and treatment of clinically ill malaria patients, with dis-
ease prevention. This involves administering antimalarial drugs
to particularly vulnerable population groups, such as pregnant
women, infants and non-immune travellers to endemic areas, to
prevent clinical disease.
Success in malaria control using these existing tools has led to re-
newed interest in the possibility of malaria elimination in some
countries or regions. Although the Global Malaria Eradication
Program of the mid-20th century was ultimately abandoned, cur-
rent calls for elimination stress the need for new technologies (in-
secticide delivery systems, new drugs and insecticides, and candi-
date vaccines) and the revitalization of older strategies (IRS and
larviciding). Mass drug administration (MDA) was a component
of many malaria elimination programmes during the eradication
era, but it is not currently recommended due to concerns about
efficacy, logistical feasibility, sustainability and the risk of acceler-
ating drug resistance (WHO 2010). However, these concerns are
not supported by firm evidence, particularly in light of the devel-
opment of new antimalarial drugs (WHO 2007).
Description of the intervention
For nearly a century, antimalarial drugs have been used in a variety
of ways to prevent infection. While the aim of early antimalar-
ial drug distribution studies was to interrupt transmission, this
was rarely accomplished. The empiric use of antimalarial drugs to
prevent malaria can be generally grouped into three, sometimes
overlapping categories: 1) chemoprophylaxis, where drugs are ad-
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ministered at suppressive doses throughout the defined period; 2)
intermittent preventive treatment (IPT), where a full curative dose
of an antimalarial is given to a target population at specified times;
or 3)MDA, where drugs are administered to the whole population
either using full therapeutic courses, known as direct MDA, or
through the fortification of dietary salt, known as indirect MDA
(Greenwood 2004; von Seidlein 2003).
Chemoprophylaxis has been found to be highly effective at reduc-
ingmortality andmorbidity frommalaria in highly endemic areas,
but this approach is often difficult to sustain and at times has im-
paired the development of natural immunity (Greenwood 2004).
These difficulties and perceived risks of implementing chemopro-
phylaxis drove many programmes that began in the 1990s towards
targeted drug administration via IPT to populations at high risk of
infection (such as pregnant women). There is considerable overlap
amongst the three strategies for preventing malaria, and the term
MDA has been used to describe varying approaches, from using
full therapeutic doses to fortifying foods, and with varying objec-
tives, from decreasing malaria morbidity to interrupting transmis-
sion.
Over the past 20 years, MDA has been a key strategy for con-
trolling or eliminating highly-prevalent neglected tropical diseases
(NTDs) such as lymphatic filariasis, soil transmitted helminthes,
onchocerciasis, schistosomiasis, and trachoma. The simultaneous
administration of essential medicines to target high-prevalence
NTDs has two main functions: to treat prevalent infection and
subsequently to reduce further transmission within the popula-
tion (Hotez 2009).Mass antimalarial drug administration, defined
as the empiric administration of a therapeutic course of an anti-
malarial regimen to an entire population at the same time without
screening or diagnostic testing prior to administration, has been
used for malaria control since the early 1930s and was advocated
by theWorld Health Organization (WHO) in the 1950s as a tool
in situations where other more conventional control measures had
failed (von Seidlein 2003 GMB).
Most early programmes did not clearly define whether their main
aim was to interrupt transmission or to control disease.While pro-
grammes that attempted to interrupt transmission nearly always
failed, there are several exampleswhereMDA, in combinationwith
other malaria control measures, had some success. For instance,
MDAwith sulfalene-pyrimethamine combined with IRS achieved
high levels of initial malaria control during a research project in
Garki, NorthernNigeria, in 1969 (Molineaux 1980 NGA). In ad-
dition, the use of MDA with other malaria control interventions
succeeded in interrupting malaria transmission for both P. falci-
parum and P. vivax on the island of Aneityum in Vanuatu (Kaneko
2000 VUT). Primaquine, the only registered drug that can elimi-
nate gametocytes, was given in combination with chloroquine to
an estimated 70% of Nicaragua’s population in 1981, preventing
an estimated 9200 cases of malaria (Garfield 1983 NIC). In these
instances, the entire population was simultaneously treated with a
therapeutic dose of an antimalarial in a single or multiple rounds
both to reduce malaria burden and potentially to interrupt trans-
mission.
How the intervention might work
Malaria transmission is dependent on mosquito vector dynamics,
the proportion of humans with peripheral gametocytaemia, and
the infectiousness of circulating gametocytes tomosquitoes. MDA
of antimalarials might reduce malaria burden by its direct effect
on individuals who receive a treatment dose of antimalarials; it
may also reduce rates of transmission in several different ways.
First, MDA could reduce parasitaemia prevalence and potentially
reducemalaria transmission by inhibiting the liver or asexual intra-
erythrocytic stages of the parasite, thereby reducing the number
of parasites that can progress to form gametocytes. Second, the
antimalarial drug could have a direct effect on gametocytes. Third,
the antimalarial drug could inhibit the sporogonic cycle in the
mosquito. If every member of a given population is treated by
antimalarial MDA then one would expect an immediate reduction
in asexual parasite prevalence in the population, and possibly a
sustained reduction in the population parasite prevalence if there
was a concomitant reduction in transmission.
Most antimalarial drugs target the asexual blood stages of the par-
asite life cycle, as these stages are responsible for symptomatic dis-
ease. Blood schizonticidal drugs reduce asexual parasitaemia and
possibly early stage gametocytes in P. falciparum by preventing the
development ofmature gametocytes, without having a direct effect
on circulating mature gametocytes. Some antimalarial drugs, such
as the artemisinins and 8-aminoquinolines (eg primaquine), have
known gametocytocidal activities and have the potential to reduce
transmission by reducing circulating gametocytaemia. In addi-
tion, primaquine is the only currently available drug with unique
activity against mature gametocytes and the hypnozoite stage of
P. vivax and P. ovale species, reducing the possibility of relapse
(WHO 2010).
Why it is important to do this review
Since itswider application in the 1950s and1960s, the use ofMDA
as a malaria control tool has fallen out of favour due to concerns
over its efficacy, logistical feasibility, and sustainability, and over
the risk of accelerating drug resistance. But with a renewed interest
in malaria elimination, limitations of currently available diagnos-
tic tools, and the development of new antimalarials that have some
gametocytocidal effect, such as the artemisinins, MDA is once
again being considered as a tool for malaria elimination (Feachem
2009). Given this renewed interest in conducting MDAs, it is
important to review the currently available literature to assess the
potential for this strategy to reduce malaria burden and transmis-
sion. In addition, a systematic review of the literature will allow us
to define the gaps in our understanding of the potential benefits
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and risks of this strategy, such as the risk of adverse drug events in
populations given MDA. This information could then guide both
the design of future antimalarial MDA interventions and their
evaluation.
O B J E C T I V E S
To assess the impact of antimalarial MDA on population asexual
parasitaemia prevalence, parasitaemia incidence, gametocytaemia
prevalence, anaemia prevalence, mortality and MDA-associated
adverse events.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We assessed randomized and non-randomized studies, including
cluster-randomized trials, non-randomized controlled studies and
uncontrolled before-and-after studies, that measured at least one
outcome of interest in the target population.
Types of participants
Children and adults living in malaria endemic areas. Due to the
nature of the intervention, only studies that were carried out on
entire populations at the same time were included. Studies where
participants left the malaria endemic area during the study period
or studies administering IPT to a sub-population, such as pregnant
women, children or infants, were excluded.
Types of interventions
Intervention
For the purposes of this review, MDA was defined as the empiric
administration of a therapeutic course (doses greater than the stan-
dard prophylactic regimens) of an antimalarial regimen to an en-
tire population at the same time without screening or diagnostic
testing prior to administration.
A therapeutic dose was defined as a dose greater than the current
standard prophylactic dose (ie chloroquine or amodiaquine at 300
mg of base weekly; pyrimethamine at 25 mg weekly; proguanil at
100 mg daily; mepacrine at 300 mg weekly in one dose or 700 mg
weekly in daily doses of 100 mg; and quinine at 325 mg twice a
day) (WHO 1951; WHO 1963).
Controls
1. No MDA or placebo for cluster-randomized trials and non-
randomized controlled studies.
2. Baseline up to one year prior to intervention for uncontrolled
before-and-after studies.
Studies that included other malaria co-interventions (eg ITNs,
IRS, source reduction activities and environmental management)
and non-malaria co-interventions (eg MDA campaigns for other
neglected tropical diseases and mass nutritional supplementation
activities such as vitamin A distribution) were included. Studies
using an indirect approach toMDA,where antimalarials are added
to essential foodstuffs, usually dietary salt, were excluded.
Types of outcome measures
Primary outcomes
1. Parasitaemia prevalence
2. Parasitaemia incidence
Secondary outcomes
1. Gametocytaemia prevalence
2. Anaemia prevalence
3. Mortality
4. Adverse events related to MDA using WHO definitions
(Edwards 2000)
Search methods for identification of studies
Electronic searches
Search strategy for identification of studies
We attempted to identify all relevant studies regardless of language
or publication status (published, unpublished, in press, ongoing).
Databases
We searched the following databases: Cochrane Infectious Disease
Group Specialized Register; Cochrane Central Register of Con-
trolled Trials (CENTRAL), published in The Cochrane Library;
MEDLINE+; EMBASE; CABS Abstracts; and LILACS, using the
search strategy detailed in Appendix 1. The final search was con-
ducted on February 6, 2013.
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Searching other resources
Reference lists
We checked the reference lists of all studies and articles identified
by the above methods, as well as references listed in review articles
(Greenwood 2004; von Seidlein 2003; Shanks 2012).
Conference proceedings
We searched the following recent conference proceedings for
relevant abstracts: Fifth MIM Pan-African Malaria Conference
(Nairobi, Kenya, November 2009); the 58th Annual American
Society of Tropical Medicine and Hygiene Conference (Washing-
ton, D.C., November 2009); the 59th Annual American Soci-
ety of Tropical Medicine and Hygiene Conference (Atlanta, G.A.,
November 2010); the 60th Annual American Society of Tropical
Medicine andHygiene Conference (Philadelphia, P.A.,November
2011); and the 61stAnnual AmericanSociety ofTropicalMedicine
and Hygiene Conference (Atlanta, G.A., November 2012).
Researchers and organizations
In addition to the electronic searches described above, we con-
tacted additional experts in the field to identify both published and
unpublished studies that might be available from other sources.
Data collection and analysis
Selection of studies
Two authors independently screened the titles and abstracts of
the search results for potentially relevant studies. We retrieved
the full report of any study identified by at least one author as
potentially eligible. Two authors then reviewed the full reports of
all retrieved studies and independently assessed eligibility using
an eligibility form based on the inclusion and exclusion criteria.
A third author resolved any discrepancies between the first two
authors. We assessed all foreign language papers for eligibility.
Excluded studies and the reasons for their exclusion were reported.
Data extraction and management
Using a pre-tested data extraction form, two authors indepen-
dently extracted information on the study characteristics, includ-
ing the parasite species of interest, study design, setting (country,
transmission season, and endemicity), MDA regimen and cover-
age, duration of follow-up, methods for ensuring comparability
between sites in multi-site studies, and outcomes. We resolved dis-
agreements between the two primary authors by consulting with
a third author.
We extracted dichotomous data (parasitaemia prevalence, game-
tocytaemia prevalence and anaemia) and rate data (parasitaemia
incidence and mortality). In all studies, parasite and gametocyte
prevalence were assessed by microscopy. Anaemia was defined as
per the definition (eg hematocrit < 33%) in the von Seidlein 2003
GMB study.
Cluster-randomized trials
We extracted clustered-adjusted measures of effect and a standard
error when the study was adjusted for clustering. If the study
did not adjust for clustering or report the intra-cluster correlation
coefficient for dichotomous outcomes, the number of personswith
events, the number analyzed and the number randomized in each
groupwas extracted. For count outcomes, we extracted the number
of episodes and the person-time risk in each group. The number
sampled was calculated as the sum of participants in both the
intervention and comparison groups at specified time points.
Non-randomized controlled studies
For non-randomized controlled trials, we extracted the number of
persons with events, the number analyzed and the number ran-
domized in each group for dichotomous data. For count outcomes,
we extracted the number of episodes and the person time at risk
in each group. We included pre-intervention data up to one year
prior to the intervention.While all post-MDA data were included,
they are reported according to our designated time points (eg < 1
month, 1-3 months, etc). The number sampled was calculated as
the sum of participants in both the intervention and comparison
groups at specified time points.
Uncontrolled before-and-after studies
For uncontrolled before-and-after studies, we extracted the num-
ber of persons with events, the number analyzed and the number
in each group for dichotomous data (ie baseline pre-intervention
data compared to duringMDA or post-MDAmeasurements). For
count outcomes, we extracted the number of episodes and the
person time at risk in each group. The number sampled was cal-
culated as the number of participants post-MDA at specified time
points.
Assessment of risk of bias in included studies
Two authors independently assessed the risk of bias for both clus-
ter-randomized trials and non-randomized controlled studies and
uncontrolled before-and-after studies using an assessment form.
We assessed all studies for random sequence generation, alloca-
tion concealment, baseline imbalance, contamination protection,
blinding of participants and personnel, blinding of outcome as-
sessment, incomplete outcome data, selective reporting, and other
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potential threats to validity. Authors assessed each element sepa-
rately and classified as ’low risk of bias’, ’high risk of bias’ or ’un-
clear’; details are presented in a separate risk of bias table for each
study. In addition, we present a risk of bias summary and a risk of
bias graph. We resolved disagreements between the two primary
authors by consulting with a third author.
Measures of treatment effect
We reported the findings in a summary of findings table for all
outcomes of interest. For cluster-randomized trials and non-ran-
domized controlled studies, we estimated risk ratios between in-
tervention and control groups. For uncontrolled before-and-after
studies, we estimated risk ratios against the pre-intervention risk.
We combined reports for specific Plasmodium species into one
composite malaria outcome for the overall analysis, but conducted
a subgroup analysis comparing outcomes for P. falciparum and P.
vivax separately. We adjusted for the contribution of studies with
more than one comparison to the overall estimate. Outcomes were
reported for all age groups whenever available. However, some
studies reported outcomes in children only or in a sample of the
treated population.
Unit of analysis issues
Cluster-randomized trials and non-randomized controlled
studies
None of the studies reported the design effect or intra-cluster cor-
relation coefficient needed to calculate valid associated variances
for the estimates of interest. Thus, we were unable to adjust for
clustering.
In addition, non-randomized controlled studies often have few in-
tervention groups/clusters and face the risk of imbalance between
groups.
For studies with multiple arms that were included in a meta-anal-
ysis more than once, the data was adjusted to account for multiple
comparisons.
All estimates were individually analyzed and thus their associated
confidence intervals (CIs) need to be cautiously interpreted as
unduly narrow.
Uncontrolled before-and-after studies
Similarly, all estimates were individually analyzed and so their
associated CIs need to be cautiously interpreted as unduly narrow.
Pre-intervention risk was determined from the presented baseline
data. Whenmultiple baseline data were presented, the data for the
most recent year prior to MDA was used.
Dealing with missing data
It should be noted that for many of the studies MDA was applied
widely, although data were only collected on a cross-sectional sam-
ple of the entire treated population. Therefore, we have not at-
tempted to apply imputation measures for working with missing
data. If data from studies were insufficient, unclear or missing,
we attempted to contact study investigators to obtain additional
information.
Assessment of heterogeneity
Heterogeneity was assessed by summarizing study and patient
characteristics across studies and by inspecting the forest plots for
overlapping CIs. The I2 statistic with a level of 50%, denoting
moderate levels of heterogeneity, and the Chi2 test with a P value
of 0.10, indicating statistical significance, were also evaluated to
assess heterogeneity.
Assessment of reporting biases
We did not assess publication bias by examining funnel plots for
symmetry, since the reported associated variance of the estimates
are invalid for the included cluster/population-targeted interven-
tion studies.
Data synthesis
Weanalyzed data inReviewManager (RevMan) 5.2. Analyseswere
stratified according to study design (ie cluster-randomized trials,
non-randomized controlled studies or uncontrolled before-and-
after studies) and by post-intervention time points (ie baseline,
during MDA, < 1 month post-MDA, 1-3 months, 4-6 months,
7-12 months, and > 12 months). The during MDA time point
refers to situations where MDA occurred over a period of time
in multiple rounds. Post-MDA time points were chosen for their
ability to assess immediate, intermediate and long-term effects. A
random-effects approach was used if heterogeneity was detected;
otherwise, a fixed-effect approach was adopted.
Subgroup analysis and investigation of heterogeneity
We carried out subgroup analyses to explore causes of heterogene-
ity, grouping by co-interventions (vector control versus no vector
control), endemicity level (≤ 5%, 6-39% and≥ 40%), co-admin-
istration of 8-aminoquinoline plus schizonticide drug treatments,
and plasmodium species (P. falciparum or P. vivax). Malaria en-
demicity classifications of low (≤ 5%), moderate (6-39%), and
high (≥ 40%) based on malaria prevalence data at baseline or
the control group in children 2-10 years of age were based on
the mapping criteria proposed by the Malaria Atlas Project (Hay
2008). Study-specific endemicity was defined preferentially using
data from 1) children 2-10 years of age, 2) children of any age,
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and lastly 3) all ages, depending on the available data. Subgroup
analyses to evaluate heterogeneity were not possible for anaemia
prevalence and mortality, due to the small number of studies.
Sensitivity analysis
Due to the heterogeneity of the studies, there were not sufficient
studies to conduct a sensitivity analysis for investigating the ro-
bustness of the results to the risk of bias components.
R E S U L T S
Description of studies
Results of the search
The initial search was conducted in May 2010, repeated in May
2011 and August 2012, and updated in February 2013. In total,
3048 records were identified through database searches. Of those,
372 abstracts were screened, 240 full-text articles were assessed
for eligibility, 48 publications were included in our review, and
32 unique studies were included in our final quantitative meta-
analysis. Nine of the studies included more than one comparison
(different drugs, number of MDA rounds or co-interventions)
resulting in 47 comparisons. One publication has been included
as two separate eligible studies (Paik 1974a SLB; Paik 1974b SLB),
since it reported interventions in two different geographic settings
with differing endemicities. The remaining 192 full-text articles
assessed for eligibility were excluded from analysis.
Included studies
Cluster-randomized trials
Two cluster-randomized trials were included: one from a set-
ting with very low endemicity in Tanzania (< 1% prevalence)
(Shekalaghe 2011 TZA) and one from a highly endemic setting
in the Gambia (≥ 40% prevalence) (von Seidlein 2003 GMB).
Both studies administered a single treatment course of artesunate
plus sulfadoxine-pyrimethamine. In Tanzania, a single dose of pri-
maquine 0.75mg/kg was also given on day three to all participants
excluding pregnant women and those with anaemia at the start
of the transmission season; individuals were followed up for four
months. In the Gambia study, drugs were given during the trans-
mission season and villages were surveyed weekly for five months.
The control group in both trials received a placebo.
Shekalaghe 2011 TZA reports a background rate of bed net use of
25.1% to36.1%during the study period and an ongoing trachoma
control programme; von Seidlein 2003 GMB did not report on
ITN or IRS use in the study areas. Shekalaghe 2011 TZA adminis-
tered the drugs at the start of the transmission season whereas von
Seidlein 2003 GMB administered drugs during the transmission
season.
Non-randomized controlled studies
We included eight non-randomized controlled studies, of which
six were conducted in Africa more than 30 years ago (Escudie
1962 BFA; Jones 1958 KEN;Molineaux 1980 NGA;Najera 1973
NGA; Roberts 1964 KEN; Schneider 1961 BFA), one was from
India in the 1950s (Singh 1953 IND) and one was from Vanuatu
in the 1990s (Kaneko 2000 VUT).Of the seven studies comparing
MDA to no MDA, three studies (seven comparisons) were from
high endemicity settings (≥ 40% prevalence) (Escudie 1962 BFA;
Molineaux 1980 NGA; Schneider 1961 BFA) and four studies
(five comparisons) were from moderate endemicity settings (6-
39% prevalence) (Jones 1958 KEN; Najera 1973 NGA; Roberts
1964 KEN; Singh 1953 IND). Four studies (six comparisons)
compared MDA with vector control measures (Kaneko 2000
VUT; Escudie 1962 BFA;Molineaux 1980NGA; Schneider 1961
BFA).
The drugs used, dosages and frequency, and number of MDA
rounds varied across the studies. One study gave a single dose
of pyrimethamine (Roberts 1964 KEN) and one study gave
pyrimethamine every six months for three rounds (Jones 1958
KEN). One study gave amodiaquine alone every two weeks
for five rounds (Singh 1953 IND), one study gave sulfalene-
pyrimethamine alone every two to ten weeks for three rounds
(Molineaux 1980 NGA) and one study gave chloroquine plus
pyrimethamine every two months for 11 rounds (Najera 1973
NGA). Three studies included primaquine in their MDA regi-
mens. Specifically, one study gave chloroquine plus sulfadoxine-
pyrimethamine plus primaquine every month for three rounds,
withweekly chloroquine andprimaquine in the interveningweeks,
sufficient to treat vivax hypnozoites (Kaneko 2000 VUT). One
study gave chloroquine or amodiaquine, plus single dose pri-
maquine every two weeks for 15 rounds (Schneider 1961 BFA)
and one study gave amodiaquine or chloroquine, plus single dose
primaquine, every two or four weeks for six months (Escudie 1962
BFA).
Two studies administered drugs during the transmission season
(Escudie 1962 BFA; Singh 1953 IND) and two before or at start of
the transmission season (Kaneko 2000 VUT;Roberts 1964 KEN).
Four studies administered drugs for a longer duration spanning
the transmission season (Jones 1958 KEN;Molineaux 1980NGA;
Najera 1973 NGA; Schneider 1961 BFA).
Three studies reported that IRS activities were underway in both
intervention and control areas, and allowed estimation of the ad-
ditive effect of MDA (Escudie 1962 BFA; Molineaux 1980 NGA;
Najera 1973 NGA).
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Uncontrolled before-and-after studies
The remaining studies (22 out of 32) were uncontrolled before-
and-after studies: eight fromAfrica (Archibald 1960NGA;Cavalie
1962 CMR; De Zulueta 1961 UGA; De Zulueta 1964 UGA;
Gaud 1953 MAR; Houel 1954 MAR; Jones 1954 KEN; Ricosse
1959 BFA), nine from Asia (Hii 1987 MYS; Kondrashin 1985
IND; Malaria_Taiwan 1991 TWN; Metselaar 1961 PNG; Paik
1974a SLB; Paik 1974b SLB; Simeons 1938 IND; Song 2010
KHM; van Dijk 1961 PNG), four from the Americas (Cáceres
Garcia 2008 VEN; Comer 1971 PAN; Gabaldon 1959 VEN;
Garfield 1983 NIC) and one from Palestine (known as British
Mandate Palestine at the time of the study’s publication; Kligler
1931 PSE).
Of the 13 studies (15 comparisons) comparing MDA to no in-
tervention, one was conducted in an area of low endemicity (≤
5%) (Malaria_Taiwan 1991 TWN), seven in areas of moder-
ate endemicity (6-39%) (Archibald 1960 NGA; Cavalie 1962
CMR; Comer 1971 PAN; Houel 1954 MAR; Jones 1954 KEN;
Metselaar 1961 PNG; van Dijk 1961 PNG) and seven in ar-
eas of high endemicity (≥ 40%) (Archibald 1960 NGA; Cavalie
1962 CMR; Gaud 1953 MAR; Hii 1987 MYS; Kligler 1931
PSE; Ricosse 1959 BFA; Song 2010 KHM). Six studies evalu-
ated MDA plus vector control measures (De Zulueta 1961 UGA;
De Zulueta 1964 UGA; Hii 1987 MYS; Metselaar 1961 PNG;
Paik 1974a SLB; Ricosse 1959 BFA). The remaining six stud-
ies (Cáceres Garcia 2008 VEN; Gabaldon 1959 VEN; Garfield
1983 NIC; Kondrashin 1985 IND; Paik 1974b SLB; Simeons
1938 IND) only reported monthly incidence estimates ranging
from 0.4/1000 to 156/1000. Due to the challenges of converting
monthly incidence to precise endemicity estimates, these studies
were analyzed separately in the meta-analysis.
Once again, the drugs used, dosages and frequency, and num-
ber of rounds varied between studies. In brief, four studies gave
pyrimethamine alone (Houel 1954 MAR, once only; Gabaldon
1959 VEN, weekly for six months; Ricosse 1959 BFA, ev-
ery two weeks for eight rounds; Jones 1954 KEN, every six
months for three rounds), six gave pyrimethamine plus chloro-
quine (Archibald 1960 NGA; Cavalie 1962 CMR; De Zulueta
1961 UGA; De Zulueta 1964 UGA; Metselaar 1961 PNG; Paik
1974a SLB) and one gave amodiaquine alone (Gaud 1953 MAR,
once only). The remaining 11 studies all included primaquine or
plasmoquine in theMDA regimen. One gave pyrimethamine plus
primaquine every two weeks for two years (Comer 1971 PAN),
one gave sulfadoxine-pyrimethamine plus primaquine once only
(Hii 1987 MYS), four gave chloroquine plus primaquine (Cáceres
Garcia 2008 VEN andGarfield 1983NIC, once only; Kondrashin
1985 IND, every six months for two rounds; Paik 1974b SLB,
every three months for three rounds) and one gave artesunate-
piperaquine plus primaquine (Song 2010 KHM). The two earliest
studies gave plasmoquine plus quinine every three weeks for three
rounds (Kligler 1931 PSE) and atebrin plus plasmochin once only
(Simeons 1938 IND). Two studies administered primaquine with
the intention of treating vivax hypnozoites (Cáceres Garcia 2008
VEN; Comer 1971 PAN).
Five studies did not describe the transmission season (Hii 1987
MYS; Malaria_Taiwan 1991 TWN; Metselaar 1961 PNG; Song
2010 KHM; van Dijk 1961 PNG). Six studies administered drugs
during the transmission season (Archibald 1960 NGA; Gabaldon
1959 VEN; Houel 1954 MAR; Kligler 1931 PSE; Ricosse 1959
BFA; Simeons 1938 IND), another six at the start or before the
transmission season (Cáceres Garcia 2008 VEN; Cavalie 1962
CMR; Garfield 1983 NIC; Gaud 1953 MAR; Kaneko 2000
VUT; Paik 1974a SLB), and four between transmission seasons
(Archibald 1960 NGA; Cavalie 1962 CMR; Kondrashin 1985
IND; Paik 1974b SLB). The remaining four studies adminis-
tered drugs for a longer duration spanning the transmission season
(Comer 1971 PAN; De Zulueta 1961 UGA; De Zulueta 1964
UGA; Jones 1954 KEN).
Six studies reported on interventions, which include MDA and
co-interventions such as IRS (De Zulueta 1961 UGA; De Zulueta
1964 UGA; Paik 1974a SLB; Ricosse 1959 BFA; Metselaar 1961
PNG) or ITNs (Hii 1987 MYS). These studies have been ana-
lyzed separately as they are confounded by the effect of the co-
intervention.
Excluded studies
Of the 192 excluded studies, we excluded 74 because they admin-
istered an inadequate treatment dose; 19 because they were indi-
vidually-randomized studies; 16 because they did not provide suf-
ficient information on reported outcomes; and 16 because they did
not provide sufficient information on drug administration (Figure
1). Several studies included in a previous review were excluded due
to inadequate treatment doses (von Seidlein 2003 GMB). Barber
1932 is often cited as the first report of MDA, but it was excluded
because plasmoquine simplex 10 mg twice a week was classified
as an inadequate treatment dose (von Seidlein 2003 GMB). The
excluded studies and reasons for their exclusion are given in the
’Characteristics of excluded studies’ table.
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Figure 1. Study flow diagram.
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Risk of bias in included studies
The risk of bias assessments are summarized in Figure 2 and Figure
3.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Figure 3. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Allocation
The two cluster-randomized trials (Shekalaghe 2011 TZA; von
Seidlein 2003 GMB) adequately randomized and concealed allo-
cation, and are at low risk of selection bias. The non-randomized
controlled studies and the uncontrolled before-and-after studies
are all considered at high risk of bias for random sequence genera-
tion and allocation concealment due to the non-randomized study
design. However, in addition to the two cluster-randomized tri-
als, three non-randomized controlled studies (Kaneko 2000 VUT;
Molineaux 1980 NGA; Schneider 1961 BFA) are at low risk of
baseline imbalance between non-randomized groups or clusters.
The remaining studies are at high risk of bias for baseline imbal-
ance due to evident baseline differences between intervention and
control groups.
Blinding
The two cluster-randomized trials used placebos and adequately
blinded participants and personnel/assessors, and so were judged
to be at low risk of performance and detection bias.
In seven non-randomized controlled studies, it was unclear if out-
come assessors were blinded to allocation group. One non-ran-
domized controlled study (Molineaux 1980 NGA) did not men-
tion whether participants and personnel were blinded; it was un-
clear if this impacted the outcomes of interest. However, blood
slides in this studywere independently re-examined; therefore, risk
for detection bias was low. All 22 uncontrolled before-and-after
studies were considered to be at high risk of performance bias and
detection bias.
Incomplete outcome data
Attrition was low in both of the cluster-randomized trials (
Shekalaghe 2011 TZA; von Seidlein 2003 GMB) and were judged
to be at low risk of bias. Of the non-randomized controlled stud-
ies, two were judged to be at high risk of bias: one study reported
that only a subset of participants were included in the evaluation
of outcomes (Schneider 1961 BFA) and the other did not report
intervention coverage (Singh 1953 IND). The remaining six non-
randomized controlled studies demonstrated low risk of bias.
Six uncontrolled before-and-after studies were considered to be at
high risk of attrition bias. Two studies had large losses to follow-
up (Kligler 1931 PSE; van Dijk 1961 PNG). Furthermore, one
study reported that only a subset of participants was included in
the evaluation of outcomes (Houel 1954 MAR); one study had
to stop MDA distribution in one study zone during the study
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period, which could impact results (Ricosse 1959 BFA); and one
reported missing data (Song 2010 KHM). Hii 1987MYS was also
assessed to be at high risk of bias: although the entire population
was treated, only a subset of 286 children were surveyed, of which
only 29.7% were present at every one of the eight sessions. An
additional six uncontrolled before-and-after studies did not pro-
vide a sufficiently adequate description to allow an assessment of
attrition bias and these were judged to be ’unclear’ (Cavalie 1962
CMR;DeZulueta 1964UGA;Gaud 1953MAR;Malaria˙Taiwan
1991 TWN; Paik 1974a SLB; Paik 1974b SLB). The other 11
uncontrolled before-and-after studies were at low risk of bias.
Selective reporting
We found evidence of selective outcome reporting in two non-ran-
domized controlled studies (Kaneko 2000 VUT; Schneider 1961
BFA) and five uncontrolled before-and-after studies (Archibald
1960 NGA; Hii 1987 MYS; Kligler 1931 PSE; Paik 1974a SLB;
Song 2010 KHM). In addition, one non-randomized controlled
trial (Roberts 1964 KEN) and seven uncontrolled before-and-af-
ter studies (Cavalie 1962 CMR; Gaud 1953 MAR; Houel 1954
MAR; Kondrashin 1985 IND; Metselaar 1961 PNG; Paik 1974b
SLB; Ricosse 1959 BFA) did not contain enough information to
assess adequately the risk of selective outcome reporting.
Contamination protection
Contamination protection was low in both of the cluster-random-
ized trials (Shekalaghe 2011 TZA; von Seidlein 2003 GMB). Of
the eight non-randomized controlled studies, four demonstrated a
low risk of contamination (Kaneko 2000 VUT; Molineaux 1980
NGA; Najera 1973 NGA; Roberts 1964 KEN). Another three
non-randomized controlled studies (Escudie 1962 BFA; Jones
1958 KEN; Schneider 1961 BFA) did not provide sufficient in-
formation to assess whether contamination bias was of concern.
However, one study (Singh 1953 IND) did show evidence of con-
tamination, as large numbers of labourers were repatriated to their
own villages each week because of high malaria incidence. Due to
the lack of a comparison group, all 22 uncontrolled before-and-
after studies demonstrated high risk of contamination.
Other potential sources of bias
One non-randomized controlled study (Jones 1958 KEN)
and seven uncontrolled before-and-after studies described other
sources of potential bias. In one study (Archibald 1960 NGA),
anecdotes of ill effects began to circulate and evidence of the ’palm-
ing’ of tablets was described by investigators. Another study (De
Zulueta 1964 UGA) reported that only about half of the popu-
lation was given treatment during the first administration, with
the resultant low coverage likely reducing the impact of the inter-
vention. Houel 1954 MAR provided no data on the coverage of
the intervention. An additional three studies (Jones 1954 KEN;
Jones 1958 KEN; Ricosse 1959 BFA) described the presence of
antimalarial drug resistance. Furthermore, due to the movement
of labour, there was likely an influx of P. falciparum cases that
could have introduced bias in the Kondrashin 1985 IND study.
Paik 1974a SLB conducted active case detection in the post-in-
tervention surveillance, which could have resulted in higher base-
line prevalence, potentially overestimating the impact of MDA.
A further three studies - two non-randomized controlled studies
(Escudie 1962 BFA; Schneider 1961 BFA) and one uncontrolled
before-and-after study (van Dijk 1961 PNG) - provided insuffi-
cient information to assess whether an important risk of bias was
present. No other sources of bias were identified in the remaining
studies.
Effects of interventions
Section 1: MDA vs no intervention
Comparison 1: MDA vs no MDA in areas of low endemicity
(≤ 5%)
Only two studies were conducted in areas of low endemicity (≤
5%): one cluster-randomized trial (Shekalaghe 2011 TZA) and
one uncontrolled before-and-after study (Malaria˙Taiwan 1991
TWN). Studies ranged from targeting 1110 (Shekalaghe 2011
TZA) to 1537 (Malaria˙Taiwan 1991 TWN) participants in the
intervention groups. See Table 1.
Parasitaemia prevalence
Cluster-randomized trials: The study from Tanzania administered
a single round of MDA as a 3-day course of artesunate (4 mg/
kg/day for three days) plus sulphadoxine-pyrimethamine (25 mg
+ 1.25 mg/kg as a single dose on the first day) plus primaquine
(0.75 mg/kg as a single dose on the third day). All participants
in both the intervention and control groups tested negative for
malaria parasites at baseline and during the five months of follow-
up (1 study, number sampled 484 to 794, Analysis 1.1).
Uncontrolled before-and-after studies: One study from a small, re-
mote island of Taiwan administered MDA as a single dose of
chloroquine (12 mg/kg). Compared to baseline data, large reduc-
tions in the prevalence of parasitaemia were reported within the
first month post-MDA (RR 0.27, 95% CI 0.14 to 0.50, 1 study,
number sampled 1537, Analysis 1.2) and over several years of post-
intervention follow-up (RR 0.02, 95% CI 0.00 to 0.12, 1 study,
number sampled 2007, Analysis 1.2).
Parasitaemia incidence
No studies from settings with low endemicity reported malaria
incidence.
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Gametocytaemia prevalence
Cluster-randomized trials: In Tanzania, no participants tested posi-
tive for gametocytes at baseline or during follow-up (1 study, num-
ber sampled 484 to 794, Analysis 1.3).
Uncontrolled before-and-after studies: The Taiwan study did not
report on gametocytaemia prevalence.
Comparison 2: MDA vs no MDA in areas of moderate
endemicity (6% to 39%)
Four non-randomized controlled studies (five comparisons) (Jones
1958 KEN; Najera 1973 NGA; Roberts 1964 KEN; Singh 1953
IND) and seven uncontrolled before-and-after studies (Archibald
1960 NGA; Cavalie 1962 CMR; Comer 1971 PAN; Houel 1954
MAR; Jones 1954 KEN; Metselaar 1961 PNG; van Dijk 1961
PNG) were conducted in areas of moderate endemicity. Study
sample sizes for those targeted in the intervention groups ranged
from 125 to 101,000 for non-randomized controlled studies and
between899 and22,500 for uncontrolled before-and-after studies.
See Table 2. One non-randomized controlled study (Najera 1973
NGA) and four uncontrolled before-and-after studies addedMDA
to existing IRS programs (Archibald 1960 NGA; Cavalie 1962
CMR; Houel 1954 MAR; Metselaar 1961 PNG).
Parasitaemia prevalence
Non-randomized controlled studies: There was evidence of baseline
imbalance in parasite prevalence in all four studies, biasing the
subsequent time points and leading to an over- or underestimate of
the effect (4 studies, number sampled 3123, Analysis 2.1). These
studies were conducted between 1952 and 1968 in India, Kenya
and Nigeria.
Only one study reported the prevalence of parasitaemia while the
MDA was ongoing and this study administered MDA as chloro-
quine (450mg) plus pyrimethamine (45mg) every two months for
11 rounds (Najera 1973 NGA). The study reported a substantial
reduction in prevalence compared to the control areas (RR 0.27,
95% CI 0.25 to 0.28, 1 study, number sampled 47,014, Analysis
2.1)
Three studies reported very large reductions in prevalence dur-
ing the first month post-MDA compared to control areas (RR
0.03, 95% CI 0.01 to 0.08, 3 studies, number sampled 1934,
Analysis 2.1). Only two studies from the 1950s conducted follow-
up for more than three months post-MDA (Jones 1958 KEN;
Roberts 1964 KEN). In Jones 1958 KEN, the baseline prevalence
of parasitaemia was higher in the intervention areas than in con-
trol areas, but was substantially lower in the intervention areas
one to three months post-MDA (RR 0.22, 95% CI 0.14 to 0.36,
1 study, number sampled 357, Analysis 2.1) and at about four
months post-MDA (RR 0.28, 95%CI 0.21 to 0.38, 1 study, num-
ber sampled 410, Analysis 2.1). This study administered MDA as
pyrimethamine (100 mg) every six months for three rounds. In
the highlands of Kenya, where MDA was administered as a single
dose of pyrimethamine (Roberts 1964 KEN), there was evidence
of continued reduction compared to the control areas by month
7 of follow-up (RR 0.19, 95% CI 0.11 to 0.33, 1 study, number
sampled 600, Analysis 2.1).
Uncontrolled before-and-after studies:Compared to baseline data, a
large reduction in parasitaemia was seen during multiple rounds of
pyrimethamine (50 mg) plus primaquine (40 mg) given every two
weeks in Panama (Comer 1971 PAN) and a smaller reduction was
seen during weekly administration of chloroquine (450mg) and
pyrimethamine (50 mg) for six weeks in New Guinea (Metselaar
1961 PNG) (RR 0.17, 95% CI 0.02 to 1.47, 2 studies, number
sampled 4209, Analysis 2.2).
Three studies reported parasitaemia within onemonth of finishing
MDA, with large and consistent reductions compared to baseline
(RR 0.29, 95%CI 0.17 to 0.48, 3 studies, number sampled 1727,
Analysis 2.2). Two studies conducted follow-up for more than
three months post-MDA with mixed results: one found no effect
(Archibald 1960 NGA) and one found a substantial increase in
prevalence compared to baseline (Cavalie 1962 CMR).
Parasitaemia incidence
None of these studies reported on parasitaemia incidence.
Gametocytaemia prevalence
Non-randomized controlled studies: One non-randomized con-
trolled study from Nigeria reported a substantial reduction in ga-
metocytaemia in the intervention area during 11 rounds of chloro-
quine plus pyrimethamine given every two months (RR 0.48,
95% CI 0.42 to 0.54, 1 study, number sampled 47,014, Analysis
2.3). A second study from Kenya reported a substantial reduction
in prevalence within the first month following three rounds of
pyrimethamine (RR 0.28, 95% CI 0.10 to 0.82, 1 study, number
sampled 433, Analysis 2.3).Only the Kenyan study conducted fol-
low-up for longer than three months post-MDA. At four months,
gametocytaemia prevalence appeared to be increasing in the inter-
vention population and was no longer substantially different from
the control population (1 study, number sampled 410, Analysis
2.3).Neither of these studies gave primaquine as part of theMDA.
Uncontrolled before-and-after studies: Three uncontrolled before-
and-after studies reported on gametocyte prevalence within one
month of MDA, with substantial effects in two studies (RR 0.47,
95% CI 0.25 to 0.87, 3 studies, number sampled 1727, Analysis
2.4). Only one study continued follow-up beyond three months
(Archibald 1960 NGA); in this study, the prevalence of gameto-
cytaemia was rising after five months but remained lower than
baseline (1 study, number sampled 125, Analysis 2.4).
Comparison 3: MDA vs no MDA in areas of high endemicity
(≥ 40%)
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One cluster-randomized trial (von Seidlein 2003 GMB), three
non-randomized controlled studies (seven comparisons) (Escudie
1962 BFA; Molineaux 1980 NGA; Schneider 1961 BFA), and
seven uncontrolled before-and-after studies (Archibald 1960
NGA; Cavalie 1962 CMR; Gaud 1953 MAR; Hii 1987 MYS;
Kligler 1931 PSE; Ricosse 1959 BFA; Song 2010 KHM) com-
pared MDA with no MDA in areas of high endemicity. Of the
16,442 participants in the von Seidlein 2003 GMB cluster-ran-
domized trial, 14,017 took part in the MDA trial and 1969
were evaluated in the intervention group. The population targeted
ranged from 1810 to 14,129 for the non-randomized controlled
studies and from 148 to 7000 for the uncontrolled before-and-
after studies; see Table 3. Two non-randomized controlled stud-
ies (Escudie 1962 BFA; Molineaux 1980 NGA) and two uncon-
trolled before-and-after studies added MDA to existing IRS pro-
grams (Archibald 1960 NGA; Cavalie 1962 CMR). Several of
these studies had multiple treatment arms and so appear more
than once in the subsequent analyses.
Parasitaemia prevalence
Cluster-randomized trials: In theGambia, no significant differences
in parasite prevalence were seen at baseline, at six to 10 weeks or
at five months following a single treatment course of artesunate
plus sulfadoxine-pyrimethamine (1 study, number sampled 1089
to 1800, Analysis 3.1).
Non-randomized controlled studies: At baseline, there was evidence
of imbalance in parasite prevalence between groups in all three
studies, biasing the subsequent time points and leading to an over-
estimate of the effect (RR 0.84, 95% CI 0.70 to 1.00, 3 stud-
ies, number sampled 9395, Analysis 3.2). These studies were con-
ducted between 1960 and 1975.
Even accounting for the baseline differences, large reductions in
parasitaemia were seen consistently during multi-round MDA
programmes (RR 0.17, 95% CI 0.11 to 0.27, 3 studies, num-
ber sampled 12,561, Analysis 3.2). In Burkina Faso, where MDA
was administered as amodiaquine or chloroquine plus primaquine,
there was still some evidence of benefit up to three months post-
MDA, although this effect was of a smaller magnitude than seen
during the MDA programmes (RR 0.52, 95% CI 0.33 to 0.81,
1 study, number sampled 7197, Analysis 3.2). These two studies
demonstrated a lessening effect back towards baseline estimates.
Uncontrolled before-and-after studies: Similarly, in uncontrolled be-
fore-and-after studies, substantial reductions in parasitaemia were
seen during multi-round MDA programmes (RR 0.10, 95% CI
0.03 to 0.34, 2 studies, number sampled 911, Analysis 3.3). Re-
ductions were also seen within one month of the MDA pro-
grammes finishing (RR 0.37, 95% CI 0.28 to 0.49, 4 studies,
number sampled 1941, Analysis 3.3), although the magnitude of
the reduction ranged from 30% to 72%. Three studies continued
to monitor prevalence for more than three months post-MDA,
with mixed findings. One recent study that administered arte-
sunate plus piperaquine with primaquine reported a large reduc-
tion over time in Cambodia (Song 2010 KHM), one 1930 study
from Palestine using plasmochin and quinine showed modest re-
ductions, while one small study fromMalaysia administering sul-
fadoxine-pyrimethamine plus primaquine demonstrated no sig-
nificant effect at any time point (Hii 1987 MYS). In the Cambo-
dia study, periodic surveys were carried out every six months for
two years after the mass treatment programme.
Parasitaemia incidence
Cluster-randomized trials: In the single cluster-randomized trial
from the Gambia, the incidence of parasitaemia was reduced by
over 50% during the first month following a single course of arte-
sunate plus sulfadoxine-pyrimethamine (RR 0.41, 95% CI 0.23
to 0.74, one study, number sampled 1225, Analysis 3.4). This sig-
nificant reduction is consistent with the adjusted geometric mean
rate ratio reported in the publication (rate ratio 0.37, 95%CI 0.17
to 0.84) (von Seidlein 2003 GMB). However, no difference was
present at six to 10 weeks or at five months in both the unadjusted
rate ratios presented in this review and the adjusted rate ratios
presented in the publication.
Gametocytaemia prevalence
Cluster-randomized trials: In the Gambia, there were no statisti-
cally significant differences in gametocytaemia at baseline or at
five months following a single treatment course of artesunate plus
sulfadoxine-pyrimethamine (1 study, number sampled 1376 to
1414, Analysis 3.5).
Non-randomized controlled studies: Three non-randomized con-
trolled studies reported substantial reductions in the prevalence
of gametocytaemia during MDA programmes (RR 0.17, 95% CI
0.10 to 0.28, 3 studies, number sampled 12,561, Analysis 3.6).
Twoof these studies administeredMDAas amodiaquine or chloro-
quine plus primaquine (Escudie 1962 BFA; Schneider 1961 BFA)
and one study gave sulfalene-pyrimethamine alone (Molineaux
1980 NGA). In Schneider 1961 BFA, the effect on gametocy-
taemia appeared to be lost within three months of the MDA pro-
gramme finishing, while in Escudie 1962 BFA some reduction still
remained after three months in three of four comparison arms,
although the impact decreased in magnitude.
Uncontrolled before-and-after studies: Five uncontrolled before-
and-after studies reported on the effect of MDA on ga-
metocytaemia prevalence. Two studies either administered
pyrimethamine alone (Ricosse 1959 BFA) or chloroquine plus
pyrimethamine (Archibald 1960 NGA). Two studies were carried
out in Asia and treated individuals with a combination drug of
sulfadoxine-pyrimethamine plus primaquine (Hii 1987 MYS) or
with artemisinin and piperaquine given with primaquine every 10
days (Song 2010 KHM). One study used plasmochin and quinine
(Kligler 1931 PSE). Only Song 2010 KHM demonstrated sus-
tained impact after six months (RR 0.19, 95% CI 0.13 to 0.27, 1
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study, number sampled 1609, Analysis 3.7), which was sustained
during the 30 month follow-up (RR 0.09, 95% CI 0.05 to 0.15,
1 study, number sampled 1175, Analysis 3.7).
Anaemia prevalence
Cluster-randomized trials: The prevalence of anaemia (hematocrit
< 33%) was only reported in a single cluster-randomized trial from
the Gambia (von Seidlein 2003 GMB). This study demonstrated
a modest reduction in anaemia prevalence at five months post-
MDA (RR 0.84, 95% CI 0.75 to 0.93, 1 study, number sampled
1414, Analysis 3.8).
Mortality
Cluster-randomized trials: Mortality was only reported in a single
cluster-randomized trial from the Gambia (von Seidlein 2003
GMB). Mortality was low in both study arms over five months
follow-up, with no statistically significant difference between the
two groups (1 study, number sampled 3655, Analysis 3.9).
Section 2: MDA + vector control vs no intervention
Comparison 4: MDA plus vector control vs no intervention
in areas of moderate endemicity (6% to 39%)
One non-randomized controlled study (Kaneko 2000 VUT) and
four uncontrolled before-and-after studies (De Zulueta 1961
UGA; De Zulueta 1964 UGA; Paik 1974a SLB; Ricosse 1959
BFA) compared MDA plus vector control with no intervention
in areas of moderate endemicity. The target population for the
Kaneko 2000 VUT study was 718 villagers. The target popula-
tion for three uncontrolled before-and-after studies (De Zulueta
1961 UGA; De Zulueta 1964 UGA; Ricosse 1959 BFA) ranged
from 5000 to 59,605; in the Paik 1974a SLB study, the targeted
population was not described. See Table 4.
Parasitaemia prevalence
Non-randomized controlled studies: Kaneko 2000 VUT included
larvivorous fish in several identified breeding sites and universal
coverage with insecticide-treated bed nets (about 0.94 nets per
villager) in its intervention group. In the comparison group, bed
net coverage was approximately 20%. Twelve months post-MDA,
the prevalence of parasitaemia was 1% in the intervention island
compared to 12% in the control island (Analysis 4.1).
Uncontrolled before-and-after studies: These four studies adminis-
teredMDA with either pyrimethamine alone (Ricosse 1959 BFA)
or chloroquine plus pyrimethamine (De Zulueta 1961 UGA; De
Zulueta 1964 UGA; Paik 1974a SLB), together with IRS. The
greatest effect on parasitaemia prevalence was seen within one
month post-MDA (RR 0.06, 95% CI 0.01 to 0.33, three stud-
ies, number sampled 2961, Analysis 4.2), which was larger than
the effect seen in Analysis 2.2 with MDA alone. Only one study
(De Zulueta 1964 UGA) from the Ugandan highlands with dis-
appearance of the vector with IRS found a sustained, large effect
lasting over 12 months (RR 0.00, 95%CI 0.00 to 0.03, one study,
number sampled 1229, Analysis 4.2).
Gametocytaemia prevalence
Uncontrolled before-and-after studies: Two studies from Uganda
(De Zulueta 1961 UGA) and Burkina Faso (Ricosse 1959 BFA)
demonstrated a reduction in gametocytaemia prevalence during
MDA (RR 0.13, 95% CI 0.06 to 0.27, two studies, number sam-
pled 2479, Analysis 4.3). Only Ricosse 1959 BFA reported esti-
mates for gametocytaemia prevalence post-MDA. The largest ef-
fect was seen within one month of administration (RR 0.01, 95%
CI 0.00 to 0.16, one study, number sampled 919, Analysis 4.3),
with a lessening effect after two months (RR 0.22, 95% CI 0.11
to 0.41, one study, number sampled 953, Analysis 4.3). Neither
of these studies administered primaquine as part of MDA.
Comparison 5: MDA plus vector control vs no intervention
in areas of high endemicity (≥ 40%)
Three non-randomized controlled studies (five comparisons)
(Escudie 1962 BFA;Molineaux 1980NGA; Schneider 1961 BFA)
and two uncontrolled before-and-after studies (Hii 1987 MYS;
Metselaar 1961 PNG) compared MDA plus vector control with
no intervention in settings of high endemicity. The number of
participants ranged from 1810 to 14,129 in the non-randomized
controlled studies and from 754 to 2500 participants in the two
uncontrolled before-after studies. See Table 4.
Parasitaemia prevalence
Non-randomized controlled studies: These studies administered
MDA at intervals of two weeks to 10 weeks for between eight and
23 rounds, alongside IRS. These studies were conducted between
1961 and 1975. In two studies (Escudie 1962 BFA; Schneider
1961 BFA), there was evidence of baseline imbalance in parasite
prevalence, biasing the subsequent time points and leading to an
overestimate of the effect (Analysis 5.1). Despite this, MDA plus
IRS appeared to reduce parasitaemia substantially during MDA
(RR 0.10, 95% CI 0.06 to 0.16, three studies, number sampled
9493, Analysis 5.1). However, by three months post-MDA, this
effect had lessened in both Schneider 1961 BFA and Escudie 1962
BFA compared to during administration (RR 0.12, 95% CI 0.06
to 0.23, two studies, number sampled 4455, Analysis 5.1). The
effect on parasitaemia prevalence both during and one to three
months post MDA with IRS were larger than noted in studies
without concomitant vector control measures (Analysis 3.2). Only
one study (Molineaux 1980 NGA) conducted follow-up for more
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than three months, reporting a continued reduction in prevalence
with a modest effect from seven to 12 months (RR 0.60, 95% CI
0.55 to 0.67, one study, number sampled 3154, Analysis 5.1).
Uncontrolled before-and-after studies:A study (Hii1987MYS) from
Malaysia issuing permethrin-impregnated bed nets to all house-
holds along with larval control measures and a study (Metselaar
1961 PNG) from New Guinea conducting IRS reported the im-
pact on parasitaemia prevalence. The largest reduction in para-
sitaemia was seen one to three months post MDA(RR 0.13, 95%
CI 0.01 to 2.51, two studies, number sampled 2722, Analysis
5.2), with lessening effect as the post-intervention time increased.
Compared to baseline, no difference was noted after nine months
of follow-up for the Malaysian study (Analysis 5.2).
Gametocytaemia prevalence
Non-randomized controlled studies: All three studies (Escudie 1962
BFA; Molineaux 1980 NGA; Schneider 1961 BFA), comprising
five comparison groups, included IRS in addition to MDA. At
baseline, two studies with three comparison groups (Escudie 1962
BFA; Schneider 1961 BFA) demonstrated higher gametocytaemia
prevalence in the intervention arms compared to the comparison
arms. These baseline imbalances could inflate the impact of the
effect at subsequent time points. Despite this, MDA appeared to
reduce substantially the prevalence of gametocytaemia during the
intervention (RR 0.08, 95% CI 0.03 to 0.20, three studies, num-
ber sampled 9493, Analysis 5.3). The effect of MDA on gameto-
cytaemia prevalence remained until three months post-MDA (RR
0.08, 95% CI 0.05 to 0.14, two studies, number sampled 4455,
Analysis 5.3). Only one study from Nigeria (Molineaux 1980
NGA) reported long-term data. This study administered MDA
using sulfalene (500 mg) plus pyrimethamine (25 mg) every 10
weeks, and noted lessening effect between seven and 11 months
(RR0.87, 95%CI 0.73 to 1.05, one study, number sampled 3154)
and no difference beyond 12 months of follow-up (RR 0.96, 95%
CI 0.81 to 1.14, one study, number sampled 3261, Analysis 5.3).
Uncontrolled before-and-after studies: A single study (Hii 1987
MYS) reporting the co-administration of ITNs demonstrated a
reduction in gametocytaemia prevalence during MDA (RR 0.29,
95% CI 0.17 to 0.50, one study, number sampled 219, Analysis
5.4). The impact on gametocytaemia prevalence decreased with
increased time post-intervention. After six months, estimates of
prevalence in the intervention villages approached those before
intervention (RR 0.93, 95% CI 0.65 to 1.33, one study, number
sampled 194, Analysis 5.4).
Section 3: Parasitaemia incidence only studies
Six uncontrolled before-and-after studies (Cáceres Garcia 2008
VEN; Gabaldon 1959 VEN; Garfield 1983 NIC; Kondrashin
1985 IND; Paik 1974b SLB; Simeons 1938 IND) only reported
baseline monthly incidence and did not provide malaria endemic-
ity estimates (Table 5). Among these, four comparedMDAwith no
intervention (Cáceres Garcia 2008 VEN; Gabaldon 1959 VEN;
Kondrashin 1985 IND; Paik 1974b SLB), while the remaining
two compared MDA plus vector control with no intervention
(Garfield 1983 NIC; Simeons 1938 IND). Targeted populations
ranged in size from 1200 to 2,300,000.
Comparison 6.1: MDA vs no MDA
Uncontrolled before-and-after studies: Compared to baseline, large
reductions in parasitaemia incidence were seen during MDA
administration in two studies - one from Venezuela where
pyrimethamine was administered in 24 weekly rounds (Gabaldon
1959 VEN) and another from the Solomon Islands (known as
the British Solomon Islands at the time of the study’s publica-
tion) where three rounds of chloroquine plus primaquine were
given three months apart (Paik 1974b SLB). In contrast, no sig-
nificant effect was seen in India during two rounds of chloroquine
plus primaquine given six months apart (Kondrashin 1985 IND)
(Analysis 6.1). In addition, three additional studies found large
reductions in incidence within the first month post-intervention
(Cáceres Garcia 2008 VEN; Gabaldon 1959 VEN; Paik 1974b
SLB), although this effect reduced over the following one to three
months (Analysis 6.1). In the two studies fromVenezuela (Cáceres
Garcia 2008 VEN; Gabaldon 1959 VEN), parasitaemia incidence
returned briefly back to baseline levels, before the incidence again
fell compared to baseline levels. These data are impossible to in-
terpret without a control group.
Comparison 6.2: MDA plus vector control vs no MDA
Uncontrolled before-and-after studies: Two studies (Garfield 1983
NIC; Simeons 1938 IND) described the effect of MDA plus vec-
tor control measures on parasitaemia incidence during adminis-
tration, with baseline monthly incidence levels ranging from 0.4/
1000 to 156/1000. During MDA, the effects appear mixed, with
an increase in incidence in one study and a decrease in the other
(Analysis 6.2). These observations are probably seasonal and again
highlight the difficulty of interpreting uncontrolled trials. At later
time points, the incidence of malaria appears substantially reduced
compared to baseline levels for up to a year (Analysis 6.2).
Both studies reported implementing larval controlmethods, which
involved either oiling (Simeons 1938 IND) or larviciding based
on large scale application of temephos to peridomiciliary breeding
sites targeting Aedes aegypti (Garfield 1983 NIC).
Section 4: MDA of regimens containing 8-
aminoquinolines versus regimens that do not
We found no studies directly comparing MDA regimens that in-
cluded 8-aminoquinolines with regimens that did not.
We have instead attempted to compare these regimens indirectly
through a subgroup analysis. This was not possible for stud-
ies conducted in settings of low endemicity due to their low
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number. The single cluster-randomized trial gave primaquine
along with artesunate plus sulphadoxine-pyrimethamine but re-
ported no episodes of parasitaemia or gametocytaemia at base-
line or during follow-up (Shekalaghe 2011 TZA), and the sin-
gle uncontrolled before-and-after study gave chloroquine alone
(Malaria˙Taiwan 1991 TWN).
Comparison 7: MDA vs no MDA; settings of moderate and
high endemicity; subgrouped by inclusion of 8-
aminoquinolines
Parasitaemia prevalence
Non-randomized controlled trials:
None of the non-randomized controlled studies from moderate
endemic settings administered primaquine as part of MDA. Of
the three studies from high endemic settings, two administered
primaquine as part of MDA (Escudie 1962 BFA; Schneider 1961
BFA) and one did not (Molineaux 1980 NGA). During multiple
MDA rounds, there was a substantial reduction in parasitaemia
prevalence regardless of the presence or absence of primaquine,
with no statistically significant differences between subgroups (test
for subgroup differences P = 0.57, Analysis 7.1). At one to three
months, the two studies without primaquine (Jones 1958 KEN;
Roberts 1964 KEN) showed a larger impact than studies that
included primaquine (Escudie 1962 BFA; Schneider 1961 BFA)
(Analysis 7.2).
Uncontrolled before-and-after studies: Four studies reporting par-
asitaemia prevalence administered an 8-aminoquinoline as part
of their MDA regimen (Kligler 1931 PSE: plasmochine 30 mg;
Comer 1971 PAN: primaquine 40 mg; Hii 1987 MYS: pri-
maquine 30 mg; Song 2010 KHM: primaquine 9 mg every 10
days). During MDA administration, there was no difference in
impact between studies that administered primaquine and those
that had not (test for subgroup differences P = 0.08, Analysis
7.3).Within the first month post-MDA, there was a substantial
reduction in parasite prevalence in all four studies regardless of
whether primaquinewas given or not (test for subgroupdifferences
P = 0.12, Analysis 7.4). At one to three months post-treatment,
uncontrolled before-and-after studies that did not include an 8-
aminoquinoline experienced greater reductions in parasitaemia
prevalence compared to the one study that did use an 8-amino-
quinoline as part of MDA (test for subgroup differences < 0.001,
Analysis 7.5). At four to six months post-MDA, there was no dif-
ference in impact between studies that administered primaquine
and those that had not (test for subgroup differences P = 0.07,
Analysis 7.6).
Section 5: MDA for different plasmodium species
Two non-randomized controlled studies (Jones 1958 KEN;
Kaneko 2000VUT) andfive uncontrolled before-and-after studies
(Malaria˙Taiwan 1991 TWN; Metselaar 1961 PNG; Paik 1974a
SLB; Song 2010 KHM; van Dijk 1961 PNG) report the effects
of MDA on the prevalence of both P. falciparum and P. vivax par-
asitaemia. Among these, two studies compared MDA plus vec-
tor control with no intervention (Kaneko 2000 VUT; Paik 1974a
SLB); the remaining studies compared MDA with no interven-
tion.
Comparison 8: Subgrouped by plasmodium species
Non-randomized controlled studies: At baseline, there was a sub-
stantial imbalance in the prevalence of P. vivax parasitaemia,
which would tend to underestimate the effect of MDA on P. vi-
vax (Analysis 8.1). These two studies administered MDA as ei-
ther pyrimethamine every six months for three rounds (Jones
1958 KEN) or as weekly doses of chloroquine, sulfadoxine-
pyrimethamine and primaquine for nine weeks (Kaneko 2000
VUT); both produced mixed results. Kaneko 2000 VUT reported
sustained impact on parasitaemia prevalence over several years of
follow-upwith no falciparum infections and few vivax cases, show-
ing that the impact of MDA was larger for P. falciparum. Jones
1958 KEN also found a larger reduction in P. falciparum than
P. vivax for up to about four months (Analysis 8.3; Analysis 8.4;
Analysis 8.5).
Uncontrolled before-and-after studies: Four studies demonstrated a
reduction in the prevalence of P. vivax parasitaemia during the
first month post-MDA, although this was of a smaller magnitude
than seen for P. falciparum (Analysis 8.3). These studies adminis-
tered artesunate-piperaquine plus primaquine (Song 2010 KHM),
chloroquine plus pyrimethamine (Paik 1974a SLB) or chloroquine
alone (Malaria˙Taiwan 1991 TWN; van Dijk 1961 PNG). After
one to three months of follow-up, the impact of MDA on para-
sitaemia prevalence for P. vivax was smaller than for P. falciparum
(Analysis 8.4). By five months of follow-up, Paik 1974a SLB de-
scribed greater reductions in parasitaemia prevalence for P. vivax
infections compared to P. falciparum cases. In contrast, two stud-
ies from Asia (Malaria˙Taiwan 1991 TWN; Song 2010 KHM)
demonstrated larger reductions in parasitaemia prevalence for P.
falciparum at six months (Song 2010 KHM) and after more than
12 months post-MDA (Malaria˙Taiwan 1991 TWN; Song 2010
KHM).
Section 6: Adverse Events
Ten studies reported on adverse events (Archibald 1960 NGA;
Comer 1971 PAN; Garfield 1983 NIC; Kaneko 2000 VUT;
Kligler 1931 PSE; Najera 1973 NGA; Shekalaghe 2011 TZA;
Simeons 1938 IND; Song 2010 KHM; von Seidlein 2003 GMB).
Of these, only four studies conducted some level of active ad-
verse event surveillance (Kligler 1931 PSE; Najera 1973 NGA;
Shekalaghe 2011 TZA; von Seidlein 2003 GMB).
Kligler 1931 PSE and Song 2010 KHM reported no adverse
events.
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Minor side effects were reported in three studies (Archibald
1960 NGA; Najera 1973 NGA; von Seidlein 2003 GMB). Two
studies conducting MDA with chloroquine plus pyrimethamine
(Archibald 1960 NGA; Najera 1973 NGA) reported a number of
children vomiting the drug. Complaints of dizziness, fever, diar-
rhoea, vomiting and itching within two days of taking sulfadox-
ine-pyrimethamine and artesunate were reported in von Seidlein
2003 GMB .
Five of the studies (Comer 1971 PAN;Garfield1983NIC;Kaneko
2000 VUT; Shekalaghe 2011 TZA; Simeons 1938 IND) report-
ing adverse events included an 8-aminoquinoline drug. Comer
1971 PAN described complaints of headache and nausea that
were ascribed to pyrimethamine plus primaquine. InKaneko 2000
VUT, some villagers reported vomiting after taking the tablets
(chloroquine and primaquine and sulphadoxine-pyrimethamine).
Common side effects described by Garfield 1983 NIC, which ad-
ministered chloroquine and primaquine to all persons, included
dizziness, nausea, vomiting and diarrhoea. In addition, Garfield
1983 NIC also reported occasional cases of psychomotor dis-
turbance, temporary psychological abnormalities and haemolysis.
One study (Shekalaghe 2011 TZA) reported a severe skin reac-
tion one week afterMDA with sulphadoxine-pyrimethamine plus
artesunate plus primaquine. This study also reported several cases
of moderate anaemia among glucose-6-phosphate dehydrogenase
(G6PD) deficient participants given primaquine and one case of
severe anaemia. Simeons 1938 IND conductedMDAwith atebrin
intramuscular and plasmochin simplex and reported four cases of
haemoglobinuria, a known toxicity of 8-aminoquinoline drugs.
Of those, two cases were fatal; the remaining two cases were mild.
Additionally, abscesses were reported in 49 cases, while accounts
of ’giddiness’ were associated with the drug atebrin.
D I S C U S S I O N
The main findings of this review, alongside assessments of the
quality of evidence for each outcome using theGRADE approach,
are summarized in three summary of findings tables: Table 6; Table
7; Table 8
Summary of main results
Two cluster-randomized trials, eight non-randomized controlled
studies and 22 uncontrolled before-and-after studies are included
in this review. The studies used a wide variety of MDA regimens
incorporating different drugs, dosages, timings and numbers of
MDA rounds. Many of the studies are now more than 30 years
old.
Areas of low endemicity (≤5%)
Within the first month post-MDA, a single uncontrolled before-
and-after study conducted in 1955 on a small Taiwanese island re-
ported a much lower prevalence of parasitaemia following a single
course of chloroquine compared to baseline (very low quality evi-
dence). This lower parasite prevalence was still present after more
than 12 months (very low quality evidence) (see Table 6).
Areas of moderate endemicity (6% to 39%)
Within the first month post-MDA, the prevalence of parasitaemia
was much lower in three non-randomized controlled studies from
Kenya and India in the 1950s (moderate quality evidence) and in
three uncontrolled before-and-after studies conducted between
1954 and 1961 (low quality evidence). The longest follow-up in
these settings was four to six months. At this time point, the preva-
lence of parasitaemia remained substantially lower than controls in
the two non-randomized controlled studies (low quality evidence).
In contrast, the two uncontrolled before-and-after studies found
mixed results: one found no difference and one found a substan-
tially higher prevalence compared to baseline (very low quality ev-
idence) (see Table 7).
Areas of high endemicity (≥ 40%)
Within the first month post-MDA, the single cluster-randomized
trial from the Gambia in 1999 found no difference in parasite
prevalence (low quality evidence). However, prevalence was much
lower during the MDA programmes in three non-randomized
controlled studies conducted in the 1960s and 1970s (moderate
quality evidence), and within one month of MDA in four uncon-
trolled before-and-after studies, including one study fromCambo-
dia in 2006 (low quality evidence). Four trials reported changes in
prevalence beyond three months. In the Gambia, the single clus-
ter-randomized trial found no difference at five months (moderate
quality evidence). The three uncontrolled before-and-after studies
had mixed findings with large studies from Palestine and Cambo-
dia showing sustained reductions at four months and 12 months,
respectively, and a small study from Malaysia showing no differ-
ence after four to six months of follow-up (low quality evidence)
(see Table 8).
MDA + vector control
In general, studies that included a vector control measure showed
a large impact on parasitaemia and gametocytaemia prevalence
both during MDA and up to three months post-intervention. In
high-endemicity settings, one large study from Nigeria reported
no difference after six months, whereas in moderate endemicity
settings one study from an island of Vanuatu and one from the
highlands of Uganda noted sustained impact after more than 12
months.
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8-aminoquinolines
We found no studies directly comparing MDA regimens that in-
cluded 8-aminoquinolines with regimens that did not. In a crude
subgroup analysis with a limited number of studies, we were un-
able to detect any evidence of additional benefit of primaquine in
moderate- or high-transmission settings.
P. falciparum vs P. vivax
Reviewing studies that reported the impact of MDA on P. falci-
parum and P. vivax separately, most reported a larger impact on P.
falciparum than P. vivax at all time intervals.
Adverse events
Adverse events were inadequately addressed in most studies. No-
table severe drug reactions, including haemolysis, haemoglobin-
uria, severe anaemia and death, were reported for the co-admin-
istration of 8-aminoquinoline plus schizonticide, and severe skin
reactions were documented with administration of sulphadoxine-
pyrimethamine plus artesunate plus primaquine.
Overall completeness and applicability of
evidence
The studies included in this review were conducted in a variety of
settings in Africa, Asia, Europe and the Americas, and employed
various designs, endemicities, drug regimens, co-intervention uses
and numbers of rounds of MDA intervention. Comparative stud-
ies of malaria interventions are always confounded by differences
in background epidemiology between diverse study areas, but, in
this case, the situation is made even more difficult by the major
differences in design between the studies. Therefore, the findings
can be reasonably applied to scenarios that coincide closely with
the aforementioned parameters but caution is advised in extrapo-
lating results too broadly; the heterogeneity of the studies included
in the overall analysis presents risks when trying to draw conclu-
sions from pooled data. Furthermore, in reviewing these results,
it is important to note the different properties of the antimalarials
employed for mass treatment. Studies using non-gametocytocidal
antimalarials should be interpreted separately from those using
gametocytocidal antimalarials, so as to allow a fair comparison
of pharmacodynamic properties. The same precautions should be
taken when contrasting the impact of short-acting antimalarials
such as the artemisinin derivatives with the impact of long-act-
ing antimalarials such as sulphadoxine-pyrimethamine or piper-
aquine-containing combinations.
Gaps remain in the research evidence and some of the evidence
presented in this overview has serious limitations. Most studies do
not explicitly describe the aims of theMDA programme (eg to in-
terrupt transmission, to reduce transmission, to reduce morbidity
frommalaria, etc), making it difficult to determine whether studies
were successful or not. Numerous studies also did not clearly indi-
cate the timing of MDA in relation to the local transmission sea-
son. Too few studies were conducted in low transmission settings
to determine the effect of MDA in these settings and the likely
impact of this intervention in eliminating malaria. Furthermore,
several outcome data includedmeta-analyses drawn from only one
or two studies. There are exceptions to this, but even within this
review the variability and high heterogeneity mean the results may
still be difficult to interpret. Under these circumstances, general-
izing findings will remain a challenge.
Many of our pre-specified outcomes were not reported in all in-
dividual studies, although the majority of studies at least reported
on parasitaemia and gametocytaemia prevalence. Few studies re-
ported on parasitaemia incidence, anaemia prevalence or mortal-
ity, making it impossible to make any meaningful conclusions on
these outcomes. Furthermore, some of the studies reporting on in-
cidence presented data graphically, making it difficult for review-
ers to extrapolate incidence estimates accurately without access to
the raw data. Thus, these estimates may be imprecise and must be
interpreted with caution.
Quality of the evidence
We assessed the quality of the evidence provided by the included
studies using the GRADE approach, and have presented these re-
sults in the Table 6, Table 7 and Table 8. The majority of the evi-
dence in this review comes from non-randomized studies, which
in most cases can provide only low or very low quality evidence.
However, in some circumstances, very well conducted non-ran-
domized studies can be upgraded to moderate or high quality ev-
idence if they possess one or more of the following features: 1) a
very large treatment effect; 2) evidence of a dose-response effect; 3)
absence of plausible confounders that could be causing the effect.
Most MDA programmes are currently being planned for settings
with low endemicity. However, studies of previous MDA pro-
grammes in these settings were assessed as providing only ’very
low’ quality evidence, meaning we cannot have any confidence in
these results. The single study that provided any data on malaria
prevalence in these settings was conducted in Taiwan in 1955 and
is highly susceptible to confounding due to the lack of an adequate
control group.
In settings withmoderate endemicity, there is moderate quality ev-
idence of substantial reductions in parasitaemia prevalence during
the first month post-MDA. This evidence, from non-randomized
controlled trials, was upgraded due to the consistently large ef-
fects seen and the supportive evidence from four uncontrolled be-
fore-and-after studies. Only two non-randomized controlled trials
followed up beyond three months: one had baseline imbalances,
which would lead to an overestimate of the observed effect, and
both used MDA regimens that are not under consideration today
(pyrimethamine). Consequently, despite the large effect seen, we
graded this evidence as low quality.
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The majority of studies of MDA have been conducted in high-
transmission settings, where there is again moderate quality evi-
dence fromnon-randomized controlled studies of large and consis-
tent effects on parasitaemia prevalence during MDA programmes.
However, only a single uncontrolled before-and-after study from
Cambodia demonstrated effects lasting beyond threemonths post-
intervention.
Potential biases in the review process
As with all reviews, there are risks of introducing bias at all stages
in the review process. Several steps were taken in an attempt to
reduce this bias. Throughout the review process, two authors inde-
pendently assessed eligibility for inclusion of studies, and carried
out data extraction. Discrepancies were resolved by a third author.
All foreign language papers were included.
Assessing the true impact of MDA programmes can be a challenge
for many MDA studies, including those investigating simultane-
ous vector control efforts and lacking proper control groups. Fur-
thermore, the impact of MDA on transmission is difficult to mea-
sure; most studies reported post-intervention effects for too short
a time after the MDA to estimate adequately its impact on long-
term transmission. Furthermore, the studies did not directly assess
the potential of MDA to induce or promote drug resistance; how-
ever, a few studies (Jones 1954 KEN; Jones 1958 KEN; Ricosse
1959 BFA) did report on the development of drug resistance fol-
lowing the use of pyrimethamine monotherapy.
Agreements and disagreements with other
studies or reviews
Antimalarial drug use for MDA has been reviewed previously
(Greenwood 2004; von Seidlein 2003). Thirteen of the studies
in this current review (Cavalie 1962 CMR; De Zulueta 1961
UGA; De Zulueta 1964 UGA; Escudie 1962 BFA; Garfield 1983
NIC;Hii 1987MYS; Kaneko 2000VUT;Kondrashin 1985 IND;
Molineaux 1980 NGA; Najera 1973 NGA; Roberts 1964 KEN;
Singh 1953 IND; von Seidlein 2003GMB)were also included in a
review ofMDA of antimalarial drugs published in 2003. However,
several studies included in the von Seidlein 2003 review were ex-
cluded from this review.Themain reasons for exclusionwere: 1) in-
adequate treatment doses (Barber 1932; Dola 1974;MacCormack
1983;Onori 1972; Strangeways-Dixon 1950); 2) individually ran-
domized (Doi 1989); 3) insufficient information on outcomes of
interest (Yip 1998); and 4) insufficient information on drug ad-
ministration (Baukapur 1984; Lakshmanacharyulu 1968; Sehgal
1968).
In this review, we agree with the conclusion of von Seidlein 2003
thatMDAwas generally unsuccessful in interrupting transmission
but had amarked effect onparasite prevalence andon the incidence
of clinical malaria in some cases. The von Seidlein 2003 review
also proposed a role for MDA in the control of epidemics and in
the control of malaria in areas with a short transmission season,
which this current review did not specifically address. Rather, this
review used a systematic approach to demonstrate and quantify
the differential impact of MDA on parasitaemia prevalence and
incidence and on gametocytaemia prevalence depending on the
timing of the post-MDA outcome measurement. Furthermore,
this review assessed the addition of 8-aminoquinoline drugs into
MDA regimens, as well as the differential impact of MDA on
different plasmodium species (ie P. falciparum vsP. vivax), which
no other review to date has attempted.
The findings of this review also appear to agree with other more
recent modelling that suggests MDA could potentially eliminate
transmission, and that the probability of this occurring goes up
with lower baseline transmission, increased frequency of MDA
and the addition of vector controlmeasures (Okell 2011). Further-
more, the findings demonstrate that a single round of MDA will
have only short-term effects in higher transmission settings. The-
oretically, multiple rounds of optimally-timed MDA in a small,
isolated community with low baseline transmission could elimi-
nate malaria.
Another model using data from Song 2010 KHM demonstrated
that in order to achieve malaria elimination a combination of dif-
ferent strategies is required (Maude 2012). Specifically,MDAwith
artemisinin-piperaquine can significantly reduce parasite preva-
lence in the short term (< 1 year), especially multiple rounds dur-
ing the low transmission season. The model predicted that the
addition of primaquine might enhance the effect of artemisinin-
based combination therapies in controlling or eliminatingmalaria,
but this was not evident from this review. The addition of long-
lasting ITNs further accelerated elimination efforts.
While this review does not completely reconcile the controversies
that surround the use of MDA, it summarizes evidence showing
that this strategy can reduce malaria burden and transmission in
various settings. It also helps to identify gaps in the data and in our
understanding of MDA, and can help to guide future antimalarial
MDA interventions and their evaluation.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
MDA of antimalarials using therapeutic doses has an immediate
and short-term impact on parasitaemia prevalence and incidence
and on gametocytaemia prevalence in all transmission settings.
Although no cluster-randomized trial showed a sustained impact
on these outcomes, a few non-randomized controlled studies and
uncontrolled before-and-after studies did show sustained impact
lasting beyond six months of follow-up. Studies with sustained
impact were conducted in low or moderate transmission settings
and on small islands or in highland areas. There is evidence that
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MDA produces larger reductions in parasitaemia prevalence for
malaria caused by P. falciparum compared to P. vivax. The impact
of adding an 8-aminoquinoline drug remains unclear, although
no obvious benefit in moderate and high transmission areas was
noted. No study directly compared MDA regimens that included
an 8-aminoquinoline with regimens that did not. Several studies
in this review that reported adverse events included an 8-amino-
quinoline drug, with two studies reporting cases of haemolysis.
Still, the optimum transmission scenarios and drug intervention
regimens for producing a sustained impact with MDA remain
largely unknown. In addition, ensuring high coverage requires
overcoming many logistical challenges; in order to achieve high
levels of coverage, a target drug profile forMDAmust be extremely
safe, acceptable and efficacious. Even in settings with highly ef-
ficacious drugs, the overall field effectiveness of MDA will be
greatly compromised if high coverage of the target population is
not achieved.
Significant progress in malaria control has been made in several
settings with an associated reduction in parasitaemia prevalence;
however, with the limitations of currently available diagnostic
tools, the elimination of all parasites may pose a challenge. MDA
may be able to achieve the elimination of remaining parasite reser-
voirs among asymptomatic carriers. However, careful considera-
tion should be given before attempting this approach, especially in
light of increasing concern over the emergence and possible spread
of artemisinin resistance by falciparum malaria. Geographically
isolated areas (ie islands) where importation risk is lower and/or
those with seasonal or lower transmission (ie highlands) may be
more suited to MDA.
Implications for research
While most analyses demonstrate favourable short-term outcomes
for MDA, additional high quality, cluster-randomized trials are
required. These should have clearly defined objectives (eg to in-
terrupt transmission, to reduce transmission or to impact malaria
morbidity) and include participants of all age-groups. They also
need to be conducted in a variety of transmission and seasonal
settings with different epidemiological and socio-cultural determi-
nants, in order to assess adequately the long-term impact of MDA
on malaria transmission. Specifically, the deficiencies in design of
many early studies have complicated the task of summarizing the
effect of MDA on transmission. In addition, few studies have ade-
quately assessed transmission endpoints. Rather, most studies use
relatively standardized measures for parasitaemia prevalence or in-
cidence. It remains unclear from current studies whether longer
beneficial effects would be seen in settings of lower transmission.
Studies that use a cluster-randomized design, withmultiple rounds
of MDA and a longer duration of follow up, are required for ad-
equately assessing the nature of the effect of MDA on transmis-
sion. Furthermore, steps towards standardized approaches formea-
suring and reporting parasitaemia incidence, adverse events and
other secondary outcomes would greatly improve comparability
between studies.
The optimal number and interval timing of rounds of MDA also
needs to be determined, as does the conditions under whichMDA
would yield the greatest benefit in terms of malaria endemicity
and degree of other control measures. The design of the MDA
intervention needs to be adapted for its purpose during initial
stages of malaria control programmes, in order to aim for large
reductions in parasitaemia prevalence, or during latter stages to
clear remaining infections. Also, although there are theoretical
benefits to decreasing gametocyte carriage and thus transmission
with the use of an 8-aminoquinoline, the actual benefits of adding
it to a blood schizonticide, especially an ACT, need to be carefully
studied. Lastly, resistance monitoring should be integrated into
future MDA studies to understand better the impact of MDA on
the development of drug resistance, especially if used in a setting
of already failing drugs.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Archibald 1960 NGA
Methods Dates of study: 1957-1959
Location of study: Nigeria
Malaria endemicity (prevalence): Intervention group 1 (Arugungu - June 1958): 28%
in children 1-10 years; 29% in children 0-15 years [Moderate]. Intervention group 1
(Gulmare and Koei - October 1957): 64% in children 1-10 years; 58.3% in children 0-
15 years [High]
Transmission season: June to October
Malaria species: P. falciparum, P. malariae
Vector species: A. gambiae, A. funestus
Study design: Uncontrolled before-and-after study
Evaluation design: Cross-sectional surveys
Participants Age groups included: All ages
Sample size
Intervention group 1 (mean): 10,000
Intervention group 2 (mean): 1300
Interventions Intervention group 1 (Arugungu): MDA to all persons with chloroquine 600 mg and
pyrimethamine 25 mg given monthly from June to October 1958. Coverage not speci-
fied. Co-intervention with IRS
Intervention group 2 (Gulmare and Koei): MDA to all persons with chloroquine 600
mg and pyrimethamine 25 mg given every six months (November 1957, May 1958,
November 1958 and March 1959). Coverage not specified. Co-intervention with IRS
Outcomes Parasitaemia prevalence
Gametocytaemia prevalence
No adverse event surveillance conducted
Adverse events reported: “There were substantial difficulties with toddlers taking chloro-
quine and a number of them vomited that drug.”
Notes MDA added to IRS programme. The outcomes for intervention groups 1 and 2 were
assessed in a sub-sample of the treated population. A third intervention group received
only pyrimethamine 25 mg but was not included in the meta-analysis due to reports of
rapid development of resistance
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk No comparison group
Allocation concealment (selection bias) High risk No comparison group
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Archibald 1960 NGA (Continued)
Baseline imbalance (selection bias) High risk No comparison group
Contamination protection High risk No comparison group
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No comparison group
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No comparison group
Incomplete outcome data (attrition bias)
All outcomes
Low risk The highest number of confirmed ab-
sentees reported by the investigators in
September 1958 in Argungu was only 625
(6%)
Selective reporting (reporting bias) High risk The number of children examined varied
greatly between surveys without any expla-
nation and a very small number of children
were examined in Arugungu
Other bias High risk Anecdotes of ill effects began to circulate
and there was evidence of ’palming’ of
tablets
Cavalie 1962 CMR
Methods Dates of study: 1960-1961
Location of study: Cameroon
Malaria endemicity (prevalence): Intervention group 1: 20% in children 2-9 years [Mod-
erate]; 13% in all ages. Intervention group 2: 76% in children 2-9 years; 65% in all ages
[High]
Transmission season: May to June, November to December
Malaria species: P. falciparum, P. malariae
Vector species: A. gambiae, A. funestus
Study design: Uncontrolled before-and-after study
Evaluation design: Cross-sectional surveys
Participants Age groups included: Ages > 3 months
Sample size
Intervention group 1 (mean): 22,500
Intervention group 2 (mean): 7000
Interventions Intervention group 1 (Secteur Sud): MDA administered to all persons aged > 3 months
with chloroquine 600 mg and pyrimethamine 50 mg once for two rounds in July and
November 1960. Coverage 76-92%. Co-intervention with IRS using DDT
Intervention group 2 (Secteur Nord): MDA administered to all persons aged > 3 months
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Cavalie 1962 CMR (Continued)
with chloroquine 600 mg and pyrimethamine 50 mg once for one round in November
1960. Coverage approximately 100%. Co-intervention with IRS using DDT
Outcomes Parasitaemia prevalence
No adverse event surveillance conducted
No adverse events reported
Notes Data presented inTable XVwas used in themeta-analysis. Parasitaemia prevalence results
only presented for children > 3 months to 9 years of age; meta-analysis includes only
first round data. Only 13 mixed infections of P. falciparum and P. malariae were found.
The remaining were P. falciparum infections only.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk No comparison group
Allocation concealment (selection bias) High risk No comparison group
Baseline imbalance (selection bias) High risk No comparison group
Contamination protection High risk No comparison group
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No comparison group
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No comparison group
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient reporting of attrition/exclu-
sions to permit judgement. No reasons for
missing data provided
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judge-
ment
Other bias Low risk No other bias detected
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Comer 1971 PAN
Methods Dates of study: 1965-1968
Location of study: Panama
Malaria endemicity (prevalence): 17.4% in all ages [Moderate]
Transmission season: Rainy season late May to late December
Malaria species: P. falciparum, P. vivax
Vector species: Not specified
Study design: Uncontrolled before-and-after study
Evaluation design: Cross-sectional surveys
Participants Age groups included: Ages > 6 months
Sample size
Intervention group 1 mean (range): 1709 (1548 - 1908)
Interventions Intervention group 1 (Valle del Rio Sambu): MDA to all persons aged > 6 months with
pyrimethamine 50 mg (cycles 1-25)/ 75 mg (cycles 26-49) and primaquine 40 mg given
every 2 weeks for 2 years from August 1966 to April 1968. Coverage 61-87%. No co-
interventions
Outcomes Parasitaemia prevalence
No adverse event surveillance conducted
Adverse events reported: The acceptance of drugs by the population was excellent. Com-
plaints of nausea and headache were reported, but no other serious side effects were de-
scribed. None of the people who complained of headaches or nausea refused to take the
medicine in subsequent cycles. The number of people who refused to take the medicine
was < 1% of the population covered by the programme
Notes No post-intervention data
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk No comparison group
Allocation concealment (selection bias) High risk No comparison group
Baseline imbalance (selection bias) High risk No comparison group
Contamination protection High risk No comparison group
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No comparison group
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No comparison group
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Comer 1971 PAN (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Coupon system used to track patients; all
persons included in the surveys
Selective reporting (reporting bias) Low risk All intended outcomes reported
Other bias Low risk No other bias detected
Cáceres Garcia 2008 VEN
Methods Dates of study: 2002-2007
Location of study: Venezuela
Malaria endemicity (incidence): 22/1000 monthly incidence in all ages
Transmission season: November
Malaria species: P. vivax
Vector species: Not specified
Study design: Uncontrolled before-and-after study
Evaluation design: Passive surveillance
Participants Age groups included: Ages > 6 months; non-pregnant
Sample size
Intervention group 1: 25,722
Interventions Intervention group 1 (6 municipalities in Estado Sucre): MDA to all non-pregnant
persons aged >6 months with chloroquine 25 mg/kg administered over 3 days and
primaquine 3.5 mg/kg administered over 7 days in November 2002. Coverage 77% (of
census)/ 86% (of included). No co-intervention specified
Outcomes Parasitaemia incidence
No adverse event surveillance conducted
No adverse events reported
Notes MDA done in setting of an outbreak
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk No comparison group
Allocation concealment (selection bias) High risk No comparison group
Baseline imbalance (selection bias) High risk No comparison group
Contamination protection High risk No comparison group
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Cáceres Garcia 2008 VEN (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No comparison group
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No comparison group
Incomplete outcome data (attrition bias)
All outcomes
Low risk Passive surveillance of large municipalities
after one round of treatment
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Other bias Low risk No other bias detected
De Zulueta 1961 UGA
Methods Dates of study: 1959-1960
Location of study: Uganda
Malaria endemicity (prevalence): 34% in children 2-9 years; 17% in all ages [Moderate]
Transmission season: Rainy season April to May, August to November
Malaria species: P. falciparum, P. malariae
Vector species: A. gambiae, A. funestus
Study design: Uncontrolled before-and-after study
Evaluation design: Cross-sectional surveys
Participants Age groups included: All ages
Sample size
Intervention group 1 mean (range): 30,384 (10,303 - 59,605)
Interventions Intervention group 1 (NorthKigezi): MDA administered to all persons with chloroquine
600 mg and pyrimethamine 50 mg every three months for four rounds at the time of
IRS application from May 1959 to May 1960. Coverage 80%. Co-intervention with
IRS
Outcomes Parasitaemia prevalence
Gametocytaemia prevalence
No adverse event surveillance conducted
No adverse events reported
Notes Outcomes assessed in a sub-sample of the treated population.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk No comparison group
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De Zulueta 1961 UGA (Continued)
Allocation concealment (selection bias) High risk No comparison group
Baseline imbalance (selection bias) High risk No comparison group
Contamination protection High risk No comparison group
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No comparison group
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No comparison group
Incomplete outcome data (attrition bias)
All outcomes
Low risk Cooperation of the local inhabitants was
remarkably good and not a single dwelling
was left unsprayed
Selective reporting (reporting bias) Low risk Increased number of samples from hyper-
endemic areas in the post-intervention sur-
vey
Other bias Low risk No other bias detected
De Zulueta 1964 UGA
Methods Dates of study: 1960
Location of study: Uganda
Malaria endemicity (prevalence): 23% in children 2-9 years; 21% in all ages [Moderate]
Transmission season: Rainy season April to May, August to November
Malaria species: P. falciparum, P. malariae
Vector species: A. gambiae
Study design: Uncontrolled before-and-after study
Evaluation design: Cross-sectional surveys
Participants Age groups included: Ages > 3 months
Sample size
Intervention group 1 (mean): 16,000
Interventions Intervention group 1 (Lake Bunyonyi): MDA to all persons aged > 3 months with
chloroquine 600 mg and pyrimethamine 50 mg once per round for two rounds (April to
May 1960 and September to October 1960). Coverage approximately 50% in the first
round. Co-intervention with IRS
Outcomes Parasitaemia prevalence
No adverse event surveillance conducted
No adverse events reported
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De Zulueta 1964 UGA (Continued)
Notes Outcomes assessed in a sub-sample of the treated population. A. funestus disappeared
after one year of spraying and no new malaria cases were noted two years later
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk No comparison group
Allocation concealment (selection bias) High risk No comparison group
Baseline imbalance (selection bias) High risk No comparison group
Contamination protection High risk No comparison group
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No comparison group
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No comparison group
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient detail, but the total number
surveyed differs greatly between surveys
Selective reporting (reporting bias) Low risk All relevant outcomes were measured
Other bias High risk Only about half of the population was
given MDA during the first round
Escudie 1962 BFA
Methods Dates of study: 1960-1961
Location of study: Burkina Faso
Malaria endemicity (prevalence): Comparison group 1: 56.1% in children 0-10 years
[High]
Transmission season: June to December
Malaria species: P. falciparum, P. ovale, P. malariae
Vector species: A. gambiae, A. funestus, A. nili
Study design: Non-randomized controlled study
Evaluation design: Cross-sectional surveys
Participants Age group included: All ages
Sample size
Intervention group 1 (mean): 1890
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Escudie 1962 BFA (Continued)
Intervention group 2 (mean): 2560
Intervention group 3 (mean): 5400
Intervention group 4 (mean): 3490
Comparison group 1 (mean): Not described
Comparison group 2 (mean): Not described
Interventions Intervention group 1: MDA to all persons with a single dose of either chloroquine-
primaquine (600 mg/15 mg) or amodiaquine-primaquine (600 mg/15 mg) every 28
days from June to December 1960. Coverage 75.2 to 91.2%. No co-interventions
Intervention group 2: MDA to all persons with a single dose of either chloroquine-
primaquine (600 mg/15 mg) or amodiaquine-primaquine (600 mg/15 mg) every 14
days from June to December 1960. Coverage 84.1 to 96.5%. No co-interventions
Intervention group 3: MDA to all persons with a single dose of either chloroquine-
primaquine (600 mg/15 mg) or amodiaquine-primaquine (600 mg/15 mg) every 28
days from June to December 1960. Coverage 80.9 to 91.8%. Co-intervention with IRS
using DDT annually
Intervention group 4: MDA to all persons with a single dose of either chloroquine-
primaquine (600 mg/15 mg) or amodiaquine-primaquine (600 mg/15 mg) every 14
days from June to December 1960. Coverage 82.1 to 93.8%. Co-intervention with IRS
using DDT annually
Comparison group 1: Control villages. No co-interventions.
Comparison group 2: Villages sprayed with IRS using DDT annually. No other co-
interventions
Outcomes Parasitaemia prevalence
Gametocytaemia prevalence
No adverse event surveillance conducted
No adverse events reported
Notes Outcomes assessed in a sub-sample of the treated population (children 0-10 years).
Baseline data from June 1960 survey. Ninety percent of cases are P. falciparum infections;
P. ovale is rare and P. malariae is very rare.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Assignment to MDA was not randomized
although drug assignment was randomized
Allocation concealment (selection bias) High risk Non-randomized controlled study
Baseline imbalance (selection bias) High risk Baseline parasitaemia estimates are not bal-
anced between the intervention groups
and the comparison groups. Also, there
was large variability in endemicity between
comparison group 1 villages
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Escudie 1962 BFA (Continued)
Contamination protection Unclear risk Insufficient information to permit judge-
ment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Participants and personnel aware of treat-
ment, but unclear if this impacted out-
comes
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not blinded, but unclear if this impacted
outcomes
Incomplete outcome data (attrition bias)
All outcomes
Low risk Adults included in MDA, but not in the
evaluation. Only children 0-10 years of age
were examined in the malaria surveys be-
fore, during and after MDA
Selective reporting (reporting bias) Low risk All pre-specified outcomes of interest are
reported
Other bias Unclear risk Atypical seasonal changes experienced in
1959-1960, but it is unclear if these
changes impacted outcomes
Gabaldon 1959 VEN
Methods Dates of study: 1956-1957
Location of study: Venezuela
Malaria endemicity (incidence): 0.4/1000 baseline monthly incidence
Transmission season: May to November
Malaria species: P. vivax
Vector species: A. aquasalis, A. nuneztovari
Study design: Uncontrolled before-and-after study
Evaluation design: Active and passive surveillance
Participants Age groups included: Ages > 1 month
Sample size
Intervention group 1 (mean): 111,995
Interventions Intervention group 1: Eastern Venezuela (174 localities, 3084 houses, 16,416 persons)
and Western Venezuela (735 localities, 17,638 houses, 95,579 persons): MDA to all
persons aged > 1 month with pyrimethamine 50 mg per week for 24 weeks from July
1957 to December 1957. Coverage not specified. Co-intervention with IRS
Outcomes Parasitaemia incidence
No adverse event surveillance conducted
No adverse events reported
Notes MDA added to IRS program
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Gabaldon 1959 VEN (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk No comparison group
Allocation concealment (selection bias) High risk No comparison group
Baseline imbalance (selection bias) High risk No comparison group
Contamination protection High risk No comparison group
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No comparison group
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No comparison group
Incomplete outcome data (attrition bias)
All outcomes
Low risk All houses numbered. Envelope system for
drug dispensers and slide collectors. Coop-
eration of the people was excellent. Active
search for all infections and passive search
at all medical dispensaries in the area
Selective reporting (reporting bias) Low risk Most persons received more than 19 treat-
ments; however, the actual figures are not
reported due to “lack of mechanical tabu-
lation of the data”. The number of persons
with relapses who had less than 19 treat-
ments demonstrated similar trends to those
who received 19 or more treatments
Other bias Low risk No other bias detected
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Garfield 1983 NIC
Methods Dates of study: 1981-1982
Location of study: Nicaragua
Malaria endemicity (incidence): 0.4/1000 baseline monthly incidence
Transmission season: November to March
Malaria species: P. falciparum, P. vivax
Vector species: A. albimanus
Study design: Uncontrolled before-and-after study
Evaluation design: Passive surveillance
Participants Age groups included: Ages > 1 year
Sample size
Intervention group 1 (mean): 2,300,000
Interventions Intervention group 1: MDA administered to all persons aged > 1 year with chloroquine
1500 mg and primaquine 45 mg over three days given once to the entire population
of Nicaragua in November 1981. Coverage 70-80%. Co-intervention with larviciding
using large scale application of temephos to peridomiciliary breeding sites targeting Aedes
aegypti, but likely to have an effect on anophelines.
Outcomes Parasitaemia incidence
No adverse event surveillance conducted
Adverse events reported: Common side effects included dizziness, nausea, vomiting and
diarrhoea. Occasional cases of psychomotor disturbance, temporary psychological ab-
normalities and haemolysis
Notes Data used in the meta-analysis was extrapolated from graphs presented in the text;
baseline MDA estimates were determined using monthly surveillance data from 1974-
1981
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk No comparison group
Allocation concealment (selection bias) High risk No comparison group
Baseline imbalance (selection bias) High risk No comparison group
Contamination protection High risk No comparison group
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No comparison group
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No comparison group
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Garfield 1983 NIC (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Single treatment episode after conducting
a census, door-to-door education and pro-
motion of community participation
Selective reporting (reporting bias) Low risk National passive surveillance
Other bias Low risk No other bias detected
Gaud 1953 MAR
Methods Dates of study: 1952
Location of study: Morocco
Malaria endemicity (prevalence): 41.5% in all ages (baseline) [High]
Transmission season: June to October
Malaria species: P. falciparum, P. vivax
Vector species: Not specified
Study design: Uncontrolled before-and-after study
Evaluation design: Cross-sectional surveys
Participants Age groups included: All ages
Sample size:
Intervention group 1 (mean): 3000
Interventions Intervention group 1:MDA administered to all persons with amodiaquine 600 mg given
once in the summer of 1952. Coverage not specified. No co-interventions
Outcomes Parasitaemia prevalence
No adverse event surveillance conducted
No adverse events reported
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk No comparison group
Allocation concealment (selection bias) High risk No comparison group
Baseline imbalance (selection bias) High risk No comparison group
Contamination protection High risk No comparison group
Blinding of participants and personnel
(performance bias)
High risk No comparison group
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Gaud 1953 MAR (Continued)
All outcomes
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No comparison group
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judge-
ment
Other bias Low risk No other bias detected
Hii 1987 MYS
Methods Dates of study: 1984-1985
Location of study: Malaysia
Malaria endemicity (prevalence): Intervention group 1 (December 1984 baseline survey)
: 46.3% in children 0-8 years [High]; Intervention group 2 (December 1984 baseline
survey): 55.6% in children 0-8 years [High]
Transmission season: Perennial
Malaria species: P. falciparum, P. malariae, P. vivax
Vector species: A. balabacensis
Study design: Uncontrolled before-and-after study
Evaluation design: Cross-sectional surveys and active surveillance
Participants Age groups included: All ages
Sample size
Intervention group 1 (mean): 754
Intervention group 2 (mean): 148
Interventions Intervention group 1: MDA administered to all persons (139 households in five villages)
with sulfadoxine-pyrimethamine (1500 mg/75 mg) and primaquine 30 mg once in
December 1984 to January 1985. Coverage 87%. Co-intervention with permethrin-
impregnated bed nets to all households
Intervention group 2: MDA administered to all persons (nine households in one village)
with sulfadoxine-pyrimethamine (1500 mg/75 mg) and primaquine 30 mg once in
December 1984 to January 1985. Coverage 76%. No co-interventions
Outcomes Parasitaemia prevalence
Parasitaemia incidence
Gametocytaemia prevalence
No adverse event surveillance conducted
No adverse events reported
Notes Though the entire population was treated, thick and thin blood films were collected
during eight surveys on a population of 286 children aged 0-8 years. Only data for these
children were reported and therefore used in the meta-analysis. Furthermore, because
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Hii 1987 MYS (Continued)
the study design included a comparison group that received MDA, the intervention and
comparison groups will be treated as two intervention groups and each intervention
group will be analyzed in the meta-analysis as a separate uncontrolled before-and-after
study. Lastly, due to insufficient information to extract incidence data, parasitaemia
incidence was not included as an outcome in the meta-analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk No comparison group
Allocation concealment (selection bias) High risk No comparison group
Baseline imbalance (selection bias) High risk No comparison group
Contamination protection High risk No comparison group
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No comparison group
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No comparison group
Incomplete outcome data (attrition bias)
All outcomes
High risk Though the entire population was treated,
thick and thin blood films were collected
during eight surveys on a population of 286
children aged 0-8 years. Only 29.7% of
children were present at every one of the
eight sessions
Selective reporting (reporting bias) High risk The study report fails to include results on
P. vivax infections that would be expected
to have been reported for such a study. The
study methods indicate that thick blood
films will be classified as “positive or neg-
ative for asexual and/or sexual parasites of
either P. falciparum, P. vivax, P. malariae,
or mixed infections”. Only parasitological
findings for P. falciparum are described and
presented in detail.
Other bias Low risk With the exception of two study villages,
which are both intervention group 1 sites,
the study villages are “well separated and
demarcated”. Therefore, it is unlikely that
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Hii 1987 MYS (Continued)
contamination between sites occurred. All
villages also received the same treatment
dose and schedule. However, it should be
noted that in the meta-analysis, the two in-
terventions were analyzed as two separate
uncontrolled before-and-after studies
Houel 1954 MAR
Methods Dates of study: 1953
Location of study: Morocco
Malaria endemicity (prevalence): 14.3%, children only (August 1953 baseline survey)
[Moderate]
Transmission season: July to November
Malaria species: P. falciparum, P. malariae, P. vivax
Vector species: Not specified
Study design: Uncontrolled before-and-after study
Evaluation design: Cross-sectional surveys
Participants Age groups included: All ages
Sample size
Intervention group 1 (mean): 9999
Interventions Intervention group 1: MDA administered to all persons with pyrimethamine 100 mg
once in June 1953 to September 1953. Coverage not specified. Co-intervention with
IRS prior to MDA
Outcomes Parasitaemia prevalence
Gametocytaemia prevalence
No adverse event surveillance conducted
No adverse events reported
Notes Only results from the 147 children examined were included in the meta-analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk No comparison group
Allocation concealment (selection bias) High risk No comparison group
Baseline imbalance (selection bias) High risk No comparison group
Contamination protection High risk No comparison group
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Houel 1954 MAR (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No comparison group
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No comparison group
Incomplete outcome data (attrition bias)
All outcomes
High risk While adults were included in MDA, only
a subset of children were included in the
evaluation
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judge-
ment
Other bias High risk No data on coverage of intervention
Jones 1954 KEN
Methods Dates of study: 1952-1953
Location of study: Kenya
Malaria endemicity (prevalence): 34.8% (baseline survey in a random sample of adults
and infants); 32.6% (baseline survey in school children) [Moderate]
Transmission season: January to March, May to August
Malaria species: P. falciparum, P. malariae
Vector species: A. gambiae, A. funestus
Study design: Uncontrolled before-and-after study
Evaluation design: Cross-sectional surveys
Participants Age groups included: All ages
Sample size
Intervention group 1 (mean): 3721 (including 297 school children)
Interventions Intervention group 1:MDA administered to all persons inMakueni with pyrimethamine
100 mg once for three rounds in September 1952, March 1953 and September 1953.
Coverage not specified. No co-interventions
Outcomes Parasitaemia prevalence
No adverse event surveillance conducted
No adverse events reported
Notes Following the first MDA round, blood smears were taken from random samples of the
adult and infant (< 5 years) population and from all school children for a year. Due to
the high degree of resistance that developed following two MDA rounds, parasitaemia
prevalence results in the meta-analysis reflect only first round MDA results for infants
and adults
Risk of bias
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Jones 1954 KEN (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk No comparison group
Allocation concealment (selection bias) High risk No comparison group
Baseline imbalance (selection bias) High risk No comparison group
Contamination protection High risk No comparison group
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No comparison group
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No comparison group
Incomplete outcome data (attrition bias)
All outcomes
Low risk Individual data kept of all school children
and of all subjects with malaria attending
the dispensary
Selective reporting (reporting bias) Low risk Blood smears collected from random sam-
ples of adults and infants and of all school
children monthly for a year following the
first MDA round. All pre-specified out-
comes have been reported
Other bias High risk Complicated by resistance
Jones 1958 KEN
Methods Dates of study: 1952-1953
Location of study: Kenya
Malaria endemicity (prevalence): Intervention group 1 (September 1952): 60% in
school-age children; Comparison group 1 (September 1953): 34% in school-age chil-
dren [Moderate]
Transmission season: January to March, May to August
Malaria species: P. falciparum, P. malariae, P. vivax
Vector species: A. gambiae, A. funestus
Study design: Non-randomized controlled study
Evaluation design: Cross-sectional surveys
Participants Age groups included: All ages; school-age children
Sample size
Intervention group 1 (range): 3721-4500
Comparison group 1: Not specified
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Jones 1958 KEN (Continued)
Interventions Intervention group 1: MDA administered to all school children in Makueni with
pyrimethamine 100 mg for three rounds in September 1952, March 1953 and Septem-
ber 1953. Coverage not specified. No co-interventions
Comparison group 1: School children in Okia used as a comparison arm. No co-inter-
ventions
Outcomes Parasitaemia prevalence
Gametocytaemia prevalence
No adverse event surveillance conducted
No adverse events reported
Notes Outcome data for the intervention group is a subset of the Jones 1954 KEN study. The
meta-analysis only included first-round results. Gametocytaemia prevalence data is forP.
falciparum only.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Non-randomized controlled study
Allocation concealment (selection bias) High risk Non-randomized controlled study
Baseline imbalance (selection bias) High risk Baseline parasitaemia estimates are not bal-
anced between the intervention group and
the comparison group
Contamination protection Unclear risk Although the comparison group site was
13 miles from the intervention group site,
there is no indication whether the con-
trol group was adequately protected against
contamination. It is quite possible that the
control group received the intervention
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Participants and personnel aware of treat-
ment, but unclear if this impacted out-
comes
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not blinded, but unclear if this impacted
outcomes
Incomplete outcome data (attrition bias)
All outcomes
Low risk Individual data kept of all school-age chil-
dren and of all subjects with malaria at-
tending the dispensary. No antimalarials
were sold in local shops. At the end of the
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Jones 1958 KEN (Continued)
12th month of evaluation, 221 children re-
mained out of the original 297 children
Selective reporting (reporting bias) Low risk Blood smears from random samples and all
school-age children. Over the course of the
study, the school population rose by 178
children. To avoid confusion, the investi-
gators excluded these additional children
from the figures used to compile prevalence
and only reported data from the original
297 children
Other bias High risk Complicated by drug resistance
Kaneko 2000 VUT
Methods Dates of study: 1991-1999
Location of study: Vanuatu
Malaria endemicity (prevalence): Intervention group 1 (January - September 1991): 15.
7% in all ages; Comparison group 1 (May 1990): 28.8% in all ages [Moderate]
Transmission season: December to April
Malaria species:P. falciparum, P. vivax
Vector species: A. farauti
Study design: Non-randomized controlled study
Evaluation design: Cross-sectional surveys
Participants Age groups included: All ages
Sample size
Intervention group 1 (mean): 718
Comparison group 1 (mean): 19,289
Interventions Intervention group 1: MDA administered to all persons in Aneityum weekly for nine
weeks with chloroquine 600 mg and sulfadoxine-pyrimethamine 1500 mg/75 mg and
primaquine 45mg once aweek inweeks 1, 5, and 9; chloroquine 300mg and primaquine
45 mg once a week in weeks 2, 3, 4, 6, 7, and 8 in September 1991 to November 1991.
Coverage 79 to 92%. Co-intervention with larvivorous fish in several identified breeding
sites and universal coverage with insecticide treated bed nets (about 0.94 nets per villager)
Comparison group 1: Persons living in Malakula Island. Co-intervention with bed nets
(approximately 20% coverage)
Outcomes Parasitaemia prevalence
No adverse event surveillance conducted
Adverse events reported: Some villagers reported vomiting after taking the tablets
Notes Another village on Futana island was included in the study for comparison; however,
because no parasitaemia was detected in the two surveys on Futuna, it was excluded from
the meta-analysis. The meta-analysis only included data from Aneityum for the months
of January and September 1991 (before MDA) and March 1998 (post-MDA)
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Kaneko 2000 VUT (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Non-randomized controlled study
Allocation concealment (selection bias) High risk Non-randomized controlled study
Baseline imbalance (selection bias) Low risk According to investigators, “the parasite
rates were initially similar onAneityum and
Malakula islands and in general, decreased
with age”
Contamination protection Low risk The comparison group was a village from
Malakula, an adjacent island; therefore, it
is unlikely that the comparison group re-
ceived the intervention
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not blinded, but unclear if this impacted
outcomes
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not blinded, but unclear if this impacted
outcomes
Incomplete outcome data (attrition bias)
All outcomes
Low risk Only 7.9% of doses unable to be adminis-
tered and only 3.8% doses were not prop-
erly reported and could not be confirmed.
The overall calculated compliance rate of
the remaining doses was 88.3%
Selective reporting (reporting bias) High risk Of the 13 surveys, two covered only school
children whereas the other 11 surveys cov-
ered the entire population of Aneityum
Other bias Low risk No other bias detected
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Kligler 1931 PSE
Methods Dates of study: 1930
Location of study: Palestine (known as British Mandate Palestine at the time of the
study’s publication)
Malaria endemicity (prevalence): 35% in all ages; 67% in children 2-10 years [High]
Transmission season: October to December
Malaria species:P. falciparum, P. malariae, P. vivax
Vector species: A. elutus
Study design: Uncontrolled before-and-after study
Evaluation design: Cross-sectional surveys and active surveillance
Participants Age groups included: All ages
Sample size
Intervention group 1 mean (range): 953 (899-993)
Interventions Intervention group 1: MDA administered to all persons in five selected villages with
plasmochine 30 mg plus quinine 900 mg twice daily for five days every three weeks
for three rounds between September and November 1930. Coverage 78.8%. No co-
interventions
Outcomes Parasitaemia prevalence
Gametocytaemia prevalence
Adverse event surveillance conducted (active during the course of the treatment)
Adverse events reported: No ill results were noted during the entire course of treatment
Notes Noted that repeated treatments tended to increase resistance
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk No comparison group
Allocation concealment (selection bias) High risk No comparison group
Baseline imbalance (selection bias) High risk No comparison group
Contamination protection High risk No comparison group
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No comparison group
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No comparison group
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Kligler 1931 PSE (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk There was a large drop in the number of
villages surveyed from baseline to post-sur-
vey without any explanation
Selective reporting (reporting bias) High risk Five villages were treated but only select vil-
lages reported outcome data
Other bias Low risk No other bias detected
Kondrashin 1985 IND
Methods Dates of study: 1981
Location of study: India
Malaria endemicity (incidence): 4/1000 baseline monthly incidence
Transmission season; April to August
Malaria species: P. falciparum, P. vivax
Vector species: Not specified
Study design: Uncontrolled before-and-after study
Evaluation design: Passive surveillance
Participants Age groups included: All ages
Sample size
Intervention group 1 (mean): 51,325
Interventions Intervention group 1: MDA administered to all persons with chloroquine 600 mg (plus
primaquine 45 mg in falciparum areas only) for one round in March to May 1981 in
four primary health centres and two rounds in February to March 1981 and June to
September 1981 in four other primary health centres. Coverage 85%. Co-intervention
with IRS
Outcomes Parasitaemia incidence
No adverse event surveillance conducted
No adverse events reported
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk No comparison group
Allocation concealment (selection bias) High risk No comparison group
Baseline imbalance (selection bias) High risk No comparison group
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Kondrashin 1985 IND (Continued)
Contamination protection High risk No comparison group
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No comparison group
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No comparison group
Incomplete outcome data (attrition bias)
All outcomes
Low risk Only 1 or 2 rounds of treatment with 85%
coverage
Selective reporting (reporting bias) Unclear risk Nomention of the thoroughness of passive
surveillance
Other bias High risk A likely increase inP. falciparum due to
labour movement into treated area
Malaria˙Taiwan 1991 TWN
Methods Dates of study: 1955
Location of study: Taiwan
Malaria endemicity (prevalence): 4.12% in all ages (May 1955 survey); 2.93% in all ages
(November 1955) [Low]
Transmission season: Not described
Malaria species: P. falciparum, P. malariae, P. vivax
Vector species: A. maculatus, A. minimus, A. sinensis
Study design: Uncontrolled before-and-after study
Evaluation design: Cross-sectional surveys and passive surveillance
Participants Age groups included: All ages, except infants
Sample size
Intervention group 1 mean (range): 1520 (1502-1537)
Interventions Intervention group 1: MDA administered to all persons, except infants, in Lanyu with a
single dose of chloroquine (12 mg/kg) in November 1955. Coverage not specified. Co-
intervention with IRS using DDT
Outcomes Parasitaemia prevalence
No adverse event surveillance conducted
No adverse events reported
Notes Post-MDA (> 12 months) estimated using survey data from April-May 1957 and April
1960
Risk of bias
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Malaria˙Taiwan 1991 TWN (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk No comparison group
Allocation concealment (selection bias) High risk No comparison group
Baseline imbalance (selection bias) High risk No comparison group
Contamination protection High risk No comparison group
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No comparison group
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No comparison group
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient reporting of attrition/exclu-
sions to permit judgement
Selective reporting (reporting bias) Low risk The first three malariometric baseline sur-
veys reported consisted of only a portion
of the entire population on the island.
Subsequent surveys examined all inhabi-
tants. While these disproportionate sam-
ples could result in a certain biaswhen com-
pared to the remaining surveys that com-
prised the entire population, the investiga-
tors weighted the first three surveys accord-
ing to the natural distribution of the pop-
ulation
Other bias Low risk No other bias detected
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Metselaar 1961 PNG
Methods Dates of study: 1958-1959
Location of study: Papua New Guinea
Malaria endemicity (prevalence): 46-80% in children 2-11 years; 46% in all ages before
spraying [High]; During spraying 13-21% in children 2-11 years; 12% in all ages [Mod-
erate]
Transmission season: Not described
Malaria species: P. falciparum, P. malariae, P. vivax
Vector species: A. punctulatus, A. farauti, A. koliensis
Study design: Uncontrolled before-and-after study
Evaluation design: Cross-sectional surveys
Participants Age groups included: All ages
Sample size
Intervention group 1 (mean): 2500
Interventions Intervention group 1 (Sentani): MDA administered to all persons in sprayed areas with
chloroquine 450 mg plus pyrimethamine 50 mg at weekly intervals for five rounds in
1958 and for one round in 1959. Two villages with high absolute parasite rates received an
additional round of treatment in 1959. In addition, during all rounds, positives received
chloroquine for an additional three successive days, completing a full course (1350 mg
base for adults). Coverage 90%. Co-intervention with IRS
Outcomes Parasite prevalence
No adverse event surveillance conducted
No adverse events reported
Notes Baseline data from 1958 survey
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk No comparison group
Allocation concealment (selection bias) High risk No comparison group
Baseline imbalance (selection bias) High risk No comparison group
Contamination protection High risk No comparison group
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No comparison group
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No comparison group
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Metselaar 1961 PNG (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk 90% coverage, but no further description
Selective reporting (reporting bias) Unclear risk Selection for inclusion in surveys not de-
scribed
Other bias Low risk No other bias detected
Molineaux 1980 NGA
Methods Dates of study: 1970-1975
Location of study: Nigeria
Malaria endemicity (prevalence): 46% in all ages [High]
Transmission season: April to October
Malaria species: P. falciparum, P. malariae, P. ovale
Vector species: A. gambiae, A. funestus
Study design: Non-randomized controlled study
Evaluation design: Cross-sectional surveys and active surveillance
Participants Age groups included: All ages, but infants not included in MDA until their first malaria
episode
Sample size
Intervention group 1 (mean): 14,129
Intervention group 2 (mean): 1810
Comparison group 1 (mean): 32,828
Comparison group 2 (mean): ND
Interventions Intervention group 1 (Low frequency MDA+IRS group): MDA administered to all
ages, except for infants who have not had their first malaria episode, with sulfalene-
pyrimethamine 500 mg/25 mg every 10 weeks from April 1972 to October 1973. Cov-
erage 85%. Co-intervention with IRS using propoxur 3-4 rounds per year
Intervention group 2 (High frequency MDA+IRS group): MDA administered to all
ages, except for infants who have not had their first malaria episode, with sulfalene-
pyrimethamine 500 mg/25 mg every two weeks during the wet season and every 10
weeks during the dry season from April 1972 to October 1973. Coverage 85%. Co-
intervention with IRS using propoxur 3-4 rounds per year
Comparison group 1: IRS using propoxur 3-4 rounds per year.
Comparison group 2: No interventions.
Outcomes Parasitaemia prevalence
Gametocytaemia prevalence
Mortality
No adverse event surveillance conducted
No adverse events reported
Notes
Risk of bias
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Molineaux 1980 NGA (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Non-randomized controlled study
Allocation concealment (selection bias) High risk Non-randomized controlled study
Baseline imbalance (selection bias) Low risk Similiar malaria characteristics between
groups
Contamination protection Low risk It was desirable to allocate contiguous areas
to the same treatment and also to reduce
the effect of migrations by having similarly
treated buffer zones around the evaluation
villages
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Notmentionedbut unclear if this impacted
outcomes
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Independent reexamination of slides
Incomplete outcome data (attrition bias)
All outcomes
Low risk Operation aimed for total coverage
Selective reporting (reporting bias) Low risk The surveys covered the total de facto pop-
ulation of selected village clusters and all
possible outcomes measured and reported
Other bias Low risk No other bias detected
Najera 1973 NGA
Methods Dates of study: 1966-1968
Location of study: Nigeria
Malaria endemicity (prevalence): Comparison group 1: 28.9% in all ages [Moderate]
Transmission season: May to September
Malaria species: P. falciparum
Vector species: A. gambiae, A. funestus
Study design: Non-randomized controlled study (no post-intervention measurements)
Evaluation design: Cross-sectional surveys
Participants Age groups included: Ages > 3 months
Sample size
Intervention 1 mean (range): 52,000 (52,060 to 53,897)
Comparison 1 mean: 11,500
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Najera 1973 NGA (Continued)
Interventions Intervention group 1: MDA administered to all persons aged > 3 months with chloro-
quine 450 mg and pyrimethamine 45 mg every 60 days for 11 rounds from November
1966 to August 1968. Coverage 78 to 92%. Co-intervention with IRS
Comparison group 1: Co-intervention with IRS only. Coverage not described
Outcomes Parasitaemia prevalence
Gametocytaemia prevalence
Active adverse event surveillance conducted
Adverse events reported: Direct observation of 5003 treatments during MDA rounds 9
and 10 revealed 2% vomiting immediately after taking the drug. When a subset of the
population was asked about vomiting, 9% reported this symptom
Notes Data collected during rounds 2 to 11 are summarized as during MDA results. This is
problematic as the initial decline and later rise of cases during the two years of drug
administration is aggregated. Evaluation conducted in a subset of treated population
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Non-randomized controlled study
Allocation concealment (selection bias) High risk Non-randomized controlled study
Baseline imbalance (selection bias) High risk The comparison area was not comparable
to the intervention area in terms of ento-
mologic or parasitological parameters
Contamination protection Low risk Treated large peripheral zone, but evalua-
tion done in central zone only
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not blinded, but unclear if this impacted
outcomes
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not mentioned, but unclear if this im-
pacted outcomes
Incomplete outcome data (attrition bias)
All outcomes
Low risk Recorded census and population move-
ment without large loss to follow-up
Selective reporting (reporting bias) Low risk Random sampling of clusters of 200 people
for the parasitological surveys
Other bias Low risk No other bias detected
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Paik 1974a SLB
Methods Dates of study: 1972
Location of study: Solomon Islands (known as British Solomon Islands at the time of
the study’s publication)
Malaria endemicity (prevalence): 27.8% all ages (May 1972 survey) [Moderate]
Transmission season: Rainy season December to April
Malaria species: P. falciparum, P. vivax
Vector species:A. farauti
Study design: Uncontrolled before-and-after study
Evaluation design: Cross-sectional surveys, passive surveillance and active surveillance
Participants Age groups included: All ages
Sample size
Intervention group 1 (mean): Not specified
Interventions Intervention group 1 (Nggela archipelago): MDA administered to all persons with
chloroquine 600 mg and pyrimethamine 50 mg monthly for four months from July to
October 1972. Coverage 90%. Co-intervention with IRS
Outcomes Parasitaemia prevalence (includes both passive and active case detection for the period
during and after the intervention)
Parasitaemia incidence (population size not given)
No adverse event surveillance conducted
No adverse events reported
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk No comparison group
Allocation concealment (selection bias) High risk No comparison group
Baseline imbalance (selection bias) High risk No comparison group
Contamination protection High risk No comparison group
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No comparison group
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No comparison group
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient reporting of attrition/exclu-
sions to permit judgement
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Paik 1974a SLB (Continued)
Selective reporting (reporting bias) High risk Only 50% of children 2-9 years old in-
cluded in the pre-MDA and post-MDA
household surveys
Other bias High risk Baseline surveillance did not include active
case detection
Paik 1974b SLB
Methods Dates of study: 1972-1973
Location of study: Solomon Islands (known as British Solomon Islands at the time of
the study’s publication)
Malaria endemicity (incidence): 15/1000 baseline monthly incidence
Transmission season: Rainy season December to April
Malaria species: P. vivax, P. malariae
Vector species: A. farauti
Study design: Uncontrolled before-and-after study
Evaluation design: Passive surveillance
Participants Age groups included: All ages
Sample size
Intervention group 1 (mean): 1200
Interventions Intervention group 1 (Wagina and Shortland): MDA administered to all persons with
chloroquine 1500 mg and primaquine 75 mg over five days every three months for three
rounds from October 1972 to March 1973. Coverage 90%. No co-interventions
Outcomes Parasitaemia incidence
No adverse event surveillance conducted
No adverse events reported
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk No comparison group
Allocation concealment (selection bias) High risk No comparison group
Baseline imbalance (selection bias) High risk No comparison group
Contamination protection High risk No comparison group
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Paik 1974b SLB (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No comparison group
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No comparison group
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judge-
ment
Other bias Low risk No other bias detected
Ricosse 1959 BFA
Methods Dates of study: 1958-1959
Location of study: Burkina Faso
Malaria endemicity (prevalence): Intervention group 1 (March-May 1958 baseline sur-
vey): 15.3% in children 0-9 years [Moderate]; Intervention group 2 (March toMay 1958
baseline survey): 56.0% in children 0-9 years [High]
Transmission season: June to October
Malaria species: P. falciparum, P. malariae
Vector species: A. gambiae, A. funestus
Study design: Uncontrolled before-and-after study
Evaluation design: Cross-sectional surveys
Participants Age groups included: All ages
Sample size
Intervention group 1 (mean): 5000
Intervention group 2 (mean): 3000
Interventions Intervention group 1 (Zone A): MDA administered to all persons with pyrimethamine
50 mg every two weeks for eight rounds in June to September 1958. Coverage 82-91%.
Co-intervention with IRS using DDT
Intervention group 2 (Zone B): MDA administered to all persons with pyrimethamine
50 mg every two weeks for eight rounds in June to September 1958. Coverage 82-91%.
No co-interventions
Outcomes Parasitaemia prevalence
Gametocytaemia prevalence
No adverse event surveillance conducted
No adverse events reported
Notes Outcomes assessed in sub-sample of treated population (0-9 years). Data presented in
Table 1 was used in the meta-analysis
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Ricosse 1959 BFA (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk No comparison group
Allocation concealment (selection bias) High risk No comparison group
Baseline imbalance (selection bias) High risk No comparison group
Contamination protection High risk No comparison group
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No comparison group
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No comparison group
Incomplete outcome data (attrition bias)
All outcomes
High risk In Zone B, pyrimethamine distribution
stopped on September 20th and resumed
in October, so the study was unable to fol-
low the entire evolution of resistance that
apparently began during the fourth month
of distribution. Also, the method of selec-
tion of children 2-9 years is unclear. They
took monthly blood samples in all children
0-23 months, but due to the large sample
size selected only a proportion of children
2-9 years to examine
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judge-
ment
Other bias High risk Complicated by resistance in the fourth
month of MDA
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Roberts 1964 KEN
Methods Dates of study: 1953-1954
Location of study: Kenya
Malaria endemicity (prevalence): 28% in 1953 [Moderate] and 22% in 1954 [Moderate]
in all ages in Tiriki
Transmission season: May to July
Malaria species:P. falciparum, P. malariae
Vector species: A. gambiae, A. funestus
Study design: Non-randomized controlled study
Evaluation design: Cross-sectional surveys
Participants Age groups included: All ages
Sample size
Intervention group 1 (mean): 101,000
Intervention group 2 (mean): 99,000
Comparison group 1 (mean): Not specified
Comparison group 2 (mean): Not specified
Interventions Intervention group 1 (Nandi District 1953): MDA administered to all persons with
pyrimethamine 50 mg once in May 1953. Coverage 95%. No co-intervention
Intervention group 2 (Nandi District 1954): MDA administered to all persons with
pyrimethamine 50 mg once in May 1954. Coverage 95%. No co-intervention
Comparison group 1 (Tiriki control area 1953): No interventions
Comparison group 2 (Tiriki control area 1954): No interventions
Outcomes Parasitaemia prevalence
No adverse event surveillance conducted
No adverse events reported
Notes Intended to control epidemics.
In the methods, it states: “one hundred thick blood films were taken in treated and
untreated areas from persons in each of the age groups 0-10 years, 11-20 years, and 21
years and older”. Therefore, we assumed that the number of total patients examined
was 300 for both intervention and comparison groups to determine the number of cases
identified in our calculations for parasitaemia prevalence
Outcomes were assessed in a sub-sample of the treated population
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Non-randomized controlled study
Allocation concealment (selection bias) High risk Non-randomized controlled study
Baseline imbalance (selection bias) High risk Higher baseline parasitaemia in the control
area
Contamination protection Low risk Not described but trial area was very large
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Roberts 1964 KEN (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not blinded but unclear if this impacted
outcomes
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Notmentionedbut unclear if this impacted
outcomes
Incomplete outcome data (attrition bias)
All outcomes
Low risk All inhabitants living in the selected area
received treatment
Selective reporting (reporting bias) Unclear risk Unclear who or how many were included
in the malaria surveys
Other bias Low risk No other bias detected
Schneider 1961 BFA
Methods Dates of study: 1960-1961
Location of study: Burkina Faso
Malaria endemicity (prevalence): Comparison group 1 (baseline survey): 59.4% in chil-
dren 2-9 years [High]
Transmission season: August to September
Malaria species: P. falciparum, P. vivax
Vector species: Not described
Study design: Non-randomized controlled study (no pre-intervention measurements)
Evaluation design: Cross-sectional surveys
Participants Age groups included: All ages
Sample size
Intervention group 1 (mean): 2500
Intervention group 2 (mean): 3535
Comparison group 1 (mean): Not specified
Interventions Intervention group 1: MDA administered to all persons with a combination of 600 mg
base chloroquine or amodiaquine and 15 mg base primaquine every 14 days in June to
December 1960 for 15 rounds. No co-intervention. Coverage 90%
Intervention group 2: MDA administered to all persons with 600 mg base amodiaquine
and 15 mg base primaquine every 14 days in June to December 1960 for eight rounds.
Coverage not specified. Co-intervention with IRS using DDT once a year in May 1960
Comparison group1:Control zone free of any intervention (house spraying or treatment)
. Coverage not specified
Outcomes Parasitaemia prevalence
Gametocytaemia prevalence
No adverse event surveillance conducted
No adverse events reported
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Schneider 1961 BFA (Continued)
Notes Data on children 0-9 years were reported; however, data could only be abstracted for
2-9 years to draw appropriate comparisons. In addition, data for during MDA for the
intervention groups were estimated using only October 1960 survey data; during MDA
data for the comparison group was only provided for October 1960
Intervention sample size is based on the 2500 inhabitants of the three villages surveyed;
half were randomized to receive amodiaquine and primaquine while the other half re-
ceived chloroquine and primaquine
A third intervention group was treated with a combination of 600 mg base chloroquine
or amodiaquine and 15 mg base primaquine every 14 days in June to December 1960;
however, due to lack of detailed data presented, this group was not included in the meta-
analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Non-randomized controlled study
Allocation concealment (selection bias) High risk Non-randomized controlled study
Baseline imbalance (selection bias) Low risk Patient outcomes were measured prior to
the intervention. According to investiga-
tors, no important differences were present
across study groups
Contamination protection Unclear risk Insufficient information to permit judge-
ment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Incomplete outcome data (attrition bias)
All outcomes
High risk Adults were treated duringMDA, but were
not included in the evaluation
Selective reporting (reporting bias) High risk A monthly distribution schedule was also
administered in the study; however due to
the poor quality data, minimal results were
described
Other bias Unclear risk Insufficient information to permit judge-
ment
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Shekalaghe 2011 TZA
Methods Dates of study: 2008
Location of study: Tanzania
Malaria endemicity (prevalence): 0% in all ages [Low]
Transmission season: March to May, October to November
Malaria species: P. falciparum
Vector species: Not described
Study design: Cluster-randomized trial
Unit of randomization: Geographical clusters of households
Adjusted analyses for clustering: Yes
Adjustment method: Generalized estimating equations
ICC: Not described
Numbers of clusters: 16
Number of people: 3457
Average cluster size: 216
Evaluation design: Cross-sectional surveys, passive surveillance and active surveillance in
children
Participants Age groups included: Ages > 1 year, but individuals who had received a full dose of ACT
in the two weeks before the intervention were excluded
Sample size
Intervention group 1 (mean): 1110
Comparison group 1 (mean): 2347
Interventions Intervention group 1: MDA administered to all persons in eight clusters in four villages
in Lower Moshi with sulphadoxine-pyrimethamine (25 mg + 1.25 mg/kg as a single
dose on the first day) plus artesunate (4 mg/kg/day for three days) plus primaquine (0.
75 mg/kg as a single dose on the third day). Pregnant women received sulphadoxine-
pyrimethamine (25 mg + 1.25 mg/kg 25 mg + 1.25 mg/kg as a single dose on the first
day) plus amodiaquine (10 mg/kg once daily for three days). Anaemic individuals re-
ceived sulphadoxine-pyrimethamine (25 mg + 1.25 mg/kg 25 mg + 1.25 mg/kg as a
single dose on the first day) plus artesunate (4 mg/kg/day for three days). Coverage 93%.
Co-intervention with background bed net use (25.1% to 36.1%) and a single treatment
campaign for trachoma with azithromycin was undertaken by a non-governmental or-
ganisation
Comparison group 1: Placebo administered to all persons in eight clusters once daily
over three days. Coverage not described. Co-intervention with background bed net use
(25.1% to 36.1%) and a single treatment campaign for trachoma with azithromycin was
undertaken by a non-governmental organisation
Outcomes Parasitaemia prevalence
Gametocytaemia prevalence
Active adverse event surveillance with haemoglobin monitoring conducted in a subset
of the population
Adverse events reported: One individual was diagnosed with a severe skin reaction in the
week following MDA. Upon review, it was determined that the event was drug related.
A second individual presented with skin hyperpigmentation on the face, which was
determined unrelated to drug treatment. Both individuals were treated with steroids and
monitored until symptoms disappeared. In those given primaquine, moderate anaemia
(Hb level of <8 g/dL) was observed in 40% (6/15 individuals) of the G6PD A-, 11.
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Shekalaghe 2011 TZA (Continued)
1% (3/27 individuals) of the G6PD A, and 4.5% (18/399 individuals) of the G6PD B
individuals; one case of severe anaemia (Hb level of <5 g/dL) was observed
Notes The prevalence outcomes were assessed in a sub-sample of the treated population
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomized using computer generated
randomization tables
Allocation concealment (selection bias) Low risk Not described, but low risk with the ran-
domization of a small number of clusters
presumably by the investigator
Baseline imbalance (selection bias) Low risk Baseline demographic and malaria charac-
teristics were similar
Contamination protection Low risk Households that were located between
clusters (ie within 1 km distance from the
boundary of intervention and/or control
clusters) were considered as buffer zones.
Members of these households received the
intervention in order to minimize contam-
ination
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Placebo was used in the comparison arm
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The measurement of outcomes for inter-
vention and comparison arms were identi-
cal
Incomplete outcome data (attrition bias)
All outcomes
Low risk High coverage of intervention and popula-
tion movement monitored
Selective reporting (reporting bias) Low risk For each cross-sectional survey, individu-
als were randomly selected from computer-
generated random tables. All planned out-
come measures were reported
Other bias Low risk No other bias detected
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Simeons 1938 IND
Methods Dates of study: 1935
Location of study: India
Malaria endemicity (incidence): 156 cases/1000 baseline monthly incidence in all age
groups
Transmission season: March to August
Malaria species: P. vivax
Vector species: A. culicifacies
Study design: Uncontrolled before-and-after study
Evaluation design: Passive surveillance
Participants Age groups included: All ages
Sample size
Intervention group 1 (mean): 5650
Interventions Intervention group 1 (Mill Area): MDA administered to all persons with atebrin intra-
muscular 300 mg daily for 2 days and plasmochin simplex 60 mg daily for three days
once in May to June 1935. Coverage 100%. Co-intervention with oiling for larval con-
trol after MDA
Outcomes Parasitaemia incidence
Passive event surveillance conducted
Adverse events reported: Haemoglobinuria occurred in 4 cases (2 severe and died; 2
mild); three of the cases were from the same household and all were taking treatment for
syphilis. Fatal cases known to have syphilis and unlikely to be associated with atebrin;
although potentially associated with plasmochin. Abcesses reported in 49 small children
and weak adults. “Giddiness” reported with atebrin
Notes Baseline monthly incidence was estimated using survey data from May 1934 to April
1935 prior to MDA. Data used in the meta-analysis was extrapolated from graphs
presented in the text
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk No comparison group
Allocation concealment (selection bias) High risk No comparison group
Baseline imbalance (selection bias) High risk No comparison group
Contamination protection High risk No comparison group
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No comparison group
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Simeons 1938 IND (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No comparison group
Incomplete outcome data (attrition bias)
All outcomes
Low risk Every person in the Mill Area was treated;
extensive propaganda was carried out to
bring every fever case to the doctor
Selective reporting (reporting bias) Low risk Passive surveillance data for the entire pop-
ulation was reported
Other bias Low risk No other bias detected
Singh 1953 IND
Methods Dates of study: 1952-1953
Location of study: India
Malaria endemicity (prevalence): 22% in all ages [Moderate]
Transmission season: September to November
Malaria species: P. falciparum
Vector species: Not described
Study design: Non-randomized controlled study
Evaluation design: Cross-sectional surveys and active surveillance
Participants Age groups included: All ages
Sample size
Intervention group 1 (mean): 125
Comparison group 1 (mean): 55
Comparison group 2 (mean): 121
Interventions Intervention group 1: MDA administered to all persons with amodiaquine 600 mg every
two weeks for ten weeks starting in September 1952. Coverage not specified. No co-
interventions
Comparison group 1 (comparison groups 1 and 2 combined): Neighboring control area.
No co-interventions
Outcomes Parasitaemia prevalence
No adverse event surveillance conducted
No adverse events reported
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Non-randomized controlled study
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Singh 1953 IND (Continued)
Allocation concealment (selection bias) High risk Non-randomized controlled study; selec-
tion of villages were made after initial sur-
vey. Communication facilities were taken
into place to decide on the intervention
Baseline imbalance (selection bias) High risk Baseline malaria characteristics were simi-
lar to comparison group 2 but not to com-
parison group 1
Contamination protection High risk Incidence of malaria was so high that every
week large numbers of labourers were being
repatriated to their own villages
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not blinded, but unclear if this impacted
outcomes
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not blinded, but unclear if this impacted
outcomes
Incomplete outcome data (attrition bias)
All outcomes
High risk No description of intervention coverage
Selective reporting (reporting bias) Low risk Entire population surveyed
Other bias Low risk No other bias detected
Song 2010 KHM
Methods Dates of study: 2003-2006
Location of study: Cambodia
Malaria endemicity (prevalence): 55.8% in children < 16 years; 52.3% in all ages [High]
Transmission season: Not described
Malaria species: P. falciparum, P. malariae, P. vivax
Vector species: Not described
Study design: Uncontrolled before-and-after study
Evaluation design: Cross-sectional surveys
Participants Age groups included: All ages
Sample size
Intervention group 1 (mean): 3653
Intervention group 2 (mean): 2387
Interventions Intervention group 1 (Kampong Speu, 17 villages, single round): MDA administered to
all ages with artesunate 125 mg daily for two days, piperaquine 750 mg daily for two
days and primaquine 9 mg every 10 days for six months starting in December 2003.
Coverage not specified. No co-interventions
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Song 2010 KHM (Continued)
Intervention group 2 (Kampot, nine villages, two rounds on days 0 and 42): MDA
administered to all ages with artesunate 125 mg daily for two days and piperaquine 750
mg daily for two days given on days 0 and 42 and primaquine 9 mg every 10 days for
six months starting in December 2003 . Coverage not specified. No co-interventions
Outcomes Parasitaemia prevalence
Gametocytaemia prevalence
Passive event surveillance conducted
Adverse events reported: No adverse reactions reported to village malaria volunteers
Notes Kampot data was not included in meta-analysis as the denominator of children for the
outcome data was not provided
The outcomes were assessed in a sub-sample of the treated population
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk No comparison group
Allocation concealment (selection bias) High risk No comparison group
Baseline imbalance (selection bias) High risk No comparison group
Contamination protection High risk No comparison group
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No comparison group
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No comparison group
Incomplete outcome data (attrition bias)
All outcomes
High risk One village missing data from one year
Selective reporting (reporting bias) High risk Monitoring was different for the different
villages. Some villages had missing data
Other bias Low risk No other bias detected
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van Dijk 1961 PNG
Methods Dates of study: 1960
Location of study: Papua New Guinea
Malaria endemicity (prevalence): 38.6% in children 2-9 years (1959 survey); 18% in all
ages (1959 and 1960 surveys) [Moderate]
Transmission season: Not described
Malaria species:P. falciparum, P. malariae, P. vivax
Vector species: A. farauti
Study design: Uncontrolled before-and-after study
Evaluation design: Cross-sectional surveys
Participants Age groups included: All ages
Sample size
Intervention group 1 (mean): 1250
Interventions Intervention group 1: MDA administered to all persons with chloroquine (450 mg)
once every four weeks for 11 rounds. Coverage 97.2% (range 93.1% to 100%). Co-
intervention with mass treatment of filariasis with diethylcarbamazine
Outcomes Parasitaemia prevalence
Gametocytaemia prevalence
No adverse event surveillance conducted
No adverse events reported
Notes Before MDA estimates include data from June 1959 and January 1960 surveys (Tables
I and II). For intervention group 1, outcome estimates come from Table V
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk No comparison group
Allocation concealment (selection bias) High risk No comparison group
Baseline imbalance (selection bias) High risk No comparison group
Contamination protection High risk No comparison group
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No comparison group
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No comparison group
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van Dijk 1961 PNG (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk Nine positives were not included in the 0-
1 month post-MDA survey; they were not
present during the last distribution
Selective reporting (reporting bias) Low risk All pre-specified outcomes of interest have
been reported
Other bias Unclear risk Visitors to the village were also treated with
the group to which they were most closely
related. Persons who stayed only a few days
were not treated. However, it is unclear
whether this introduced bias
von Seidlein 2003 GMB
Methods Dates of study: 1999
Location of study: Gambia
Malaria endemicity: 42.9% in children ≤ 5 years [High]; describes 17-19% in all ages
but this data was not from this study
Transmission season: June to December
Malaria species: P. falciparum
Vector species: Not described
Study design: Cluster-randomized trial
Unit of randomization: Villages
Adjusted analyses for clustering: Yes
Adjustment method: Poisson regression model adjusting for population size
ICC: Not described
Number of clusters: 18 villages
Number of people: 3655
Average cluster size: 203
Feature: Matched villages
Evaluation design: Cross-sectional surveys, active surveillance and passive surveillance
Participants Age groups included: Ages > 6 months old; non-pregnant
A total of 16,442 people, of which 14,017 people (85%) where treated (placebo or
MDA) including the buffer zone
Sample size (of number evaluated)
Intervention group 1 (mean): 1969
Comparison group 1 (mean): 1686
Interventions Intervention group 1: MDA administered to all non-pregnant persons aged > 6 months
with sulfadoxine-pyrimethamine 1500 mg/75 mg and artesunate 200 mg once in June
1999. Coverage 89% in total population (90.8% in evaluated group). No co-interven-
tions
Comparison group 1: Placebo administered to all non-pregnant persons aged > 6months
once in June 1999. Coverage 89% in total population (89.6% in evaluated group). No
co-interventions
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von Seidlein 2003 GMB (Continued)
Outcomes Parasitaemia prevalence
Parasitaemia incidence
Gametocytaemia prevalence
Anaemia prevalence (defined as hematocrit < 33%)
Mortality
Passive and active adverse event surveillance conducted
Adverse events reported (passive surveillance system): 1 episode of pruritus
Adverse events reported (active surveillance system): 25 of 75 individuals remembered
one or more complaints within 2 days of taking the drug including dizziness (13), fever
(6), diarrhoea (5), vomiting (5) and itching (4)
Notes Incidence, gametocyte prevalence, anaemia prevalence and mortality reported for chil-
dren only
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk While the study is a cluster-randomized,
double blind, placebo-controlled trial, the
method of randomization is not described.
Author correspondence revealed that ran-
domization was computer generated
Allocation concealment (selection bias) Low risk Drugs allocated to each of the 18 study
villages were delivered to the study site in
identical containers. One nurse was aware
of the identity of the drugs, administered
the drugs in the study villages and then left
the study area
Baseline imbalance (selection bias) Low risk Intervention and control villages did not
differ appreciably in the demographic of
malaria transmission characteristics
Contamination protection Low risk All inhabitants of the non-randomized
controlled villages in the study area were
treated, tominimize possible dilutionof the
effect of the intervention
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Cluster-randomized,
double blind, placebo-controlled trial; nei-
ther study personnel nor the study popula-
tion were aware of which villages received
placebo
Blinding of outcome assessment (detection
bias)
Low risk Cluster-randomized, double blind,
placebo-controlled trial
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von Seidlein 2003 GMB (Continued)
All outcomes
Incomplete outcome data (attrition bias)
All outcomes
Low risk All children in the surveillance villages were
visited weekly; all 18 study villages that
were randomized were analyzed
Selective reporting (reporting bias) Low risk All primary and secondary endpoints re-
ported
Other bias Low risk No other bias detected
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abraham 1944 Inadequate treatment dose
Afridi 1959 Inadequate treatment dose
Ahorlu 2009 Treatment not administered to entire population; intermittent preventive treatment for children (IPTc)
study
Ahorlu 2011 Treatment not administered to entire population; intermittent preventive treatment for children (IPTc)
study
Aikins 1993 Inadequate treatment dose; knowledge, attitudes, and prevention component of an individually ran-
domized study
Alicata 1955 Inadequate treatment dose; individually randomized study
Aliev 2000 Inadequate treatment dose
Aliev 2001 Inadequate treatment dose
Allen 1990 Inadequate treatment dose
Alonso 1993a Inadequate treatment dose; individually randomized study
Alonso 1993b Inadequate treatment dose; individually randomized study
Alving 1952 Individually randomized study; study participants did not remain in endemic area
Amangel’diev 2001 Inadequate treatment dose; testing conducted prior to treatment; insufficient information on drug
administration
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(Continued)
Annual Report 1932 Inadequate treatment dose
Archambeault 1954 Study participants did not remain in endemic area
Archibald 1956 Individually randomized study
Babione 1966 Insufficient information on drug administration
Banerjea 1949 Inadequate treatment dose
Barber 1932 Inadequate treatment dose
Barger 2009 Individually randomized study
Baukapur 1984 Insufficient information on drug administration
Berberian 1948 Testing conducted prior to treatment
Berny 1936 Inadequate treatment dose
Bloch 1982 Insufficient information on drug administration
Bojang 2009 Insufficient information on outcomes reported
Bojang 2010 Individually randomized study
Bojang 2011 Insufficient information on outcomes reported
Boulanger 2009 Individually randomized study
Boulanger 2010 Individually randomized study
Brink 1958 Inadequate treatment dose
Butler 1943 Insufficient information on drug administration
Canet 1936 Inadequate treatment dose
Canet 1939 Insufficient information on outcomes reported
Canet 1949 Insufficient information on drug administration; insufficient information on outcomes reported (no
outcome of interest reported)
Canet 1952 Inadequate treatment dose
Canet 1953 Inadequate treatment dose
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(Continued)
Capponi 1953 Inadequate treatment dose
Celli 1914 Insufficient information on drug administration
Charles 1958 Individually randomized study; testing conducted prior to treatment
Charles 1960 Inadequate treatment dose
Charles 1962 Inadequate treatment dose
Chaudhuri 1950 Inadequate treatment dose
Chen 1999 Insufficient information on outcomes reported; treatment not administered to entire population
Cisse 2006 Individually randomized study
Cisse 2009 Treatment not administered to entire population; intermittent preventive treatment for children (IPTc)
study
Ciuca 1937 Mixed curative and prophylactic dosing
Clark 1942 Testing conducted prior to treatment
Clarke 2008 Treatment not administered to entire population; intermittent preventive treatment for children (IPTc)
study
Clyde 1958 Insufficient information on drug administration
Clyde 1961a Insufficient information on outcomes reported
Clyde 1961b Insufficient information on outcomes reported
Clyde 1962 Inadequate treatment dose
Coutinho 1962 Inadequate treatment dose
D’Anfreville 1930 Insufficient information on drug administration; insufficient information on outcomes reported (no
outcome of interest reported)
Danquah 2009 Individually randomized study
Dapeng 1996 Insufficient information on drug administration; insufficient information on outcomes reported
de Mello 1938 Inadequate treatment dose
Decourt 1935 Inadequate treatment dose; individually randomized study
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(Continued)
Decourt 1936 Inadequate treatment dose
Delmont 1981 Inadequate treatment dose; individually randomized study
Desowitz 1987 Insufficient information on drug administration
Diallo 1977 Inadequate treatment dose
Diallo 1983 Treatment not administered to entire population; intermittent preventive treatment in children (IPTc)
study
Dicko 2008 Individually randomized study; testing conducted prior to treatment
Dicko 2011 Individually randomized study
Dixon 1950 Inadeqaute treatment dose
Doi 1989 Individually randomized study; testing conducted prior to treatment
Dola 1974 Inadequate treatment dose
Doucet 1947 Inadequate treatment dose
Downs 1946 Study participants did not remain in endemic area
Dupoux 1937 Insufficient information on outcomes reported
Dupoux 1939 Inadequate treatment dose
Edeson 1957 Inadequate treatment dose
Farinaud 1934 Insufficient information on drug administration
Farinaud 1950 Inadequate treatment dose
Gaud 1949 Inadequate treatment dose
Gilroy 1952 Inadequate treatment dose
Gomez Mendoza 1960 Insufficient information on outcomes reported
Gribben 1933 Inadequate treatment dose
Gruer 1962 Insufficient information on drug administration; insufficient information on outcomes of interest
Gunther 1951 Inadequate treatment dose
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(Continued)
Gunther 1952 Mixed curative and prophylactic dosing
Gusmao 1970 Inadequate treatment dose; individually randomized study
Han 2006 Inadequate treatment dose
Harwin 1973 Individually randomized study
Henderson 1934 Mixed curative and prophylactic dosing
Ho 1965 Insufficient information on outcomes reported (no outcome of interest reported)
Houel 1954b Treatment not administered to entire population (children only)
Huehne 1971 Post-only outcomes reported
Janssens 1950 Inadequate treatment dose
Joncour 1956 Inadequate treatment dose
Kaneko 2010 Insufficient information on drug administration; insufficient information on outcomes reported
Karimov 2008 Inadequate treatment dose
Kingsbury 1931 Inadequate treatment dose
Klopfer 1949 Inadequate treatment dose
Komp 1935 Testing conducted prior to treatment
Konate 2011 Individually randomized study
Kweku 2008 Individually randomized study
Kweku 2009 Insufficient information on outcomes reported; comparison of delivery strategies; treatment not admin-
istered to entire population (both arms included intermittent preventive treatment in children (IPTc))
Lacroix 1952 Inadequate treatment dose
Lahon 1960 Inadequate treatment dose
Laing 1970 Testing conducted prior to treatment
Laing 1984 Inadequate treatment dose
Lakshmanacharyulu 1968 Insufficient information on drug administration
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Levenson 1943 Mixed curative and prophylactic dosing
Liljander 2010 Individually randomized study
Lui 1986 Mixed curative and prophylactic dosing
Lysenko 1960 Mixed curative and prophylactic dosing
MacCormack 1983 Inadequate treatment dose
Mackerras 1954 Inadequate treatment dose
Maiga 2009 Individually randomized study
Malaria Army 1934 Inadequate treatment dose; insufficient information on outcomes reported
Mason 1973 Insufficient information on drug administration
Mason 1977 Insufficient information on drug administration
Mastbaum 1957a Inadequate treatment dose
Mastbaum 1957b Inadequate treatment dose
McGregor 1966 Individually randomized study; testing conducted prior to treatment
Melik-Adamian 1938 Testing conducted prior to treatment
Mendez Galvan 1984 Insufficient information on drug administration; insufficient information on outcomes reported
Mercier 1953 Inadequate treatment dose
Merle 1955 Inadequate treatment dose; treatment not administered to entire population (eg intermittent preventive
treatment for children (IPTc))
Mezincesco 1935 Inadequate treatment dose
Miller 1955 Inadequate treatment dose; individually randomized study; treatment not administered to entire popu-
lation
Monteny 1960 Inadequate treatment dose
Mühlens 1913 Insufficient information on drug administration; insufficient information on outcomes of interest
Nakibuuka 2009 Individually randomized study; testing conducted prior to treatment
Nankabirwa 2010 Individually randomized study
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Nave 1973 Insufficient information on outcomes reported
Norman 1952 Inadequate treatment dose; insufficient information on outcomes of interest
Ntab 2007 Individually randomized study; insufficient information on outcomes reported
Omer 1978 Inadequate treatment dose
Onori 1972 Inadequate treatment dose
Ossi 1967 Insufficient information on outcomes reported
Ouedraogo 2010 Individually randomized study
Parrot 1937 Inadequate treatment dose
Parrot 1943 Inadequate treatment dose
Parrot 1944 Inadequate treatment dose
Parrot 1946 Inadequate treatment dose
Peters 1962 Inadequate treatment dose
Phillips 1954 Inadequate treatment dose
Pikul 1934 Insufficient information on outcomes reported
Pribadi 1986 Inadequate treatment dose
Prokopenko 1945 Inadequate treatment dose
Rachou 1965 Inadequate treatment dose
Rafi 1951 Inadequate treatment dose
Ray 1948 Inadequate treatment dose
Robin 1946 Testing conducted prior to treatment
Rodríguez 1994 Testing conducted prior to treatment
Rohner 2010 Individually randomized study
Saarinen 1987 Mixed curative and prophylactic dosing
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Salako 1990 Individually randomized study; testing conducted prior to treatment
Salihu 2000 Inadequate treatment dose
Santos 1993 Inadequate treatment dose
Schliessmann 1973 Insufficient information on outcomes reported
Schneider 1948a Inadequate treatment dose
Schneider 1948b Inadequate treatment dose
Schneider 1958 Inadequate treatment dose
Schneider 1962 Individually randomized study; treatment not administered to entire population (eg intermittent pre-
ventive treatment for children (IPTc))
Seckinger 1935 Inadequate treatment dose
Sehgal 1968 Insufficient information on drug administration
Sergent 1913 Inadequate treatment dose; insufficient information on outcomes reported
Sesay 2011 Individually randomized study
Shanks 1992 Inadequate treatment dose; individually randomized study; testing conducted prior to treatment
Shanks 1993 Individually randomized study; study participants did not remain in endemic area
Shanks 1995a Inadequate treatment dose; study participants did not remain in endemic area
Shanks 1995b Study participants did not remain in endemic area
Sheinker 1945 Testing conducted prior to treatment
Singh 1968 Insufficient information on outcomes reported
Snowden 2006 Insufficient information on drug administration; insufficient information on outcomes reported
Sokhna 2008 Individually randomized study
Sorel 1913 Insufficient information on drug administration
Srivastava 1950 Inadequate treatment dose
Strangeways-Dixon 1950 Inadequate treatment dose
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Strickland 1986 Testing conducted prior to treatment
Swellengrebel 1931 Inadequate treatment dose
Tagbor 2011 Treatment not administered to entire population; intermittent preventive treatment for children (IPTc)
study
Tine 2011 Treatment not administered to entire population; intermittent preventive treatment for children (IPTc)
study
Turner 1977 Insufficient information on outcomes reported
Usenbaev 2006 Insufficient information on drug administration
Usenbaev 2008 Insufficient information on drug administration
Van Dijk 1958 Inadequate treatment dose
Van Goor 1950 Inadequate treatment dose
Verhoef 2002 Individually randomized study
Villegas 2010 Testing conducted prior to treatment
Wallace 1936 Mixed curative and prophylactic dosing
Wallace 1954 Insufficient information on drug administration
Watkins 1987 Individually randomized; mixed curative and prophylactic dosing
White 1934 Inadequate treatment dose
White 1937 Mixed curative and prophylactic dosing
Winter 1934 Insufficient information on outcomes reported
Wone 1967 Inadequate treatment dose
Yip 1998 Insufficient information on outcomes reported
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D A T A A N D A N A L Y S E S
Comparison 1. MDA versus no MDA in areas of low endemicity (Stratified by study design)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Parasitaemia Prevalence:
Cluster-randomized trials
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 At baseline 1 496 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 <1 month post MDA 1 484 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
1.3 1-3 months post MDA 1 794 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
1.4 4-6 months post MDA 1 660 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2 Parasitaemia Prevalence:
Uncontrolled before-and-after
studies
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 <1 month post MDA 1 3039 Risk Ratio (M-H, Random, 95% CI) 0.27 [0.14, 0.50]
2.2 >12 months post MDA 1 3509 Risk Ratio (M-H, Random, 95% CI) 0.02 [0.00, 0.12]
3 Gametocytaemia Prevalence:
Cluster randomized trials
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 At baseline 1 496 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3.2 < 1 month post MDA 1 484 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3.3 1-3 months post MDA 1 794 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3.4 4-6 months post MDA 1 660 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 2. MDA versus no MDA in areas of moderate endemicity (Stratified by study design)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Parasitaemia Prevalence:
Non-randomized controlled
studies
4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 At baseline 4 3123 Risk Ratio (M-H, Random, 95% CI) 0.73 [0.43, 1.24]
1.2 During MDA 1 47014 Risk Ratio (M-H, Random, 95% CI) 0.27 [0.25, 0.28]
1.3 < 1 month post MDA 3 1934 Risk Ratio (M-H, Random, 95% CI) 0.03 [0.01, 0.08]
1.4 1-3 months post MDA 2 1557 Risk Ratio (M-H, Random, 95% CI) 0.15 [0.10, 0.23]
1.5 4-6 months post MDA 2 1610 Risk Ratio (M-H, Random, 95% CI) 0.18 [0.10, 0.33]
1.6 7-12 months post MDA 1 600 Risk Ratio (M-H, Random, 95% CI) 0.19 [0.11, 0.33]
2 Parasitaemia Prevalence:
Uncontrolled before-and-after
studies
7 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 During MDA 2 7965 Risk Ratio (M-H, Random, 95% CI) 0.17 [0.02, 1.47]
2.2 <1 month post MDA 3 3096 Risk Ratio (M-H, Random, 95% CI) 0.29 [0.17, 0.48]
2.3 1-3 months post MDA 4 7925 Risk Ratio (M-H, Random, 95% CI) 0.16 [0.08, 0.31]
2.4 4-6 months post MDA 2 3797 Risk Ratio (M-H, Random, 95% CI) 1.75 [0.41, 7.41]
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3 Gametocytaemia Prevalence:
Non-randomized controlled
studies
2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 At baseline 2 1622 Risk Ratio (M-H, Random, 95% CI) 1.40 [0.76, 2.57]
3.2 During MDA 1 47014 Risk Ratio (M-H, Random, 95% CI) 0.48 [0.42, 0.54]
3.3 <1 month post MDA 1 433 Risk Ratio (M-H, Random, 95% CI) 0.28 [0.10, 0.82]
3.4 1-3 months post MDA 1 357 Risk Ratio (M-H, Random, 95% CI) 0.17 [0.03, 0.86]
3.5 4-6 months post MDA 1 410 Risk Ratio (M-H, Random, 95% CI) 0.52 [0.24, 1.11]
4 Gametocytaemia Prevalence:
Uncontrolled before-and-after
studies
3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 <1 month post MDA 3 3096 Risk Ratio (M-H, Random, 95% CI) 0.47 [0.25, 0.87]
4.2 1-3 months post MDA 1 294 Risk Ratio (M-H, Random, 95% CI) 0.36 [0.12, 1.12]
4.3 4-6 months post MDA 1 204 Risk Ratio (M-H, Random, 95% CI) 0.35 [0.12, 1.01]
Comparison 3. MDA versus no MDA in areas of high endemicity (Stratified by study design)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Parasitaemia Prevalence:
Cluster-randomized trials
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 At baseline 1 1376 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.86, 1.10]
1.2 1-3 months post MDA 1 1800 Risk Ratio (M-H, Random, 95% CI) 0.82 [0.67, 1.01]
1.3 4-6 months post MDA 1 1089 Risk Ratio (M-H, Random, 95% CI) 1.16 [0.93, 1.44]
2 Parasitaemia Prevalence:
Non-randomized controlled
studies
3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 At baseline 3 9395 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.70, 1.00]
2.2 During MDA 3 12561 Risk Ratio (M-H, Random, 95% CI) 0.17 [0.11, 0.27]
2.3 1-3 months post MDA 2 7197 Risk Ratio (M-H, Random, 95% CI) 0.52 [0.33, 0.81]
3 Parasitaemia Prevalence:
Uncontrolled before-and-after
studies
7 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 During MDA 2 2011 Risk Ratio (M-H, Random, 95% CI) 0.10 [0.03, 0.34]
3.2 <1 month post MDA 4 3863 Risk Ratio (M-H, Random, 95% CI) 0.37 [0.28, 0.49]
3.3 1-3 months post MDA 4 5132 Risk Ratio (M-H, Random, 95% CI) 0.35 [0.15, 0.84]
3.4 4-6 months post MDA 3 2979 Risk Ratio (M-H, Random, 95% CI) 0.41 [0.24, 0.72]
3.5 7-12 months post MDA 1 75 Risk Ratio (M-H, Random, 95% CI) 0.72 [0.43, 1.20]
3.6 >12 months post MDA 1 2375 Risk Ratio (M-H, Random, 95% CI) 0.10 [0.07, 0.12]
4 Parasitaemia Incidence:
Cluster-randomized trials
1 Rate Ratio (Random, 95% CI) 0.84 [0.53, 1.32]
4.1 < 1 month post MDA 1 Rate Ratio (Random, 95% CI) 0.41 [0.23, 0.74]
4.2 1-3 months post MDA 1 Rate Ratio (Random, 95% CI) 1.03 [0.75, 1.41]
4.3 4-6 months post MDA 1 Rate Ratio (Random, 95% CI) 1.11 [0.84, 1.45]
5 Gametocytaemia Prevalence:
Cluster-randomized trials
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
5.1 At baseline 1 1376 Risk Ratio (M-H, Random, 95% CI) 0.66 [0.33, 1.29]
5.2 4-6 months post MDA 1 1414 Risk Ratio (M-H, Random, 95% CI) 1.07 [0.62, 1.85]
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6 Gametocytaemia Prevalence:
Non-randomized controlled
studies
3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
6.1 At baseline 3 9395 Risk Ratio (M-H, Random, 95% CI) 0.72 [0.55, 0.95]
6.2 During MDA 3 12561 Risk Ratio (M-H, Random, 95% CI) 0.17 [0.10, 0.28]
6.3 1-3 months post MDA 2 7197 Risk Ratio (M-H, Random, 95% CI) 0.55 [0.28, 1.07]
7 Gametocytaemia Prevalence:
Uncontrolled before-and-after
studies
5 Risk Ratio (M-H, Random, 95% CI) Subtotals only
7.1 During MDA 2 2011 Risk Ratio (M-H, Random, 95% CI) 0.35 [0.09, 1.40]
7.2 <1 month post MDA 3 2582 Risk Ratio (M-H, Random, 95% CI) 0.38 [0.13, 1.08]
7.3 1-3 months post MDA 2 1199 Risk Ratio (M-H, Random, 95% CI) 1.14 [0.64, 2.01]
7.4 4-6 months post MDA 2 2789 Risk Ratio (M-H, Random, 95% CI) 0.35 [0.10, 1.28]
7.5 7-12 months post MDA 1 75 Risk Ratio (M-H, Random, 95% CI) 0.86 [0.41, 1.79]
7.6 >12 months post MDA 1 2269 Risk Ratio (M-H, Random, 95% CI) 0.09 [0.05, 0.15]
8 Anaemia Prevalence:
Cluster-randomized trials
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
8.1 4-6 months post MDA 1 1414 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.75, 0.93]
9 Mortality: Cluster-randomized
trials
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
9.1 4-6 months post MDA 1 3655 Risk Ratio (M-H, Random, 95% CI) 1.43 [0.34, 5.96]
Comparison 4. MDA + vector control versus no intervention in areas of moderate endemicity (Stratified by study
design)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Parasitaemia Prevalence:
Non-randomized controlled
studies
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 At baseline 1 1080 Risk Ratio (M-H, Random, 95% CI) 2.09 [1.48, 2.98]
1.2 >12 months post MDA 1 1331 Risk Ratio (M-H, Random, 95% CI) 0.10 [0.05, 0.20]
2 Parasitaemia Prevalence:
Uncontrolled before-and-after
studies
4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 During MDA 2 2336 Risk Ratio (M-H, Random, 95% CI) 0.12 [0.02, 0.62]
2.2 <1 month post MDA 3 5006 Risk Ratio (M-H, Random, 95% CI) 0.06 [0.01, 0.33]
2.3 1-3 months post MDA 3 4724 Risk Ratio (M-H, Random, 95% CI) 0.14 [0.04, 0.57]
2.4 4-6 months post MDA 1 939 Risk Ratio (M-H, Random, 95% CI) 0.57 [0.39, 0.85]
2.5 >12 months post MDA 1 1758 Risk Ratio (M-H, Random, 95% CI) 0.00 [5.43, 0.03]
3 Gametocytaemia Prevalence:
Uncontrolled before-and-after
studies
2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 During MDA 2 4425 Risk Ratio (M-H, Random, 95% CI) 0.13 [0.06, 0.27]
3.2 < 1 month post MDA 1 1907 Risk Ratio (M-H, Random, 95% CI) 0.01 [6.21, 0.16]
3.3 1-3 months post MDA 1 1941 Risk Ratio (M-H, Random, 95% CI) 0.22 [0.11, 0.41]
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Comparison 5. MDA + vector control versus no intervention in areas of high endemicity (Stratified by study
design)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Parasitaemia Prevalence:
Non-randomized controlled
studies
3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 At baseline 3 8042 Risk Ratio (M-H, Random, 95% CI) 0.56 [0.37, 0.84]
1.2 During MDA 3 9493 Risk Ratio (M-H, Random, 95% CI) 0.10 [0.06, 0.16]
1.3 1-3 months post MDA 2 4455 Risk Ratio (M-H, Random, 95% CI) 0.12 [0.06, 0.23]
1.4 7-12 months post MDA 1 3154 Risk Ratio (M-H, Random, 95% CI) 0.60 [0.55, 0.67]
1.5 >12 months post MDA 1 3261 Risk Ratio (M-H, Random, 95% CI) 0.77 [0.70, 0.84]
2 Parasitaemia Prevalence:
Uncontrolled before-and-after
studies
2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 During MDA 2 5437 Risk Ratio (M-H, Random, 95% CI) 0.17 [0.09, 0.31]
2.2 1-3 months post MDA 2 5440 Risk Ratio (M-H, Random, 95% CI) 0.13 [0.01, 2.51]
2.3 4-6 months post MDA 1 415 Risk Ratio (M-H, Random, 95% CI) 0.83 [0.66, 1.04]
2.4 7-12 months post MDA 1 412 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.75, 1.16]
3 Gametocytaemia Prevalence:
Non-randomized controlled
studies
3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 At baseline 3 8042 Risk Ratio (M-H, Random, 95% CI) 0.53 [0.31, 0.90]
3.2 During MDA 3 9493 Risk Ratio (M-H, Random, 95% CI) 0.08 [0.03, 0.20]
3.3 1-3 months post MDA 2 4455 Risk Ratio (M-H, Random, 95% CI) 0.08 [0.05, 0.14]
3.4 7-12 months post MDA 1 3154 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.73, 1.05]
3.5 > 12 months post MDA 1 3261 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.81, 1.14]
4 Gametocytaemia Prevalence:
Uncontrolled before-and-after
studies
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 During MDA 1 437 Risk Ratio (M-H, Random, 95% CI) 0.29 [0.17, 0.50]
4.2 1-3 months post MDA 1 440 Risk Ratio (M-H, Random, 95% CI) 0.52 [0.34, 0.80]
4.3 4-6 months post MDA 1 415 Risk Ratio (M-H, Random, 95% CI) 0.76 [0.52, 1.12]
4.4 7-12 months post MDA 1 412 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.65, 1.33]
Comparison 6. Parasitaemia Incidence studies
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 MDA versus no MDA:
Uncontrolled before-and-after
studies
4 Rate Ratio (Random, 95% CI) Subtotals only
1.1 During MDA 3 Rate Ratio (Random, 95% CI) 0.29 [0.07, 1.14]
1.2 < 1 month post MDA 4 Rate Ratio (Random, 95% CI) 0.21 [0.05, 0.84]
1.3 1-3 months post MDA 4 Rate Ratio (Random, 95% CI) 0.61 [0.26, 1.40]
1.4 4-6 months post MDA 1 Rate Ratio (Random, 95% CI) 0.65 [0.41, 1.02]
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1.5 7-12 months post MDA 1 Rate Ratio (Random, 95% CI) 0.15 [0.07, 0.34]
1.6 >12 months post MDA 1 Rate Ratio (Random, 95% CI) 0.48 [0.42, 0.55]
2 MDA + vector control versus
no MDA: Uncontrolled
before-and-after studies
2 Rate Ratio (Random, 95% CI) Subtotals only
2.1 During MDA 2 Rate Ratio (Random, 95% CI) 0.92 [0.49, 1.75]
2.2 < 1 month post MDA 2 Rate Ratio (Random, 95% CI) 0.04 [8.50, 1.54]
2.3 1-3 months post MDA 2 Rate Ratio (Random, 95% CI) 0.08 [0.01, 0.98]
2.4 4-6 months post MDA 2 Rate Ratio (Random, 95% CI) 0.11 [0.01, 1.97]
2.5 7-12 months post MDA 2 Rate Ratio (Random, 95% CI) 0.16 [0.01, 3.10]
2.6 > 12 months post MDA 1 Rate Ratio (Random, 95% CI) 0.04 [0.03, 0.07]
Comparison 7. MDA versus no MDA in areas of moderate and high endemicity (Stratified by study design;
subgrouped by 8-aminoquinoline)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Parasitaemia Prevalence during
MDA
4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Non-randomized
controlled studies - with
8-aminoquinoline
2 6634 Risk Ratio (M-H, Random, 95% CI) 0.20 [0.12, 0.32]
1.2 Non-randomized
controlled studies - without
8-aminoquinoline
2 52941 Risk Ratio (M-H, Random, 95% CI) 0.16 [0.08, 0.31]
2 Parasitaemia Prevalence 1-3
months post MDA
4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Non-randomized
controlled studies - with
8-aminoquinoline
2 7197 Risk Ratio (M-H, Random, 95% CI) 0.52 [0.33, 0.81]
2.2 Non-randomized
controlled studies - without
8-aminoquinoline
2 1557 Risk Ratio (M-H, Random, 95% CI) 0.15 [0.10, 0.23]
3 Parasitaemia Prevalence during
MDA
4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Uncontrolled
before-and-after studies - with
8-aminoquinoline
1 2965 Risk Ratio (M-H, Random, 95% CI) 0.06 [0.03, 0.10]
3.2 Uncontrolled
before-and-after studies -
without 8-aminoquinoline
3 7011 Risk Ratio (M-H, Random, 95% CI) 0.17 [0.06, 0.51]
4 Parasitaemia Prevalence <1
month post MDA
7 Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 Uncontrolled
before-and-after studies - with
8-aminoquinoline
3 2650 Risk Ratio (M-H, Random, 95% CI) 0.42 [0.29, 0.61]
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4.2 Uncontrolled
before-and-after studies -
without 8-aminoquinoline
4 4309 Risk Ratio (M-H, Random, 95% CI) 0.29 [0.22, 0.38]
5 Parasitaemia Prevalence 1-3
months post MDA
7 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 Uncontrolled
before-and-after studies - with
8-aminoquinoline
1 98 Risk Ratio (M-H, Fixed, 95% CI) 0.65 [0.41, 1.01]
5.2 Uncontrolled
before-and-after studies -
without 8-aminoquinoline
6 12959 Risk Ratio (M-H, Fixed, 95% CI) 0.32 [0.29, 0.34]
6 Parasitaemia Prevalence 4-6
months post MDA
5 Risk Ratio (M-H, Random, 95% CI) Subtotals only
6.1 Uncontrolled
before-and-after studies - with
8-aminoquinoline
3 2979 Risk Ratio (M-H, Random, 95% CI) 0.41 [0.24, 0.72]
6.2 Uncontrolled
before-and-after studies -
without 8-aminoquinoline
2 3797 Risk Ratio (M-H, Random, 95% CI) 1.75 [0.41, 7.41]
Comparison 8. MDA versus no MDA for all endemicity levels (Stratified by study design; subgrouped by plas-
modium species)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Parasitaemia Prevalence at
baseline
2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Non-randomized
controlled studies - falciparum
2 1537 Risk Ratio (M-H, Random, 95% CI) 1.34 [1.03, 1.74]
1.2 Non-randomized
controlled studies - vivax
2 1537 Risk Ratio (M-H, Random, 95% CI) 3.84 [1.33, 11.04]
2 Parasitaemia Prevalence during
MDA
2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Uncontrolled
before-and-after studies -
falciparum
2 5561 Risk Ratio (M-H, Random, 95% CI) 0.40 [0.08, 1.97]
2.2 Uncontrolled
before-and-after studies - vivax
2 5561 Risk Ratio (M-H, Random, 95% CI) 0.60 [0.40, 0.90]
3 Parasitaemia Prevalence <1
month post MDA
5 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Non-randomized
controlled studies - falciparum
1 433 Risk Ratio (M-H, Random, 95% CI) 0.02 [0.00, 0.08]
3.2 Non-randomized
controlled studies - vivax
1 433 Risk Ratio (M-H, Random, 95% CI) 0.05 [0.00, 0.82]
3.3 Uncontrolled
before-and-after studies -
falciparum
4 7367 Risk Ratio (M-H, Random, 95% CI) 0.22 [0.18, 0.29]
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3.4 Uncontrolled
before-and-after studies - vivax
4 7367 Risk Ratio (M-H, Random, 95% CI) 0.50 [0.41, 0.61]
4 Parasitaemia Prevalence 1-3
months post MDA
3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 Non-randomized
controlled studies - falciparum
1 357 Risk Ratio (M-H, Random, 95% CI) 0.03 [0.01, 0.12]
4.2 Non-randomized
controlled studies - vivax
1 357 Risk Ratio (M-H, Random, 95% CI) 1.37 [0.46, 4.11]
4.3 Uncontrolled
before-and-after studies -
falciparum
2 5754 Risk Ratio (M-H, Random, 95% CI) 0.22 [0.09, 0.51]
4.4 Uncontrolled
before-and-after studies - vivax
2 5754 Risk Ratio (M-H, Random, 95% CI) 0.49 [0.32, 0.76]
5 Parasitaemia Prevalence 4-6
months post MDA
3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
5.1 Non-randomized
controlled studies - falciparum
1 410 Risk Ratio (M-H, Random, 95% CI) 0.22 [0.14, 0.33]
5.2 Non-randomized
controlled studies - vivax
1 410 Risk Ratio (M-H, Random, 95% CI) 0.81 [0.31, 2.08]
5.3 Uncontrolled
before-and-after studies -
falciparum
2 3642 Risk Ratio (M-H, Random, 95% CI) 0.40 [0.13, 1.23]
5.4 Uncontrolled
before-and-after studies - vivax
2 3642 Risk Ratio (M-H, Random, 95% CI) 0.31 [0.24, 0.39]
6 Parasitaemia Prevalence >12
months post MDA
3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
6.1 Non-randomized
controlled studies - falciparum
1 1331 Risk Ratio (M-H, Random, 95% CI) 0.01 [4.99, 0.13]
6.2 Non-randomized
controlled studies - vivax
1 1331 Risk Ratio (M-H, Random, 95% CI) 0.36 [0.15, 0.86]
6.3 Uncontrolled
before-and-after studies -
falciparum
2 5884 Risk Ratio (M-H, Random, 95% CI) 0.06 [0.04, 0.09]
6.4 Uncontrolled
before-and-after studies - vivax
2 5884 Risk Ratio (M-H, Random, 95% CI) 0.17 [0.12, 0.24]
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Analysis 1.1. Comparison 1 MDA versus no MDA in areas of low endemicity (Stratified by study design),
Outcome 1 Parasitaemia Prevalence: Cluster-randomized trials.
Review: Mass drug administration for malaria
Comparison: 1 MDA versus no MDA in areas of low endemicity (Stratified by study design)
Outcome: 1 Parasitaemia Prevalence: Cluster-randomized trials
Study or subgroup MDA No MDA Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 At baseline
Shekalaghe 2011 TZA (1) 0/284 0/212 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 284 212 0.0 [ 0.0, 0.0 ]
Total events: 0 (MDA), 0 (No MDA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
2 <1 month post MDA
Shekalaghe 2011 TZA 0/261 0/223 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 261 223 0.0 [ 0.0, 0.0 ]
Total events: 0 (MDA), 0 (No MDA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
3 1-3 months post MDA
Shekalaghe 2011 TZA 0/399 0/395 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 399 395 0.0 [ 0.0, 0.0 ]
Total events: 0 (MDA), 0 (No MDA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
4 4-6 months post MDA
Shekalaghe 2011 TZA 0/360 0/300 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 360 300 0.0 [ 0.0, 0.0 ]
Total events: 0 (MDA), 0 (No MDA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.0, df = -1 (P = 0.0), I2 =0.0%
0.01 0.1 1 10 100
Favours MDA Favours control
(1) Shekalaghe 2011 TZA: MDA (AS+SP+PQ once only) + low background ITN use vs placebo + low background ITN use
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Analysis 1.2. Comparison 1 MDA versus no MDA in areas of low endemicity (Stratified by study design),
Outcome 2 Parasitaemia Prevalence: Uncontrolled before-and-after studies.
Review: Mass drug administration for malaria
Comparison: 1 MDA versus no MDA in areas of low endemicity (Stratified by study design)
Outcome: 2 Parasitaemia Prevalence: Uncontrolled before-and-after studies
Study or subgroup MDA No MDA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 <1 month post MDA
Malaria˙Taiwan 1991 TWN (1) 12/1537 44/1502 100.0 % 0.27 [ 0.14, 0.50 ]
Subtotal (95% CI) 1537 1502 100.0 % 0.27 [ 0.14, 0.50 ]
Total events: 12 (MDA), 44 (No MDA)
Heterogeneity: not applicable
Test for overall effect: Z = 4.09 (P = 0.000044)
2 >12 months post MDA
Malaria˙Taiwan 1991 TWN 1/2007 44/1502 100.0 % 0.02 [ 0.00, 0.12 ]
Subtotal (95% CI) 2007 1502 100.0 % 0.02 [ 0.00, 0.12 ]
Total events: 1 (MDA), 44 (No MDA)
Heterogeneity: not applicable
Test for overall effect: Z = 4.03 (P = 0.000056)
Test for subgroup differences: Chi2 = 6.72, df = 1 (P = 0.01), I2 =85%
0.001 0.01 0.1 1 10 100 1000
Favours MDA Favours control
(1) Malaria˙Taiwan 1991 TWN: MDA (CQ once only) + IRS vs. IRS only baseline data
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Analysis 1.3. Comparison 1 MDA versus no MDA in areas of low endemicity (Stratified by study design),
Outcome 3 Gametocytaemia Prevalence: Cluster randomized trials.
Review: Mass drug administration for malaria
Comparison: 1 MDA versus no MDA in areas of low endemicity (Stratified by study design)
Outcome: 3 Gametocytaemia Prevalence: Cluster randomized trials
Study or subgroup MDA No MDA Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 At baseline
Shekalaghe 2011 TZA (1) 0/284 0/212 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 284 212 0.0 [ 0.0, 0.0 ]
Total events: 0 (MDA), 0 (No MDA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
2 < 1 month post MDA
Shekalaghe 2011 TZA 0/261 0/223 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 261 223 0.0 [ 0.0, 0.0 ]
Total events: 0 (MDA), 0 (No MDA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
3 1-3 months post MDA
Shekalaghe 2011 TZA 0/399 0/395 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 399 395 0.0 [ 0.0, 0.0 ]
Total events: 0 (MDA), 0 (No MDA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
4 4-6 months post MDA
Shekalaghe 2011 TZA 0/360 0/300 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 360 300 0.0 [ 0.0, 0.0 ]
Total events: 0 (MDA), 0 (No MDA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.0, df = -1 (P = 0.0), I2 =0.0%
0.01 0.1 1 10 100
Favours MDA Favours control
(1) Shekalaghe 2011 TZA: MDA (AS+SP+PQ once only) + low background ITN use vs. placebo+ low background ITN use
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Analysis 2.1. Comparison 2 MDA versus no MDA in areas of moderate endemicity (Stratified by study
design), Outcome 1 Parasitaemia Prevalence: Non-randomized controlled studies.
Review: Mass drug administration for malaria
Comparison: 2 MDA versus no MDA in areas of moderate endemicity (Stratified by study design)
Outcome: 1 Parasitaemia Prevalence: Non-randomized controlled studies
Study or subgroup MDA no MDA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 At baseline
Jones 1958 KEN (1) 178/297 54/160 21.0 % 1.78 [ 1.40, 2.25 ]
Singh 1953 IND (2) 18/125 39/176 18.2 % 0.65 [ 0.39, 1.08 ]
Roberts 1964 KEN (3) 47/300 83/300 20.3 % 0.57 [ 0.41, 0.78 ]
Roberts 1964 KEN (4) 30/300 67/300 19.5 % 0.45 [ 0.30, 0.67 ]
Najera 1973 NGA (5) 152/802 105/363 21.1 % 0.66 [ 0.53, 0.81 ]
Subtotal (95% CI) 1824 1299 100.0 % 0.73 [ 0.43, 1.24 ]
Total events: 425 (MDA), 348 (no MDA)
Heterogeneity: Tau2 = 0.34; Chi2 = 60.32, df = 4 (P<0.00001); I2 =93%
Test for overall effect: Z = 1.18 (P = 0.24)
2 During MDA
Najera 1973 NGA 4163/40950 2319/6064 100.0 % 0.27 [ 0.25, 0.28 ]
Subtotal (95% CI) 40950 6064 100.0 % 0.27 [ 0.25, 0.28 ]
Total events: 4163 (MDA), 2319 (no MDA)
Heterogeneity: not applicable
Test for overall effect: Z = 60.34 (P < 0.00001)
3 < 1 month post MDA
Singh 1953 IND 0/125 55/176 9.1 % 0.01 [ 0.00, 0.20 ]
Jones 1958 KEN 3/288 64/145 33.4 % 0.02 [ 0.01, 0.07 ]
Roberts 1964 KEN (6) 7/300 118/300 48.4 % 0.06 [ 0.03, 0.13 ]
Roberts 1964 KEN (7) 0/300 72/300 9.1 % 0.01 [ 0.00, 0.11 ]
Subtotal (95% CI) 1013 921 100.0 % 0.03 [ 0.01, 0.08 ]
Total events: 10 (MDA), 309 (no MDA)
Heterogeneity: Tau2 = 0.28; Chi2 = 4.60, df = 3 (P = 0.20); I2 =35%
Test for overall effect: Z = 7.60 (P < 0.00001)
4 1-3 months post MDA
Jones 1958 KEN 21/251 40/106 34.0 % 0.22 [ 0.14, 0.36 ]
Roberts 1964 KEN (8) 20/300 140/300 36.7 % 0.14 [ 0.09, 0.22 ]
Roberts 1964 KEN (9) 13/300 118/300 29.3 % 0.11 [ 0.06, 0.19 ]
0.001 0.01 0.1 1 10 100 1000
Favours MDA Favours control
(Continued . . . )
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(. . . Continued)
Study or subgroup MDA no MDA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 851 706 100.0 % 0.15 [ 0.10, 0.23 ]
Total events: 54 (MDA), 298 (no MDA)
Heterogeneity: Tau2 = 0.06; Chi2 = 4.02, df = 2 (P = 0.13); I2 =50%
Test for overall effect: Z = 9.21 (P < 0.00001)
5 4-6 months post MDA
Jones 1958 KEN 44/262 88/148 38.5 % 0.28 [ 0.21, 0.38 ]
Roberts 1964 KEN (10) 12/300 78/300 29.9 % 0.15 [ 0.09, 0.28 ]
Roberts 1964 KEN (11) 14/300 111/300 31.6 % 0.13 [ 0.07, 0.21 ]
Subtotal (95% CI) 862 748 100.0 % 0.18 [ 0.10, 0.33 ]
Total events: 70 (MDA), 277 (no MDA)
Heterogeneity: Tau2 = 0.20; Chi2 = 9.31, df = 2 (P = 0.01); I2 =79%
Test for overall effect: Z = 5.74 (P < 0.00001)
6 7-12 months post MDA
Roberts 1964 KEN (12) 15/300 78/300 100.0 % 0.19 [ 0.11, 0.33 ]
Subtotal (95% CI) 300 300 100.0 % 0.19 [ 0.11, 0.33 ]
Total events: 15 (MDA), 78 (no MDA)
Heterogeneity: not applicable
Test for overall effect: Z = 6.11 (P < 0.00001)
Test for subgroup differences: Chi2 = 45.96, df = 5 (P = 0.00), I2 =89%
0.001 0.01 0.1 1 10 100 1000
Favours MDA Favours control
(1) Jones 1958 KEN: MDA (Pyr every 6 months for 3 rounds) vs. no intervention
(2) Singh 1953 IND: MDA (AQ every 2 weeks for 5 rounds) vs. no intervention
(3) Roberts 1964 KEN: MDA (Pyr once only) vs. no intervention (1953 data)
(4) Roberts 1964 KEN: MDA (Pyr once only) vs. no intervention (1954 data)
(5) Najera 1973 NGA: MDA (CQ+Pyr every 2 months for 11 rounds ) + IRS vs. IRS only
(6) Roberts 1964: MDA (Pyr once only) vs. no intervention (1953 data)
(7) Roberts 1964: MDA (Pyr once only) vs. no intervention (1954 data)
(8) Roberts 1964 KEN: MDA (Pyr once only) vs. no intervention (1953 data)
(9) Roberts 1964 KEN: MDA (Pyr once only) vs. no intervention (1954 data)
(10) Roberts 1964 KEN: MDA (Pyr once only) vs. no intervention (1953 data)
(11) Roberts 1964 KEN: MDA (Pyr once only) vs. no intervention (1954 data)
(12) Roberts 1964 KEN: MDA (Pyr once only) vs. no intervention (1954 data)
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Analysis 2.2. Comparison 2 MDA versus no MDA in areas of moderate endemicity (Stratified by study
design), Outcome 2 Parasitaemia Prevalence: Uncontrolled before-and-after studies.
Review: Mass drug administration for malaria
Comparison: 2 MDA versus no MDA in areas of moderate endemicity (Stratified by study design)
Outcome: 2 Parasitaemia Prevalence: Uncontrolled before-and-after studies
Study or subgroup MDA no MDA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 During MDA
Metselaar 1961 PNG (1) 143/2500 300/2500 50.6 % 0.48 [ 0.39, 0.58 ]
Comer 1971 PAN (2) 16/1709 204/1256 49.4 % 0.06 [ 0.03, 0.10 ]
Subtotal (95% CI) 4209 3756 100.0 % 0.17 [ 0.02, 1.47 ]
Total events: 159 (MDA), 504 (no MDA)
Heterogeneity: Tau2 = 2.42; Chi2 = 64.99, df = 1 (P<0.00001); I2 =98%
Test for overall effect: Z = 1.61 (P = 0.11)
2 <1 month post MDA
Houel 1954 MAR (3) 8/147 21/147 24.1 % 0.38 [ 0.17, 0.83 ]
Archibald 1960 NGA (4) 14/300 23/79 30.1 % 0.16 [ 0.09, 0.30 ]
van Dijk 1961 PNG (5) 79/1280 196/1143 45.9 % 0.36 [ 0.28, 0.46 ]
Subtotal (95% CI) 1727 1369 100.0 % 0.29 [ 0.17, 0.48 ]
Total events: 101 (MDA), 240 (no MDA)
Heterogeneity: Tau2 = 0.14; Chi2 = 5.91, df = 2 (P = 0.05); I2 =66%
Test for overall effect: Z = 4.65 (P < 0.00001)
3 1-3 months post MDA
Jones 1954 KEN (6) 3/135 47/135 16.8 % 0.06 [ 0.02, 0.20 ]
Houel 1954 MAR 4/147 21/147 18.4 % 0.19 [ 0.07, 0.54 ]
Metselaar 1961 PNG 38/2500 300/2500 32.3 % 0.13 [ 0.09, 0.18 ]
Cavalie 1962 CMR (7) 45/1143 162/1218 32.5 % 0.30 [ 0.21, 0.41 ]
Subtotal (95% CI) 3925 4000 100.0 % 0.16 [ 0.08, 0.31 ]
Total events: 90 (MDA), 530 (no MDA)
Heterogeneity: Tau2 = 0.31; Chi2 = 17.04, df = 3 (P = 0.00069); I2 =82%
Test for overall effect: Z = 5.53 (P < 0.00001)
4 4-6 months post MDA
Archibald 1960 NGA 30/125 23/79 48.8 % 0.82 [ 0.52, 1.31 ]
Cavalie 1962 CMR 1130/2375 162/1218 51.2 % 3.58 [ 3.08, 4.15 ]
Subtotal (95% CI) 2500 1297 100.0 % 1.75 [ 0.41, 7.41 ]
Total events: 1160 (MDA), 185 (no MDA)
Heterogeneity: Tau2 = 1.06; Chi2 = 35.13, df = 1 (P<0.00001); I2 =97%
Test for overall effect: Z = 0.76 (P = 0.45)
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(1) Metselaar 1961 PNG: MDA (CQ+Pyr weekly for 6 rounds) +IRS vs. IRS only baseline data
(2) Comer 1971 PAN: MDA (Pyr+PQ every 2 weeks for 2 years) vs. baseline data
(3) Houel 1954 MAR: MDA (Pyr once only) + IRS vs. IRS only baseline data
(4) Archibald 1960 NGA: MDA (CQ+Pyr monthly for 5 rounds) + IRS vs. IRS only baseline data
(5) van Dijk 1961 PNG: MDA (CQ every four weeks for 11 rounds) vs. baseline data
(6) Jones 1954 KEN: MDA (Pyr every 6 months for 3 rounds) vs. baseline data
(7) Cavalie 1962 CMR: MDA (CQ+Pyr every 4 months for 2 rounds) + IRS vs. IRS only baseline data
Analysis 2.3. Comparison 2 MDA versus no MDA in areas of moderate endemicity (Stratified by study
design), Outcome 3 Gametocytaemia Prevalence: Non-randomized controlled studies.
Review: Mass drug administration for malaria
Comparison: 2 MDA versus no MDA in areas of moderate endemicity (Stratified by study design)
Outcome: 3 Gametocytaemia Prevalence: Non-randomized controlled studies
Study or subgroup MDA no MDA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 At baseline
Jones 1958 KEN (1) 27/297 7/160 37.9 % 2.08 [ 0.93, 4.67 ]
Najera 1973 NGA (2) 46/802 19/363 62.1 % 1.10 [ 0.65, 1.84 ]
Subtotal (95% CI) 1099 523 100.0 % 1.40 [ 0.76, 2.57 ]
Total events: 73 (MDA), 26 (no MDA)
Heterogeneity: Tau2 = 0.09; Chi2 = 1.71, df = 1 (P = 0.19); I2 =42%
Test for overall effect: Z = 1.07 (P = 0.28)
2 During MDA
Najera 1973 NGA 950/40950 295/6064 100.0 % 0.48 [ 0.42, 0.54 ]
Subtotal (95% CI) 40950 6064 100.0 % 0.48 [ 0.42, 0.54 ]
Total events: 950 (MDA), 295 (no MDA)
Heterogeneity: not applicable
Test for overall effect: Z = 11.35 (P < 0.00001)
3 <1 month post MDA
Jones 1958 KEN 5/288 9/145 100.0 % 0.28 [ 0.10, 0.82 ]
Subtotal (95% CI) 288 145 100.0 % 0.28 [ 0.10, 0.82 ]
Total events: 5 (MDA), 9 (no MDA)
0.01 0.1 1 10 100
Favours MDA Favours control
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(. . . Continued)
Study or subgroup MDA no MDA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Heterogeneity: not applicable
Test for overall effect: Z = 2.32 (P = 0.020)
4 1-3 months post MDA
Jones 1958 KEN 2/251 5/106 100.0 % 0.17 [ 0.03, 0.86 ]
Subtotal (95% CI) 251 106 100.0 % 0.17 [ 0.03, 0.86 ]
Total events: 2 (MDA), 5 (no MDA)
Heterogeneity: not applicable
Test for overall effect: Z = 2.15 (P = 0.032)
5 4-6 months post MDA
Jones 1958 KEN 12/262 13/148 100.0 % 0.52 [ 0.24, 1.11 ]
Subtotal (95% CI) 262 148 100.0 % 0.52 [ 0.24, 1.11 ]
Total events: 12 (MDA), 13 (no MDA)
Heterogeneity: not applicable
Test for overall effect: Z = 1.68 (P = 0.092)
Test for subgroup differences: Chi2 = 14.21, df = 4 (P = 0.01), I2 =72%
0.01 0.1 1 10 100
Favours MDA Favours control
(1) Jones 1958 KEN: MDA (Pyr every 6 months for 3 rounds) vs. no intervention
(2) Najera 1973 NGA: MDA (CQ+Pyr every 2 months for 11 rounds) + IRS vs. IRS only
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Analysis 2.4. Comparison 2 MDA versus no MDA in areas of moderate endemicity (Stratified by study
design), Outcome 4 Gametocytaemia Prevalence: Uncontrolled before-and-after studies.
Review: Mass drug administration for malaria
Comparison: 2 MDA versus no MDA in areas of moderate endemicity (Stratified by study design)
Outcome: 4 Gametocytaemia Prevalence: Uncontrolled before-and-after studies
Study or subgroup MDA no MDA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 <1 month post MDA
Houel 1954 MAR (1) 7/147 11/147 26.4 % 0.64 [ 0.25, 1.60 ]
Archibald 1960 NGA (2) 7/300 9/79 25.2 % 0.20 [ 0.08, 0.53 ]
van Dijk 1961 PNG (3) 37/1280 55/1143 48.4 % 0.60 [ 0.40, 0.90 ]
Subtotal (95% CI) 1727 1369 100.0 % 0.47 [ 0.25, 0.87 ]
Total events: 51 (MDA), 75 (no MDA)
Heterogeneity: Tau2 = 0.17; Chi2 = 4.33, df = 2 (P = 0.11); I2 =54%
Test for overall effect: Z = 2.39 (P = 0.017)
2 1-3 months post MDA
Houel 1954 MAR 4/147 11/147 100.0 % 0.36 [ 0.12, 1.12 ]
Subtotal (95% CI) 147 147 100.0 % 0.36 [ 0.12, 1.12 ]
Total events: 4 (MDA), 11 (no MDA)
Heterogeneity: not applicable
Test for overall effect: Z = 1.77 (P = 0.077)
3 4-6 months post MDA
Archibald 1960 NGA 5/125 9/79 100.0 % 0.35 [ 0.12, 1.01 ]
Subtotal (95% CI) 125 79 100.0 % 0.35 [ 0.12, 1.01 ]
Total events: 5 (MDA), 9 (no MDA)
Heterogeneity: not applicable
Test for overall effect: Z = 1.94 (P = 0.052)
Test for subgroup differences: Chi2 = 0.28, df = 2 (P = 0.87), I2 =0.0%
0.01 0.1 1 10 100
Favours MDA Favours control
(1) Houel 1954 MAR: MDA (Pyr once only) + IRS vs. IRS only baseline data
(2) Archibald 1960 NGA: MDA (CQ+Pyr monthly for 5 rounds) + IRS vs. IRS only baseline data
(3) van Dijk 1961 PNG: MDA (CQ every 4 weeks for 11 rounds) vs. baseline data
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Analysis 3.1. Comparison 3 MDA versus no MDA in areas of high endemicity (Stratified by study design),
Outcome 1 Parasitaemia Prevalence: Cluster-randomized trials.
Review: Mass drug administration for malaria
Comparison: 3 MDA versus no MDA in areas of high endemicity (Stratified by study design)
Outcome: 1 Parasitaemia Prevalence: Cluster-randomized trials
Study or subgroup MDA no MDA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 At baseline
von Seidlein 2003 GMB (1) 320/769 260/607 100.0 % 0.97 [ 0.86, 1.10 ]
Subtotal (95% CI) 769 607 100.0 % 0.97 [ 0.86, 1.10 ]
Total events: 320 (MDA), 260 (no MDA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.46 (P = 0.65)
2 1-3 months post MDA
von Seidlein 2003 GMB 134/894 165/906 100.0 % 0.82 [ 0.67, 1.01 ]
Subtotal (95% CI) 894 906 100.0 % 0.82 [ 0.67, 1.01 ]
Total events: 134 (MDA), 165 (no MDA)
Heterogeneity: not applicable
Test for overall effect: Z = 1.83 (P = 0.067)
3 4-6 months post MDA
von Seidlein 2003 GMB 131/543 114/546 100.0 % 1.16 [ 0.93, 1.44 ]
Subtotal (95% CI) 543 546 100.0 % 1.16 [ 0.93, 1.44 ]
Total events: 131 (MDA), 114 (no MDA)
Heterogeneity: not applicable
Test for overall effect: Z = 1.28 (P = 0.20)
Test for subgroup differences: Chi2 = 4.79, df = 2 (P = 0.09), I2 =58%
0.5 0.7 1 1.5 2
Favours MDA Favours control
(1) von Seidlein 2003 GMB: MDA (AS+SP once only) vs. placebo
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Analysis 3.2. Comparison 3 MDA versus no MDA in areas of high endemicity (Stratified by study design),
Outcome 2 Parasitaemia Prevalence: Non-randomized controlled studies.
Review: Mass drug administration for malaria
Comparison: 3 MDA versus no MDA in areas of high endemicity (Stratified by study design)
Outcome: 2 Parasitaemia Prevalence: Non-randomized controlled studies
Study or subgroup MDA no MDA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 At baseline
Schneider 1961 BFA (1) 131/390 129/217 14.4 % 0.57 [ 0.47, 0.67 ]
Escudie 1962 BFA (2) 243/380 78/139 14.6 % 1.14 [ 0.97, 1.34 ]
Escudie 1962 BFA (3) 262/1223 58/284 12.5 % 1.05 [ 0.81, 1.35 ]
Escudie 1962 BFA (4) 165/545 78/139 14.0 % 0.54 [ 0.44, 0.66 ]
Escudie 1962 BFA (5) 183/850 58/284 12.3 % 1.05 [ 0.81, 1.37 ]
Molineaux 1980 NGA (6) 525/1257 493/1004 16.1 % 0.85 [ 0.78, 0.93 ]
Molineaux 1980 NGA (7) 754/1679 493/1004 16.2 % 0.91 [ 0.84, 0.99 ]
Subtotal (95% CI) 6324 3071 100.0 % 0.84 [ 0.70, 1.00 ]
Total events: 2263 (MDA), 1387 (no MDA)
Heterogeneity: Tau2 = 0.05; Chi2 = 61.63, df = 6 (P<0.00001); I2 =90%
Test for overall effect: Z = 1.94 (P = 0.052)
2 During MDA
Escudie 1962 BFA (8) 122/420 338/467 14.7 % 0.40 [ 0.34, 0.47 ]
Schneider 1961 BFA 33/467 517/691 13.9 % 0.09 [ 0.07, 0.13 ]
Escudie 1962 BFA (9) 76/573 338/467 14.5 % 0.18 [ 0.15, 0.23 ]
Escudie 1962 BFA (10) 121/1171 318/837 14.6 % 0.27 [ 0.22, 0.33 ]
Escudie 1962 BFA (11) 41/704 318/837 14.0 % 0.15 [ 0.11, 0.21 ]
Molineaux 1980 NGA (12) 40/2099 380/1171 13.9 % 0.06 [ 0.04, 0.08 ]
Molineaux 1980 NGA (13) 109/1486 380/1171 14.5 % 0.23 [ 0.19, 0.28 ]
Subtotal (95% CI) 6920 5641 100.0 % 0.17 [ 0.11, 0.27 ]
Total events: 542 (MDA), 2589 (no MDA)
Heterogeneity: Tau2 = 0.37; Chi2 = 173.71, df = 6 (P<0.00001); I2 =97%
Test for overall effect: Z = 7.51 (P < 0.00001)
3 1-3 months post MDA
Escudie 1962 BFA (14) 382/634 250/382 20.4 % 0.92 [ 0.84, 1.01 ]
Escudie 1962 BFA (15) 136/384 250/382 20.1 % 0.54 [ 0.46, 0.63 ]
Schneider 1961 BFA 286/466 386/534 20.4 % 0.85 [ 0.78, 0.93 ]
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(. . . Continued)
Study or subgroup MDA no MDA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Escudie 1962 BFA (16) 61/1025 303/972 19.2 % 0.19 [ 0.15, 0.25 ]
Escudie 1962 BFA (17) 196/1446 303/972 20.0 % 0.43 [ 0.37, 0.51 ]
Subtotal (95% CI) 3955 3242 100.0 % 0.52 [ 0.33, 0.81 ]
Total events: 1061 (MDA), 1492 (no MDA)
Heterogeneity: Tau2 = 0.25; Chi2 = 231.04, df = 4 (P<0.00001); I2 =98%
Test for overall effect: Z = 2.90 (P = 0.0038)
Test for subgroup differences: Chi2 = 40.98, df = 2 (P = 0.00), I2 =95%
0.002 0.1 1 10 500
Favours MDA Favours control
(1) Schneider 1961 BFA: MDA (AQ+PQ or CQ+PQ every 2 weeks for 15 rounds) vs. no intervention
(2) Escudie 1962 BFA: MDA (CQ+PQ or AQ+PQ every 28 days for 8 rounds) vs. no intervention
(3) Escudie 1962 BFA: MDA (CQ+PQ or AQ+PQ every 28 days for 8 rounds) + IRS vs. IRS only
(4) Escudie 1962 BFA: MDA (CQ+PQ or AQ+PQ every 14 days for 15 rounds) vs. no intervention
(5) Escudie 1962 BFA: MDA (CQ+PQ or AQ+PQ every 14 days for 15 rounds) + IRS vs. IRS only
(6) Molineaux 1980 NGA: MDA (SP every 10 weeks for 3 rounds) + IRS vs. IRS only
(7) Molineaux 1980 NGA: MDA (SP every 2 weeks during the wet season and 10 weeks during the dry season) + IRS vs. IRS only
(8) Escudie 1962 BFA: MDA (CQ+PQ or AQ+PQ every 28 days for 8 rounds) vs. no intervention
(9) Escudie 1962 BFA: MDA (CQ+PQ or AQ+PQ every 14 days for 15 rounds) vs. no intervention
(10) Escudie 1962 BFA: MDA (CQ+PQ or AQ+PQ every 28 days for 8 rounds) + IRS vs. IRS only
(11) Escudie 1962 BFA: MDA (CQ+PQ or AQ+PQ every 14 days for 15 rounds) + IRS vs. IRS only
(12) Molineaux 1980 NGA: MDA (SP every 2 weeks during the wet season and 10 weeks during the dry season) + IRS vs. IRS only
(13) Molineaux 1980 NGA: MDA (SP every 10 weeks for 3 rounds) + IRS vs. IRS only
(14) Escudie 1962 BFA: MDA (CQ+PQ or AQ+PQ every 14 days for 15 rounds) vs. no intervention
(15) Escudie 1962 BFA: MDA (CQ+PQ or AQ+PQ every 28 days for 8 rounds) vs. no intervention
(16) Escudie 1962 BFA: MDA (CQ+PQ or AQ+PQ every 14 days for 15 rounds) + IRS vs. IRS only
(17) Escudie 1962 BFA: MDA (CQ+PQ or AQ+PQ every 28 days for 8 rounds) + IRS vs. IRS only
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Analysis 3.3. Comparison 3 MDA versus no MDA in areas of high endemicity (Stratified by study design),
Outcome 3 Parasitaemia Prevalence: Uncontrolled before-and-after studies.
Review: Mass drug administration for malaria
Comparison: 3 MDA versus no MDA in areas of high endemicity (Stratified by study design)
Outcome: 3 Parasitaemia Prevalence: Uncontrolled before-and-after studies
Study or subgroup MDA no MDA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 During MDA
Ricosse 1959 BFA (1) 12/409 315/563 48.1 % 0.05 [ 0.03, 0.09 ]
Archibald 1960 NGA (2) 51/502 313/537 51.9 % 0.17 [ 0.13, 0.23 ]
Subtotal (95% CI) 911 1100 100.0 % 0.10 [ 0.03, 0.34 ]
Total events: 63 (MDA), 628 (no MDA)
Heterogeneity: Tau2 = 0.77; Chi2 = 16.14, df = 1 (P = 0.00006); I2 =94%
Test for overall effect: Z = 3.64 (P = 0.00027)
2 <1 month post MDA
Kligler 1931 PSE (3) 66/470 221/635 25.7 % 0.40 [ 0.31, 0.52 ]
Ricosse 1959 BFA 103/650 315/563 28.1 % 0.28 [ 0.23, 0.34 ]
Hii 1987 MYS (4) 17/44 25/45 17.0 % 0.70 [ 0.44, 1.10 ]
Song 2010 KHM (5) 136/777 379/679 29.2 % 0.31 [ 0.27, 0.37 ]
Subtotal (95% CI) 1941 1922 100.0 % 0.37 [ 0.28, 0.49 ]
Total events: 322 (MDA), 940 (no MDA)
Heterogeneity: Tau2 = 0.06; Chi2 = 15.64, df = 3 (P = 0.001); I2 =81%
Test for overall effect: Z = 7.17 (P < 0.00001)
3 1-3 months post MDA
Gaud 1953 MAR (6) 185/1527 634/1527 25.6 % 0.29 [ 0.25, 0.34 ]
Ricosse 1959 BFA 241/538 315/563 25.6 % 0.80 [ 0.71, 0.90 ]
Cavalie 1962 CMR (7) 31/466 265/413 24.7 % 0.10 [ 0.07, 0.15 ]
Hii 1987 MYS 19/53 25/45 24.1 % 0.65 [ 0.41, 1.01 ]
Subtotal (95% CI) 2584 2548 100.0 % 0.35 [ 0.15, 0.84 ]
Total events: 476 (MDA), 1239 (no MDA)
Heterogeneity: Tau2 = 0.76; Chi2 = 220.30, df = 3 (P<0.00001); I2 =99%
Test for overall effect: Z = 2.35 (P = 0.019)
4 4-6 months post MDA
Kligler 1931 PSE 50/131 61/70 35.0 % 0.44 [ 0.35, 0.55 ]
Hii 1987 MYS 12/30 25/45 28.4 % 0.72 [ 0.43, 1.20 ]
Song 2010 KHM 212/1609 572/1094 36.6 % 0.25 [ 0.22, 0.29 ]
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Study or subgroup MDA no MDA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 1770 1209 100.0 % 0.41 [ 0.24, 0.72 ]
Total events: 274 (MDA), 658 (no MDA)
Heterogeneity: Tau2 = 0.21; Chi2 = 28.78, df = 2 (P<0.00001); I2 =93%
Test for overall effect: Z = 3.14 (P = 0.0017)
5 7-12 months post MDA
Hii 1987 MYS 12/30 25/45 100.0 % 0.72 [ 0.43, 1.20 ]
Subtotal (95% CI) 30 45 100.0 % 0.72 [ 0.43, 1.20 ]
Total events: 12 (MDA), 25 (no MDA)
Heterogeneity: not applicable
Test for overall effect: Z = 1.26 (P = 0.21)
6 >12 months post MDA
Song 2010 KHM 64/1281 572/1094 100.0 % 0.10 [ 0.07, 0.12 ]
Subtotal (95% CI) 1281 1094 100.0 % 0.10 [ 0.07, 0.12 ]
Total events: 64 (MDA), 572 (no MDA)
Heterogeneity: not applicable
Test for overall effect: Z = 18.75 (P < 0.00001)
Test for subgroup differences: Chi2 = 87.36, df = 5 (P = 0.00), I2 =94%
0.01 0.1 1 10 100
Favours MDA Favours control
(1) Ricosse 1959 BFA: MDA (Pyr every 2 weeks for 8 rounds) vs. baseline data
(2) Archibald 1960 NGA: MDA (CQ+Pyr every 6 months for 4 rounds) + IRS vs. IRS only baseline data
(3) Kligler 1931 PSE: MDA (Plas+Q every 3 weeks for 3 rounds) vs. baseline data
(4) Hii 1987 MYS: MDA (SP+PQ once only) vs. baseline data
(5) Song 2010 KHM: MDA (AS+Pip once only plus PQ every 10 days for 6 months) vs. baseline data
(6) Gaud 1953 MAR: MDA (AQ once only) vs. baseline data
(7) Cavalie 1962 CMR: MDA (CQ+Pyr once only) + IRS vs. IRS only baseline data
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Analysis 3.4. Comparison 3 MDA versus no MDA in areas of high endemicity (Stratified by study design),
Outcome 4 Parasitaemia Incidence: Cluster-randomized trials.
Review: Mass drug administration for malaria
Comparison: 3 MDA versus no MDA in areas of high endemicity (Stratified by study design)
Outcome: 4 Parasitaemia Incidence: Cluster-randomized trials
Study or subgroup log [Rate Ratio] Rate Ratio Weight Rate Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 < 1 month post MDA
von Seidlein 2003 GMB (1) -0.89 (0.3) 25.4 % 0.41 [ 0.23, 0.74 ]
Subtotal (95% CI) 25.4 % 0.41 [ 0.23, 0.74 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.97 (P = 0.0030)
2 1-3 months post MDA
von Seidlein 2003 GMB 0.03 (0.16) 36.5 % 1.03 [ 0.75, 1.41 ]
Subtotal (95% CI) 36.5 % 1.03 [ 0.75, 1.41 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.19 (P = 0.85)
3 4-6 months post MDA
von Seidlein 2003 GMB 0.1 (0.14) 38.1 % 1.11 [ 0.84, 1.45 ]
Subtotal (95% CI) 38.1 % 1.11 [ 0.84, 1.45 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.71 (P = 0.48)
Total (95% CI) 100.0 % 0.84 [ 0.53, 1.32 ]
Heterogeneity: Tau2 = 0.12; Chi2 = 9.22, df = 2 (P = 0.01); I2 =78%
Test for overall effect: Z = 0.76 (P = 0.45)
Test for subgroup differences: Chi2 = 9.22, df = 2 (P = 0.01), I2 =78%
0.01 0.1 1 10 100
Favours MDA Favours Control
(1) von Seidlein 2003 GMB: MDA (AS+SP once only) vs. placebo
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Analysis 3.5. Comparison 3 MDA versus no MDA in areas of high endemicity (Stratified by study design),
Outcome 5 Gametocytaemia Prevalence: Cluster-randomized trials.
Review: Mass drug administration for malaria
Comparison: 3 MDA versus no MDA in areas of high endemicity (Stratified by study design)
Outcome: 5 Gametocytaemia Prevalence: Cluster-randomized trials
Study or subgroup MDA no MDA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 At baseline
von Seidlein 2003 GMB (1) 15/769 18/607 100.0 % 0.66 [ 0.33, 1.29 ]
Subtotal (95% CI) 769 607 100.0 % 0.66 [ 0.33, 1.29 ]
Total events: 15 (MDA), 18 (no MDA)
Heterogeneity: not applicable
Test for overall effect: Z = 1.21 (P = 0.23)
2 4-6 months post MDA
von Seidlein 2003 GMB 30/808 21/606 100.0 % 1.07 [ 0.62, 1.85 ]
Subtotal (95% CI) 808 606 100.0 % 1.07 [ 0.62, 1.85 ]
Total events: 30 (MDA), 21 (no MDA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.25 (P = 0.80)
Test for subgroup differences: Chi2 = 1.21, df = 1 (P = 0.27), I2 =17%
0.01 0.1 1 10 100
Favours MDA Favours control
(1) von Seidlein 2003 GMB: MDA (AS+SP once only) vs. placebo
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Analysis 3.6. Comparison 3 MDA versus no MDA in areas of high endemicity (Stratified by study design),
Outcome 6 Gametocytaemia Prevalence: Non-randomized controlled studies.
Review: Mass drug administration for malaria
Comparison: 3 MDA versus no MDA in areas of high endemicity (Stratified by study design)
Outcome: 6 Gametocytaemia Prevalence: Non-randomized controlled studies
Study or subgroup MDA no MDA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 At baseline
Escudie 1962 BFA (1) 38/545 25/139 12.5 % 0.39 [ 0.24, 0.62 ]
Schneider 1961 BFA (2) 32/390 42/217 13.4 % 0.42 [ 0.28, 0.65 ]
Escudie 1962 BFA (3) 91/1223 22/284 13.0 % 0.96 [ 0.61, 1.50 ]
Escudie 1962 BFA (4) 68/380 25/139 13.6 % 0.99 [ 0.66, 1.51 ]
Escudie 1962 BFA (5) 43/850 22/284 12.0 % 0.65 [ 0.40, 1.07 ]
Molineaux 1980 NGA (6) 127/1257 124/1004 17.5 % 0.82 [ 0.65, 1.03 ]
Molineaux 1980 NGA (7) 208/1679 124/1004 18.0 % 1.00 [ 0.81, 1.24 ]
Subtotal (95% CI) 6324 3071 100.0 % 0.72 [ 0.55, 0.95 ]
Total events: 607 (MDA), 384 (no MDA)
Heterogeneity: Tau2 = 0.09; Chi2 = 24.52, df = 6 (P = 0.00042); I2 =76%
Test for overall effect: Z = 2.36 (P = 0.018)
2 During MDA
Escudie 1962 BFA (8) 11/573 73/467 14.0 % 0.12 [ 0.07, 0.23 ]
Escudie 1962 BFA (9) 6/704 71/837 12.2 % 0.10 [ 0.04, 0.23 ]
Escudie 1962 BFA (10) 21/420 73/467 15.3 % 0.32 [ 0.20, 0.51 ]
Schneider 1961 BFA 9/467 97/691 13.5 % 0.14 [ 0.07, 0.27 ]
Escudie 1962 BFA (11) 16/1171 71/837 14.7 % 0.16 [ 0.09, 0.28 ]
Molineaux 1980 NGA (12) 12/2099 92/1171 14.2 % 0.07 [ 0.04, 0.13 ]
Molineaux 1980 NGA (13) 48/1486 92/1171 16.1 % 0.41 [ 0.29, 0.58 ]
Subtotal (95% CI) 6920 5641 100.0 % 0.17 [ 0.10, 0.28 ]
Total events: 123 (MDA), 569 (no MDA)
Heterogeneity: Tau2 = 0.42; Chi2 = 39.84, df = 6 (P<0.00001); I2 =85%
Test for overall effect: Z = 6.64 (P < 0.00001)
3 1-3 months post MDA
Escudie 1962 BFA (14) 44/384 68/382 20.3 % 0.64 [ 0.45, 0.92 ]
Escudie 1962 BFA (15) 31/1446 71/972 19.9 % 0.29 [ 0.19, 0.44 ]
0.01 0.1 1 10 100
Favours MDA Favours control
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Study or subgroup MDA no MDA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Escudie 1962 BFA (16) 11/1025 71/972 18.0 % 0.15 [ 0.08, 0.28 ]
Escudie 1962 BFA (17) 141/634 68/382 20.8 % 1.25 [ 0.96, 1.62 ]
Schneider 1961 BFA 107/466 102/534 20.9 % 1.20 [ 0.94, 1.53 ]
Subtotal (95% CI) 3955 3242 100.0 % 0.55 [ 0.28, 1.07 ]
Total events: 334 (MDA), 380 (no MDA)
Heterogeneity: Tau2 = 0.53; Chi2 = 76.37, df = 4 (P<0.00001); I2 =95%
Test for overall effect: Z = 1.76 (P = 0.078)
Test for subgroup differences: Chi2 = 23.55, df = 2 (P = 0.00), I2 =92%
0.01 0.1 1 10 100
Favours MDA Favours control
(1) Escudie 1962 BFA: MDA (CQ+PQ or AQ+PQ every 14 days for 15 rounds) vs. no intervention
(2) Schneider 1961 BFA: MDA (AQ+PQ or CQ+PQ every 2 weeks for 15 rounds) vs. no intervention
(3) Escudie 1962 BFA: MDA (CQ+PQ or AQ+PQ every 28 days for 8 rounds) + IRS vs. IRS only
(4) Escudie 1962 BFA: MDA (CQ+PQ or AQ+PQ every 28 days for 8 rounds) vs. no intervention
(5) Escudie 1962 BFA: MDA (CQ+PQ or AQ+PQ every 14 days for 15 rounds) + IRS vs. IRS only
(6) Molineaux 1980 NGA: MDA (SP every 10 weeks for 3 rounds) + IRS vs. IRS only
(7) Molineaux 1980 NGA: MDA (SP every 2 weeks during the wet season and 10 weeks during the dry season) + IRS vs. IRS only
(8) Escudie 1962 BFA: MDA (CQ+PQ or AQ+PQ every 14 days for 15 rounds) vs. no intervention
(9) Escudie 1962 BFA: MDA (CQ+PQ or AQ+PQ every 14 days for 15 rounds) + IRS vs. IRS only
(10) Escudie 1962 BFA: MDA (CQ+PQ or AQ+PQ every 28 days for 8 rounds) vs. no intervention
(11) Escudie 1962 BFA: MDA (CQ+PQ or AQ+PQ every 28 days for 8 rounds) + IRS vs. IRS only
(12) Molineaux 1980 NGA: MDA (SP every 2 weeks during the wet season and 10 weeks during the dry season) + IRS vs. IRS only
(13) Molineaux 1980 NGA: MDA (SP every 10 weeks for 3 rounds) + IRS vs. IRS only
(14) Escudie 1962 BFA: MDA (CQ+PQ or AQ+PQ every 28 days for 8 rounds) vs. no intervention
(15) Escudie 1962 BFA: MDA (CQ+PQ or AQ+PQ every 28 days for 8 rounds) + IRS vs. IRS only
(16) Escudie 1962 BFA: MDA (CQ+PQ or AQ+PQ every 14 days for 15 rounds) + IRS vs. IRS only
(17) Escudie 1962 BFA: MDA (CQ+PQ or AQ+PQ every 14 days for 15 rounds) vs. no intervention
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Analysis 3.7. Comparison 3 MDA versus no MDA in areas of high endemicity (Stratified by study design),
Outcome 7 Gametocytaemia Prevalence: Uncontrolled before-and-after studies.
Review: Mass drug administration for malaria
Comparison: 3 MDA versus no MDA in areas of high endemicity (Stratified by study design)
Outcome: 7 Gametocytaemia Prevalence: Uncontrolled before-and-after studies
Study or subgroup MDA no MDA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 During MDA
Archibald 1960 NGA (1) 37/502 59/537 52.9 % 0.67 [ 0.45, 0.99 ]
Ricosse 1959 BFA (2) 7/409 57/563 47.1 % 0.17 [ 0.08, 0.37 ]
Subtotal (95% CI) 911 1100 100.0 % 0.35 [ 0.09, 1.40 ]
Total events: 44 (MDA), 116 (no MDA)
Heterogeneity: Tau2 = 0.91; Chi2 = 10.26, df = 1 (P = 0.001); I2 =90%
Test for overall effect: Z = 1.48 (P = 0.14)
2 <1 month post MDA
Kligler 1931 PSE (3) 7/550 41/730 31.5 % 0.23 [ 0.10, 0.50 ]
Ricosse 1959 BFA 15/650 57/563 34.6 % 0.23 [ 0.13, 0.40 ]
Hii 1987 MYS (4) 14/44 14/45 33.9 % 1.02 [ 0.55, 1.89 ]
Subtotal (95% CI) 1244 1338 100.0 % 0.38 [ 0.13, 1.08 ]
Total events: 36 (MDA), 112 (no MDA)
Heterogeneity: Tau2 = 0.74; Chi2 = 15.70, df = 2 (P = 0.00039); I2 =87%
Test for overall effect: Z = 1.82 (P = 0.069)
3 1-3 months post MDA
Ricosse 1959 BFA 78/538 57/563 61.2 % 1.43 [ 1.04, 1.97 ]
Hii 1987 MYS 13/53 14/45 38.8 % 0.79 [ 0.41, 1.50 ]
Subtotal (95% CI) 591 608 100.0 % 1.14 [ 0.64, 2.01 ]
Total events: 91 (MDA), 71 (no MDA)
Heterogeneity: Tau2 = 0.11; Chi2 = 2.67, df = 1 (P = 0.10); I2 =63%
Test for overall effect: Z = 0.44 (P = 0.66)
4 4-6 months post MDA
Hii 1987 MYS 9/41 14/45 47.0 % 0.71 [ 0.34, 1.45 ]
Song 2010 KHM (5) 37/1609 131/1094 53.0 % 0.19 [ 0.13, 0.27 ]
Subtotal (95% CI) 1650 1139 100.0 % 0.35 [ 0.10, 1.28 ]
Total events: 46 (MDA), 145 (no MDA)
Heterogeneity: Tau2 = 0.78; Chi2 = 10.17, df = 1 (P = 0.001); I2 =90%
Test for overall effect: Z = 1.59 (P = 0.11)
5 7-12 months post MDA
Hii 1987 MYS 8/30 14/45 100.0 % 0.86 [ 0.41, 1.79 ]
0.01 0.1 1 10 100
Favours MDA Favours control
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Study or subgroup MDA no MDA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 30 45 100.0 % 0.86 [ 0.41, 1.79 ]
Total events: 8 (MDA), 14 (no MDA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.41 (P = 0.68)
6 >12 months post MDA
Song 2010 KHM 12/1175 131/1094 100.0 % 0.09 [ 0.05, 0.15 ]
Subtotal (95% CI) 1175 1094 100.0 % 0.09 [ 0.05, 0.15 ]
Total events: 12 (MDA), 131 (no MDA)
Heterogeneity: not applicable
Test for overall effect: Z = 8.24 (P < 0.00001)
Test for subgroup differences: Chi2 = 43.79, df = 5 (P = 0.00), I2 =89%
0.01 0.1 1 10 100
Favours MDA Favours control
(1) Achibald 1960 NGA: MDA (CQ+Pyr every 6 months) + IRS vs. IRS only baseline data
(2) Ricosse 1959 BFA: MDA (Pyr every 2 weeks for 8 rounds) vs. baseline data
(3) Kligler 1931 PSE: MDA (Plas+Q every 3 weeks for 3 rounds) vs. baseline data
(4) Hii 1987 MYS: MDA (SP+PQ once only) vs. no intervention
(5) Song 2010 KHM: MDA (AS+Pip once only plus PQ every 10 days for 6 months) vs. baseline data
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Analysis 3.8. Comparison 3 MDA versus no MDA in areas of high endemicity (Stratified by study design),
Outcome 8 Anaemia Prevalence: Cluster-randomized trials.
Review: Mass drug administration for malaria
Comparison: 3 MDA versus no MDA in areas of high endemicity (Stratified by study design)
Outcome: 8 Anaemia Prevalence: Cluster-randomized trials
Study or subgroup MDA no MDA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 4-6 months post MDA
von Seidlein 2003 GMB (1) 360/808 323/606 100.0 % 0.84 [ 0.75, 0.93 ]
Subtotal (95% CI) 808 606 100.0 % 0.84 [ 0.75, 0.93 ]
Total events: 360 (MDA), 323 (no MDA)
Heterogeneity: not applicable
Test for overall effect: Z = 3.28 (P = 0.0010)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours MDA Favours control
(1) von Seidlein 2003 GMB: MDA (AS+SP once only) vs. placebo
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Analysis 3.9. Comparison 3 MDA versus no MDA in areas of high endemicity (Stratified by study design),
Outcome 9 Mortality: Cluster-randomized trials.
Review: Mass drug administration for malaria
Comparison: 3 MDA versus no MDA in areas of high endemicity (Stratified by study design)
Outcome: 9 Mortality: Cluster-randomized trials
Study or subgroup MDA no MDA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 4-6 months post MDA
von Seidlein 2003 GMB (1) 5/1969 3/1686 100.0 % 1.43 [ 0.34, 5.96 ]
Subtotal (95% CI) 1969 1686 100.0 % 1.43 [ 0.34, 5.96 ]
Total events: 5 (MDA), 3 (no MDA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.49 (P = 0.63)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours MDA Favours control
(1) von Seidlein 2003 GMB: MDA (AS+SP once only) vs. placebo
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Analysis 4.1. Comparison 4 MDA + vector control versus no intervention in areas of moderate endemicity
(Stratified by study design), Outcome 1 Parasitaemia Prevalence: Non-randomized controlled studies.
Review: Mass drug administration for malaria
Comparison: 4 MDA + vector control versus no intervention in areas of moderate endemicity (Stratified by study design)
Outcome: 1 Parasitaemia Prevalence: Non-randomized controlled studies
Study or subgroup MDA no MDA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 At baseline
Kaneko 2000 VUT (1) 80/508 43/572 100.0 % 2.09 [ 1.48, 2.98 ]
Subtotal (95% CI) 508 572 100.0 % 2.09 [ 1.48, 2.98 ]
Total events: 80 (MDA), 43 (no MDA)
Heterogeneity: not applicable
Test for overall effect: Z = 4.13 (P = 0.000036)
2 >12 months post MDA
Kaneko 2000 VUT 8/691 75/640 100.0 % 0.10 [ 0.05, 0.20 ]
Subtotal (95% CI) 691 640 100.0 % 0.10 [ 0.05, 0.20 ]
Total events: 8 (MDA), 75 (no MDA)
Heterogeneity: not applicable
Test for overall effect: Z = 6.29 (P < 0.00001)
Test for subgroup differences: Chi2 = 55.74, df = 1 (P = 0.00), I2 =98%
0.01 0.1 1 10 100
Favours MDA Favours control
(1) Kaneko 2000 VUT: MDA (CQ+SP+PQ weekly for 9 rounds) + ITNs + larvivorous fish vs. ITNs only
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Analysis 4.2. Comparison 4 MDA + vector control versus no intervention in areas of moderate endemicity
(Stratified by study design), Outcome 2 Parasitaemia Prevalence: Uncontrolled before-and-after studies.
Review: Mass drug administration for malaria
Comparison: 4 MDA + vector control versus no intervention in areas of moderate endemicity (Stratified by study design)
Outcome: 2 Parasitaemia Prevalence: Uncontrolled before-and-after studies
Study or subgroup MDA no MDA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 During MDA
Ricosse 1959 BFA (1) 14/787 300/988 49.9 % 0.06 [ 0.03, 0.10 ]
Paik 1974a SLB (2) 27/462 23/99 50.1 % 0.25 [ 0.15, 0.42 ]
Subtotal (95% CI) 1249 1087 100.0 % 0.12 [ 0.02, 0.62 ]
Total events: 41 (MDA), 323 (no MDA)
Heterogeneity: Tau2 = 1.32; Chi2 = 19.79, df = 1 (P<0.00001); I2 =95%
Test for overall effect: Z = 2.53 (P = 0.012)
2 <1 month post MDA
Ricosse 1959 BFA 9/919 300/988 33.5 % 0.03 [ 0.02, 0.06 ]
De Zulueta 1961 UGA (3) 6/1692 159/958 32.6 % 0.02 [ 0.01, 0.05 ]
Paik 1974a SLB 20/350 23/99 33.9 % 0.25 [ 0.14, 0.43 ]
Subtotal (95% CI) 2961 2045 100.0 % 0.06 [ 0.01, 0.33 ]
Total events: 35 (MDA), 482 (no MDA)
Heterogeneity: Tau2 = 2.29; Chi2 = 41.66, df = 2 (P<0.00001); I2 =95%
Test for overall effect: Z = 3.21 (P = 0.0013)
3 1-3 months post MDA
Ricosse 1959 BFA 147/953 300/988 37.1 % 0.51 [ 0.43, 0.61 ]
De Zulueta 1964 UGA 2/1500 111/529 26.9 % 0.01 [ 0.00, 0.03 ]
Paik 1974a SLB 62/655 23/99 36.0 % 0.41 [ 0.27, 0.63 ]
Subtotal (95% CI) 3108 1616 100.0 % 0.14 [ 0.04, 0.57 ]
Total events: 211 (MDA), 434 (no MDA)
Heterogeneity: Tau2 = 1.31; Chi2 = 53.35, df = 2 (P<0.00001); I2 =96%
Test for overall effect: Z = 2.77 (P = 0.0057)
4 4-6 months post MDA
Paik 1974a SLB 112/840 23/99 100.0 % 0.57 [ 0.39, 0.85 ]
Subtotal (95% CI) 840 99 100.0 % 0.57 [ 0.39, 0.85 ]
Total events: 112 (MDA), 23 (no MDA)
Heterogeneity: not applicable
Test for overall effect: Z = 2.74 (P = 0.0062)
5 >12 months post MDA
De Zulueta 1964 UGA 1/1229 111/529 100.0 % 0.00 [ 0.00, 0.03 ]
0.01 0.1 1 10 100
Favours MDA Favours control
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Study or subgroup MDA no MDA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 1229 529 100.0 % 0.00 [ 0.00, 0.03 ]
Total events: 1 (MDA), 111 (no MDA)
Heterogeneity: not applicable
Test for overall effect: Z = 5.54 (P < 0.00001)
Test for subgroup differences: Chi2 = 33.34, df = 4 (P = 0.00), I2 =88%
0.01 0.1 1 10 100
Favours MDA Favours control
(1) Ricosse 1959 BFA: MDA (Pyr every 2 weeks for 8 rounds) + IRS vs. no intervention
(2) Paik 1974a SLB: MDA (CQ+Pyr monthly for 4 rounds) + IRS vs. no intervention
(3) DeZulueta 1961 UGA: MDA (CQ+Pyr every 3 months for 4 rounds) + IRS vs. no intervention
Analysis 4.3. Comparison 4 MDA + vector control versus no intervention in areas of moderate endemicity
(Stratified by study design), Outcome 3 Gametocytaemia Prevalence: Uncontrolled before-and-after studies.
Review: Mass drug administration for malaria
Comparison: 4 MDA + vector control versus no intervention in areas of moderate endemicity (Stratified by study design)
Outcome: 3 Gametocytaemia Prevalence: Uncontrolled before-and-after studies
Study or subgroup MDA no MDA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 During MDA
Ricosse 1959 BFA (1) 6/787 53/988 76.0 % 0.14 [ 0.06, 0.33 ]
De Zulueta 1961 UGA (2) 2/1692 12/958 24.0 % 0.09 [ 0.02, 0.42 ]
Subtotal (95% CI) 2479 1946 100.0 % 0.13 [ 0.06, 0.27 ]
Total events: 8 (MDA), 65 (no MDA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.22, df = 1 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 5.49 (P < 0.00001)
2 < 1 month post MDA
Ricosse 1959 BFA 0/919 53/988 100.0 % 0.01 [ 0.00, 0.16 ]
Subtotal (95% CI) 919 988 100.0 % 0.01 [ 0.00, 0.16 ]
0.01 0.1 1 10 100
Favours experimental Favours control
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Study or subgroup MDA no MDA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 0 (MDA), 53 (no MDA)
Heterogeneity: not applicable
Test for overall effect: Z = 3.24 (P = 0.0012)
3 1-3 months post MDA
Ricosse 1959 BFA 11/953 53/988 100.0 % 0.22 [ 0.11, 0.41 ]
Subtotal (95% CI) 953 988 100.0 % 0.22 [ 0.11, 0.41 ]
Total events: 11 (MDA), 53 (no MDA)
Heterogeneity: not applicable
Test for overall effect: Z = 4.68 (P < 0.00001)
Test for subgroup differences: Chi2 = 4.95, df = 2 (P = 0.08), I2 =60%
0.01 0.1 1 10 100
Favours experimental Favours control
(1) Ricosse 1959 BFA: MDA (Pyr every 2 weeks for 8 rounds) + IRS vs. no intervention
(2) DeZulueta 1961 UGA: MDA (CQ+Pyr every 3 months for 4 rounds) + IRS vs. no intervention
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Analysis 5.1. Comparison 5 MDA + vector control versus no intervention in areas of high endemicity
(Stratified by study design), Outcome 1 Parasitaemia Prevalence: Non-randomized controlled studies.
Review: Mass drug administration for malaria
Comparison: 5 MDA + vector control versus no intervention in areas of high endemicity (Stratified by study design)
Outcome: 1 Parasitaemia Prevalence: Non-randomized controlled studies
Study or subgroup MDA no MDA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 At baseline
Schneider 1961 BFA (1) 149/624 129/217 19.8 % 0.40 [ 0.34, 0.48 ]
Escudie 1962 BFA (2) 262/1223 78/139 19.8 % 0.38 [ 0.32, 0.46 ]
Escudie 1962 BFA (3) 183/850 78/139 19.7 % 0.38 [ 0.32, 0.47 ]
Molineaux 1980 NGA (4) 525/1257 442/957 20.4 % 0.90 [ 0.82, 0.99 ]
Molineaux 1980 NGA (5) 754/1679 442/957 20.4 % 0.97 [ 0.89, 1.06 ]
Subtotal (95% CI) 5633 2409 100.0 % 0.56 [ 0.37, 0.84 ]
Total events: 1873 (MDA), 1169 (no MDA)
Heterogeneity: Tau2 = 0.21; Chi2 = 196.72, df = 4 (P<0.00001); I2 =98%
Test for overall effect: Z = 2.79 (P = 0.0052)
2 During MDA
Escudie 1962 BFA (6) 121/1171 338/467 20.8 % 0.14 [ 0.12, 0.17 ]
Schneider 1961 BFA 30/586 517/691 19.3 % 0.07 [ 0.05, 0.10 ]
Escudie 1962 BFA (7) 41/704 338/467 19.8 % 0.08 [ 0.06, 0.11 ]
Molineaux 1980 NGA (8) 40/2099 336/911 19.6 % 0.05 [ 0.04, 0.07 ]
Molineaux 1980 NGA (9) 109/1486 336/911 20.6 % 0.20 [ 0.16, 0.24 ]
Subtotal (95% CI) 6046 3447 100.0 % 0.10 [ 0.06, 0.16 ]
Total events: 341 (MDA), 1865 (no MDA)
Heterogeneity: Tau2 = 0.30; Chi2 = 76.65, df = 4 (P<0.00001); I2 =95%
Test for overall effect: Z = 9.24 (P < 0.00001)
3 1-3 months post MDA
Schneider 1961 BFA 46/686 386/534 32.7 % 0.09 [ 0.07, 0.12 ]
Escudie 1962 BFA (10) 196/1446 250/382 34.2 % 0.21 [ 0.18, 0.24 ]
Escudie 1962 BFA (11) 61/1025 250/382 33.1 % 0.09 [ 0.07, 0.12 ]
Subtotal (95% CI) 3157 1298 100.0 % 0.12 [ 0.06, 0.23 ]
Total events: 303 (MDA), 886 (no MDA)
Heterogeneity: Tau2 = 0.32; Chi2 = 50.41, df = 2 (P<0.00001); I2 =96%
Test for overall effect: Z = 6.34 (P < 0.00001)
4 7-12 months post MDA
0.01 0.1 1 10 100
Favours MDA Favours control
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Study or subgroup MDA no MDA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Molineaux 1980 NGA (12) 523/2071 453/1083 100.0 % 0.60 [ 0.55, 0.67 ]
Subtotal (95% CI) 2071 1083 100.0 % 0.60 [ 0.55, 0.67 ]
Total events: 523 (MDA), 453 (no MDA)
Heterogeneity: not applicable
Test for overall effect: Z = 9.69 (P < 0.00001)
5 >12 months post MDA
Molineaux 1980 NGA (13) 705/2138 484/1123 100.0 % 0.77 [ 0.70, 0.84 ]
Subtotal (95% CI) 2138 1123 100.0 % 0.77 [ 0.70, 0.84 ]
Total events: 705 (MDA), 484 (no MDA)
Heterogeneity: not applicable
Test for overall effect: Z = 5.81 (P < 0.00001)
Test for subgroup differences: Chi2 = 97.25, df = 4 (P = 0.00), I2 =96%
0.01 0.1 1 10 100
Favours MDA Favours control
(1) Schneider 1961 BFA: MDA (AQ+PQ or CQ+PQ every 2 weeks for 8 rounds) + IRS vs. no intervention
(2) Escudie 1962 BFA: MDA (CQ+PQ or AQ+PQ every 28 days for 8 rounds) + IRS vs. no intervention
(3) Escudie 1962 BFA: MDA (CQ+PQ or AQ+PQ every 14 days for 15 rounds) + IRS vs. no intervention
(4) Molineaux 1980 NGA: MDA (SP every 10 weeks for 3 rounds) + IRS vs. no intervention
(5) Molineaux 1980 NGA: MDA (SP every 2 weeks during the wet season and 10 weeks during the dry season) + IRS vs. no intervention
(6) Escudie 1962 BFA: MDA (CQ+PQ or AQ+PQ every 28 days for 8 rounds) + IRS vs. no intervention
(7) Escudie 1962 BFA: MDA (CQ+PQ or AQ+PQ every 14 days for 15 rounds) + IRS vs. no intervention
(8) Molineaux 1980 NGA: MDA (SP every 2 weeks during the wet season and 10 weeks during the dry season) + IRS vs. no intervention
(9) Molineaux 1980 NGA: MDA (SP every 10 weeks for 3 rounds) + IRS vs. no intervention
(10) Escudie 1962 BFA: MDA (CQ+PQ or AQ+PQ every 28 days for 8 rounds) + IRS vs. no intervention
(11) Escudie 1962 BFA: MDA (CQ+PQ or AQ+PQ every 14 days for 15 rounds) + IRS vs. no intervention
(12) Molineaux 1980 NGA: MDA (SP every 2 weeks during the wet season and 10 weeks during the dry season) + IRS vs. no intervention
(13) Molineaux 1980 NGA: MDA (SP every 2 weeks during the wet season and 10 weeks during the dry season) + IRS vs. no intervention
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Analysis 5.2. Comparison 5 MDA + vector control versus no intervention in areas of high endemicity
(Stratified by study design), Outcome 2 Parasitaemia Prevalence: Uncontrolled before-and-after studies.
Review: Mass drug administration for malaria
Comparison: 5 MDA + vector control versus no intervention in areas of high endemicity (Stratified by study design)
Outcome: 2 Parasitaemia Prevalence: Uncontrolled before-and-after studies
Study or subgroup MDA no MDA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 During MDA
Metselaar 1961 PNG (1) 143/2500 1150/2500 54.2 % 0.12 [ 0.11, 0.15 ]
Hii 1987 MYS (2) 24/219 101/218 45.8 % 0.24 [ 0.16, 0.35 ]
Subtotal (95% CI) 2719 2718 100.0 % 0.17 [ 0.09, 0.31 ]
Total events: 167 (MDA), 1251 (no MDA)
Heterogeneity: Tau2 = 0.18; Chi2 = 8.43, df = 1 (P = 0.004); I2 =88%
Test for overall effect: Z = 5.56 (P < 0.00001)
2 1-3 months post MDA
Metselaar 1961 PNG 38/2500 1150/2500 50.0 % 0.03 [ 0.02, 0.05 ]
Hii 1987 MYS 49/222 101/218 50.0 % 0.48 [ 0.36, 0.63 ]
Subtotal (95% CI) 2722 2718 100.0 % 0.13 [ 0.01, 2.51 ]
Total events: 87 (MDA), 1251 (no MDA)
Heterogeneity: Tau2 = 4.65; Chi2 = 196.25, df = 1 (P<0.00001); I2 =99%
Test for overall effect: Z = 1.36 (P = 0.17)
3 4-6 months post MDA
Hii 1987 MYS 76/197 101/218 100.0 % 0.83 [ 0.66, 1.04 ]
Subtotal (95% CI) 197 218 100.0 % 0.83 [ 0.66, 1.04 ]
Total events: 76 (MDA), 101 (no MDA)
Heterogeneity: not applicable
Test for overall effect: Z = 1.58 (P = 0.11)
4 7-12 months post MDA
Hii 1987 MYS 84/194 101/218 100.0 % 0.93 [ 0.75, 1.16 ]
Subtotal (95% CI) 194 218 100.0 % 0.93 [ 0.75, 1.16 ]
Total events: 84 (MDA), 101 (no MDA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.62 (P = 0.54)
Test for subgroup differences: Chi2 = 27.31, df = 3 (P = 0.00), I2 =89%
0.01 0.1 1 10 100
Favours MDA Favours control
(1) Metselaar 1961 PNG: MDA (CQ+Pyr weekly for 6 rounds) +IRS vs. pre-spray baseline data
(2) Hii 1987 MYS: MDA (SP+PQ once only) + ITNs vs. baseline data
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Analysis 5.3. Comparison 5 MDA + vector control versus no intervention in areas of high endemicity
(Stratified by study design), Outcome 3 Gametocytaemia Prevalence: Non-randomized controlled studies.
Review: Mass drug administration for malaria
Comparison: 5 MDA + vector control versus no intervention in areas of high endemicity (Stratified by study design)
Outcome: 3 Gametocytaemia Prevalence: Non-randomized controlled studies
Study or subgroup MDA no MDA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 At baseline
Escudie 1962 BFA (1) 91/1223 25/139 19.5 % 0.41 [ 0.28, 0.62 ]
Schneider 1961 BFA (2) 38/624 42/217 19.4 % 0.31 [ 0.21, 0.47 ]
Escudie 1962 BFA (3) 43/850 25/139 18.9 % 0.28 [ 0.18, 0.45 ]
Molineaux 1980 NGA (4) 208/1679 109/957 21.2 % 1.09 [ 0.87, 1.35 ]
Molineaux 1980 NGA (5) 127/1257 109/957 21.0 % 0.89 [ 0.70, 1.13 ]
Subtotal (95% CI) 5633 2409 100.0 % 0.53 [ 0.31, 0.90 ]
Total events: 507 (MDA), 310 (no MDA)
Heterogeneity: Tau2 = 0.34; Chi2 = 56.09, df = 4 (P<0.00001); I2 =93%
Test for overall effect: Z = 2.35 (P = 0.019)
2 During MDA
Schneider 1961 BFA 1/586 97/691 12.3 % 0.01 [ 0.00, 0.09 ]
Escudie 1962 BFA (6) 16/1171 73/467 22.2 % 0.09 [ 0.05, 0.15 ]
Escudie 1962 BFA (7) 6/704 73/467 20.4 % 0.05 [ 0.02, 0.12 ]
Molineaux 1980 NGA (8) 48/1486 94/911 23.1 % 0.31 [ 0.22, 0.44 ]
Molineaux 1980 NGA (9) 12/2099 94/911 21.9 % 0.06 [ 0.03, 0.10 ]
Subtotal (95% CI) 6046 3447 100.0 % 0.08 [ 0.03, 0.20 ]
Total events: 83 (MDA), 431 (no MDA)
Heterogeneity: Tau2 = 1.09; Chi2 = 49.89, df = 4 (P<0.00001); I2 =92%
Test for overall effect: Z = 5.08 (P < 0.00001)
3 1-3 months post MDA
Schneider 1961 BFA 9/686 102/534 27.8 % 0.07 [ 0.04, 0.13 ]
Escudie 1962 BFA (10) 31/1446 68/382 42.2 % 0.12 [ 0.08, 0.18 ]
Escudie 1962 BFA (11) 11/1025 68/382 30.0 % 0.06 [ 0.03, 0.11 ]
Subtotal (95% CI) 3157 1298 100.0 % 0.08 [ 0.05, 0.14 ]
Total events: 51 (MDA), 238 (no MDA)
Heterogeneity: Tau2 = 0.10; Chi2 = 4.44, df = 2 (P = 0.11); I2 =55%
Test for overall effect: Z = 10.07 (P < 0.00001)
4 7-12 months post MDA
0.01 0.1 1 10 100
Favours MDA Favours control
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Study or subgroup MDA no MDA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Molineaux 1980 NGA (12) 261/2071 156/1083 100.0 % 0.87 [ 0.73, 1.05 ]
Subtotal (95% CI) 2071 1083 100.0 % 0.87 [ 0.73, 1.05 ]
Total events: 261 (MDA), 156 (no MDA)
Heterogeneity: not applicable
Test for overall effect: Z = 1.42 (P = 0.16)
5 > 12 months post MDA
Molineaux 1980 NGA (13) 320/2138 175/1123 100.0 % 0.96 [ 0.81, 1.14 ]
Subtotal (95% CI) 2138 1123 100.0 % 0.96 [ 0.81, 1.14 ]
Total events: 320 (MDA), 175 (no MDA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.47 (P = 0.64)
Test for subgroup differences: Chi2 = 112.20, df = 4 (P = 0.00), I2 =96%
0.01 0.1 1 10 100
Favours MDA Favours control
(1) Escudie 1962 BFA: MDA (CQ+PQ or AQ+PQ every 28 days for 8 rounds) + IRS vs. no intervention
(2) Schneider 1961 BFA: MDA (AQ+PQ or CQ+PQ every 2 weeks for 8 rounds) + IRS vs. no intervention
(3) Escudie 1962 BFA: MDA (CQ+PQ or AQ+PQ every 14 days for 15 rounds) + IRS vs. no intervention
(4) Molineaux 1980 NGA: MDA (SP every 2 weeks during the wet season and 10 weeks during the dry season) + IRS vs. no intervention
(5) Molineaux 1980 NGA: MDA (SP every 2 weeks during the wet season and 10 weeks during the dry season) + IRS vs. no intervention
(6) Escudie 1962 BFA: MDA (CQ+PQ or AQ+PQ every 28 days for 8 rounds) + IRS vs. no intervention
(7) Escudie 1962 BFA: MDA (CQ+PQ or AQ+PQ every 14 days for 15 rounds) + IRS vs. no intervention
(8) Molineaux 1980 NGA: MDA (SP every 10 weeks for 3 rounds) + IRS vs. no intervention
(9) Molineaux 1980 NGA: MDA (SP every 2 weeks during the wet season and 10 weeks during the dry season) + IRS vs. no intervention
(10) Escudie 1962 BFA: MDA (CQ+PQ or AQ+PQ every 28 days for 8 rounds) + IRS vs. no intervention
(11) Escudie 1962 BFA: MDA (CQ+PQ or AQ+PQ every 14 days for 15 rounds) + IRS vs. no intervention
(12) Molineaux 1980 NGA: MDA (SP every 2 weeks during the wet season and 10 weeks during the dry season) + IRS vs. no intervention
(13) Molineaux 1980 NGA: MDA (SP every 2 weeks during the wet season and 10 weeks during the dry season) + IRS vs. no intervention
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Analysis 5.4. Comparison 5 MDA + vector control versus no intervention in areas of high endemicity
(Stratified by study design), Outcome 4 Gametocytaemia Prevalence: Uncontrolled before-and-after studies.
Review: Mass drug administration for malaria
Comparison: 5 MDA + vector control versus no intervention in areas of high endemicity (Stratified by study design)
Outcome: 4 Gametocytaemia Prevalence: Uncontrolled before-and-after studies
Study or subgroup MDA no MDA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 During MDA
Hii 1987 MYS (1) 15/219 51/218 100.0 % 0.29 [ 0.17, 0.50 ]
Subtotal (95% CI) 219 218 100.0 % 0.29 [ 0.17, 0.50 ]
Total events: 15 (MDA), 51 (no MDA)
Heterogeneity: not applicable
Test for overall effect: Z = 4.42 (P < 0.00001)
2 1-3 months post MDA
Hii 1987 MYS 27/222 51/218 100.0 % 0.52 [ 0.34, 0.80 ]
Subtotal (95% CI) 222 218 100.0 % 0.52 [ 0.34, 0.80 ]
Total events: 27 (MDA), 51 (no MDA)
Heterogeneity: not applicable
Test for overall effect: Z = 3.00 (P = 0.0027)
3 4-6 months post MDA
Hii 1987 MYS 35/197 51/218 100.0 % 0.76 [ 0.52, 1.12 ]
Subtotal (95% CI) 197 218 100.0 % 0.76 [ 0.52, 1.12 ]
Total events: 35 (MDA), 51 (no MDA)
Heterogeneity: not applicable
Test for overall effect: Z = 1.40 (P = 0.16)
4 7-12 months post MDA
Hii 1987 MYS 42/194 51/218 100.0 % 0.93 [ 0.65, 1.33 ]
Subtotal (95% CI) 194 218 100.0 % 0.93 [ 0.65, 1.33 ]
Total events: 42 (MDA), 51 (no MDA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.42 (P = 0.67)
Test for subgroup differences: Chi2 = 13.63, df = 3 (P = 0.00), I2 =78%
0.01 0.1 1 10 100
Favours MDA Favours control
(1) Hii 1987 MYS: MDA (SP+PQ once only) + ITNs vs. baseline data
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Analysis 6.1. Comparison 6 Parasitaemia Incidence studies, Outcome 1 MDA versus no MDA: Uncontrolled
before-and-after studies.
Review: Mass drug administration for malaria
Comparison: 6 Parasitaemia Incidence studies
Outcome: 1 MDA versus no MDA: Uncontrolled before-and-after studies
Study or subgroup log [Rate Ratio] Rate Ratio Weight Rate Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 During MDA
Gabaldon 1959 VEN (1) -1.75 (0.38) 34.8 % 0.17 [ 0.08, 0.37 ]
Kondrashin 1985 IND (2) -2.14 (0.75) 26.8 % 0.12 [ 0.03, 0.51 ]
Paik 1974b SLB (3) -0.16 (0.1) 38.4 % 0.85 [ 0.70, 1.04 ]
Subtotal (95% CI) 100.0 % 0.29 [ 0.07, 1.14 ]
Heterogeneity: Tau2 = 1.26; Chi2 = 22.53, df = 2 (P = 0.00001); I2 =91%
Test for overall effect: Z = 1.78 (P = 0.076)
2 < 1 month post MDA
C ceres Garcia 2008 VEN (4) -2.04 (0.43) 25.7 % 0.13 [ 0.06, 0.30 ]
Gabaldon 1959 VEN -2.83 (1.03) 17.7 % 0.06 [ 0.01, 0.44 ]
Kondrashin 1985 IND 0.02 (0.1) 28.3 % 1.02 [ 0.84, 1.24 ]
Paik 1974b SLB -1.89 (0.12) 28.2 % 0.15 [ 0.12, 0.19 ]
Subtotal (95% CI) 100.0 % 0.21 [ 0.05, 0.84 ]
Heterogeneity: Tau2 = 1.74; Chi2 = 161.92, df = 3 (P<0.00001); I2 =98%
Test for overall effect: Z = 2.21 (P = 0.027)
3 1-3 months post MDA
C ceres Garcia 2008 VEN 0.04 (0.21) 26.5 % 1.04 [ 0.69, 1.57 ]
Gabaldon 1959 VEN -1.73 (0.63) 17.5 % 0.18 [ 0.05, 0.61 ]
Kondrashin 1985 IND 0.25 (0.09) 28.0 % 1.28 [ 1.08, 1.53 ]
Paik 1974b SLB -0.98 (0.08) 28.1 % 0.38 [ 0.32, 0.44 ]
Subtotal (95% CI) 100.0 % 0.61 [ 0.26, 1.40 ]
Heterogeneity: Tau2 = 0.64; Chi2 = 113.52, df = 3 (P<0.00001); I2 =97%
Test for overall effect: Z = 1.17 (P = 0.24)
4 4-6 months post MDA
Gabaldon 1959 VEN -0.43 (0.23) 100.0 % 0.65 [ 0.41, 1.02 ]
Subtotal (95% CI) 100.0 % 0.65 [ 0.41, 1.02 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.87 (P = 0.062)
5 7-12 months post MDA
Gabaldon 1959 VEN -1.88 (0.41) 100.0 % 0.15 [ 0.07, 0.34 ]
0.01 0.1 1 10 100
Favours MDA Favours no MDA
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Study or subgroup log [Rate Ratio] Rate Ratio Weight Rate Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 100.0 % 0.15 [ 0.07, 0.34 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.59 (P < 0.00001)
6 >12 months post MDA
C ceres Garcia 2008 VEN -0.73 (0.07) 100.0 % 0.48 [ 0.42, 0.55 ]
Subtotal (95% CI) 100.0 % 0.48 [ 0.42, 0.55 ]
Heterogeneity: not applicable
Test for overall effect: Z = 10.43 (P < 0.00001)
Test for subgroup differences: Chi2 = 11.75, df = 5 (P = 0.04), I2 =57%
0.01 0.1 1 10 100
Favours MDA Favours no MDA
(1) Gabaldon 1959 VEN: MDA (Pyr weekly for 24 rounds) + IRS vs. IRS only baseline data
(2) Kondrashin 1985 IND: MDA (CQ+PQ every 4 months for 2 rounds) + IRS vs. IRS only baseline
(3) Paik 1974b SLB: MDA (CQ+PQ every month for 3 rounds) vs. baseline data
(4) Caceres Garcia 2008 VEN: MDA (CQ+PQ once only) vs. baseline data
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Analysis 6.2. Comparison 6 Parasitaemia Incidence studies, Outcome 2 MDA + vector control versus no
MDA: Uncontrolled before-and-after studies.
Review: Mass drug administration for malaria
Comparison: 6 Parasitaemia Incidence studies
Outcome: 2 MDA + vector control versus no MDA: Uncontrolled before-and-after studies
Study or subgroup log [Rate Ratio] Rate Ratio Weight Rate Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 During MDA
Garfield 1983 NIC (1) 0.25 (0.07) 49.5 % 1.28 [ 1.12, 1.47 ]
Simeons 1938 IND (2) -0.4 (0.03) 50.5 % 0.67 [ 0.63, 0.71 ]
Subtotal (95% CI) 100.0 % 0.92 [ 0.49, 1.75 ]
Heterogeneity: Tau2 = 0.21; Chi2 = 72.84, df = 1 (P<0.00001); I2 =99%
Test for overall effect: Z = 0.24 (P = 0.81)
2 < 1 month post MDA
Garfield 1983 NIC -5.3 (0.71) 48.3 % 0.00 [ 0.00, 0.02 ]
Simeons 1938 IND -1.47 (0.05) 51.7 % 0.23 [ 0.21, 0.25 ]
Subtotal (95% CI) 100.0 % 0.04 [ 0.00, 1.54 ]
Heterogeneity: Tau2 = 7.08; Chi2 = 28.96, df = 1 (P<0.00001); I2 =97%
Test for overall effect: Z = 1.73 (P = 0.083)
3 1-3 months post MDA
Garfield 1983 NIC -3.91 (0.36) 49.1 % 0.02 [ 0.01, 0.04 ]
Simeons 1938 IND -1.3 (0.04) 50.9 % 0.27 [ 0.25, 0.29 ]
Subtotal (95% CI) 100.0 % 0.08 [ 0.01, 0.98 ]
Heterogeneity: Tau2 = 3.34; Chi2 = 51.92, df = 1 (P<0.00001); I2 =98%
Test for overall effect: Z = 1.98 (P = 0.048)
4 4-6 months post MDA
Garfield 1983 NIC -3.69 (0.32) 49.4 % 0.02 [ 0.01, 0.05 ]
Simeons 1938 IND -0.75 (0.04) 50.6 % 0.47 [ 0.44, 0.51 ]
Subtotal (95% CI) 100.0 % 0.11 [ 0.01, 1.97 ]
Heterogeneity: Tau2 = 4.27; Chi2 = 83.11, df = 1 (P<0.00001); I2 =99%
Test for overall effect: Z = 1.50 (P = 0.13)
5 7-12 months post MDA
Garfield 1983 NIC -3.35 (0.27) 49.6 % 0.04 [ 0.02, 0.06 ]
Simeons 1938 IND -0.33 (0.03) 50.4 % 0.72 [ 0.68, 0.76 ]
Subtotal (95% CI) 100.0 % 0.16 [ 0.01, 3.10 ]
Heterogeneity: Tau2 = 4.52; Chi2 = 123.58, df = 1 (P<0.00001); I2 =99%
Test for overall effect: Z = 1.21 (P = 0.23)
6 > 12 months post MDA
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Study or subgroup log [Rate Ratio] Rate Ratio Weight Rate Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
Simeons 1938 IND -3.16 (0.25) 100.0 % 0.04 [ 0.03, 0.07 ]
Subtotal (95% CI) 100.0 % 0.04 [ 0.03, 0.07 ]
Heterogeneity: not applicable
Test for overall effect: Z = 12.64 (P < 0.00001)
Test for subgroup differences: Chi2 = 57.17, df = 5 (P = 0.00), I2 =91%
0.001 0.01 0.1 1 10 100 1000
Favours MDA Favours no MDA
(1) Garfield 1983 NIC: MDA (CQ+PQ once only) + larviciding vs. baseline data
(2) Simeons 1938 IND: MDA (Ate+Plas once only) + oiling vs. baseline data
Analysis 7.1. Comparison 7 MDA versus no MDA in areas of moderate and high endemicity (Stratified by
study design; subgrouped by 8-aminoquinoline), Outcome 1 Parasitaemia Prevalence during MDA.
Review: Mass drug administration for malaria
Comparison: 7 MDA versus no MDA in areas of moderate and high endemicity (Stratified by study design; subgrouped by 8-aminoquinoline)
Outcome: 1 Parasitaemia Prevalence during MDA
Study or subgroup MDA no MDA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Non-randomized controlled studies - with 8-aminoquinoline
Schneider 1961 BFA (1) 33/467 517/691 19.2 % 0.09 [ 0.07, 0.13 ]
Escudie 1962 BFA (2) 41/704 318/837 19.4 % 0.15 [ 0.11, 0.21 ]
Escudie 1962 BFA (3) 121/1171 318/837 20.4 % 0.27 [ 0.22, 0.33 ]
Escudie 1962 BFA (4) 122/420 338/467 20.6 % 0.40 [ 0.34, 0.47 ]
Escudie 1962 BFA (5) 76/573 338/467 20.3 % 0.18 [ 0.15, 0.23 ]
Subtotal (95% CI) 3335 3299 100.0 % 0.20 [ 0.12, 0.32 ]
Total events: 393 (MDA), 1829 (no MDA)
Heterogeneity: Tau2 = 0.29; Chi2 = 94.69, df = 4 (P<0.00001); I2 =96%
Test for overall effect: Z = 6.50 (P < 0.00001)
2 Non-randomized controlled studies - without 8-aminoquinoline
0.01 0.1 1 10 100
Favours MDA Favours control
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Study or subgroup MDA no MDA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Najera 1973 NGA (6) 4163/40950 2319/6064 34.4 % 0.27 [ 0.25, 0.28 ]
Molineaux 1980 NGA (7) 109/1486 380/1171 33.5 % 0.23 [ 0.19, 0.28 ]
Molineaux 1980 NGA (8) 40/2099 380/1171 32.1 % 0.06 [ 0.04, 0.08 ]
Subtotal (95% CI) 44535 8406 100.0 % 0.16 [ 0.08, 0.31 ]
Total events: 4312 (MDA), 3079 (no MDA)
Heterogeneity: Tau2 = 0.36; Chi2 = 94.98, df = 2 (P<0.00001); I2 =98%
Test for overall effect: Z = 5.28 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.33, df = 1 (P = 0.57), I2 =0.0%
0.01 0.1 1 10 100
Favours MDA Favours control
(1) Schneider 1961 BFA: MDA (AQ+PQ or CQ+PQ every 2 weeks for 15 rounds) vs. no intervention
(2) Escudie 1962 BFA: MDA (CQ+PQ or AQ+PQ every 14 days for 15 rounds) + IRS vs. IRS only
(3) Escudie 1962 BFA: MDA (CQ+PQ or AQ+PQ every 28 days for 8 rounds) + IRS vs. IRS only
(4) Escudie 1962 BFA: MDA (CQ+PQ or AQ+PQ every 28 days for 8 rounds) vs. no intervention
(5) Escudie 1962 BFA: MDA (CQ+PQ or AQ+PQ every 14 days for 15 rounds) vs. no intervention
(6) Najera 1973 NGA: MDA (CQ+Pyr every 2 months for 11 rounds ) + IRS vs. IRS only
(7) Molineaux 1980 NGA: MDA (SP every 10 weeks for 3 rounds) + IRS vs. IRS only
(8) Molineaux 1980 NGA: MDA (SP every 2 weeks during the wet season and 10 weeks during the dry season) + IRS vs. IRS only
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Analysis 7.2. Comparison 7 MDA versus no MDA in areas of moderate and high endemicity (Stratified by
study design; subgrouped by 8-aminoquinoline), Outcome 2 Parasitaemia Prevalence 1-3 months post MDA.
Review: Mass drug administration for malaria
Comparison: 7 MDA versus no MDA in areas of moderate and high endemicity (Stratified by study design; subgrouped by 8-aminoquinoline)
Outcome: 2 Parasitaemia Prevalence 1-3 months post MDA
Study or subgroup MDA no MDA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Non-randomized controlled studies - with 8-aminoquinoline
Escudie 1962 BFA (1) 61/1025 303/972 19.2 % 0.19 [ 0.15, 0.25 ]
Escudie 1962 BFA (2) 382/634 250/382 20.4 % 0.92 [ 0.84, 1.01 ]
Escudie 1962 BFA (3) 136/384 250/382 20.1 % 0.54 [ 0.46, 0.63 ]
Schneider 1961 BFA (4) 286/466 386/534 20.4 % 0.85 [ 0.78, 0.93 ]
Escudie 1962 BFA (5) 196/1446 303/972 20.0 % 0.43 [ 0.37, 0.51 ]
Subtotal (95% CI) 3955 3242 100.0 % 0.52 [ 0.33, 0.81 ]
Total events: 1061 (MDA), 1492 (no MDA)
Heterogeneity: Tau2 = 0.25; Chi2 = 231.04, df = 4 (P<0.00001); I2 =98%
Test for overall effect: Z = 2.90 (P = 0.0038)
2 Non-randomized controlled studies - without 8-aminoquinoline
Jones 1958 KEN (6) 21/251 40/106 34.0 % 0.22 [ 0.14, 0.36 ]
Roberts 1964 KEN (7) 13/300 118/300 29.3 % 0.11 [ 0.06, 0.19 ]
Roberts 1964 KEN (8) 20/300 140/300 36.7 % 0.14 [ 0.09, 0.22 ]
Subtotal (95% CI) 851 706 100.0 % 0.15 [ 0.10, 0.23 ]
Total events: 54 (MDA), 298 (no MDA)
Heterogeneity: Tau2 = 0.06; Chi2 = 4.02, df = 2 (P = 0.13); I2 =50%
Test for overall effect: Z = 9.21 (P < 0.00001)
Test for subgroup differences: Chi2 = 15.88, df = 1 (P = 0.00), I2 =94%
0.01 0.1 1 10 100
Favours MDA Favours control
(1) Escudie 1962 BFA: MDA (CQ+PQ or AQ+PQ every 14 days for 15 rounds) + IRS vs. IRS only
(2) Escudie 1962 BFA: MDA (CQ+PQ or AQ+PQ every 14 days for 15 rounds) vs. no intervention
(3) Escudie 1962 BFA: MDA (CQ+PQ or AQ+PQ every 28 days for 8 rounds) vs. no intervention
(4) Schneider 1961 BFA: MDA (AQ+PQ or CQ+PQ every 2 weeks for 15 rounds) vs. no intervention
(5) Escudie 1962 BFA: MDA (CQ+PQ or AQ+PQ every 28 days for 8 rounds) + IRS vs. IRS only
(6) Jones 1958 KEN: MDA (Pyr every 6 months for 3 rounds) vs. no intervention
(7) Roberts 1964 KEN: MDA (Pyr once only) vs. no intervention (1954 data)
(8) Roberts 1964 KEN: MDA (Pyr once only) vs. no intervention (1953 data)
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Analysis 7.3. Comparison 7 MDA versus no MDA in areas of moderate and high endemicity (Stratified by
study design; subgrouped by 8-aminoquinoline), Outcome 3 Parasitaemia Prevalence during MDA.
Review: Mass drug administration for malaria
Comparison: 7 MDA versus no MDA in areas of moderate and high endemicity (Stratified by study design; subgrouped by 8-aminoquinoline)
Outcome: 3 Parasitaemia Prevalence during MDA
Study or subgroup MDA no MDA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Uncontrolled before-and-after studies - with 8-aminoquinoline
Comer 1971 PAN (1) 16/1709 204/1256 100.0 % 0.06 [ 0.03, 0.10 ]
Subtotal (95% CI) 1709 1256 100.0 % 0.06 [ 0.03, 0.10 ]
Total events: 16 (MDA), 204 (no MDA)
Heterogeneity: not applicable
Test for overall effect: Z = 11.11 (P < 0.00001)
2 Uncontrolled before-and-after studies - without 8-aminoquinoline
Ricosse 1959 BFA (2) 12/409 315/563 31.8 % 0.05 [ 0.03, 0.09 ]
Metselaar 1961 PNG (3) 143/2500 300/2500 34.3 % 0.48 [ 0.39, 0.58 ]
Archibald 1960 NGA (4) 51/502 313/537 33.9 % 0.17 [ 0.13, 0.23 ]
Subtotal (95% CI) 3411 3600 100.0 % 0.17 [ 0.06, 0.51 ]
Total events: 206 (MDA), 928 (no MDA)
Heterogeneity: Tau2 = 0.92; Chi2 = 82.45, df = 2 (P<0.00001); I2 =98%
Test for overall effect: Z = 3.17 (P = 0.0015)
Test for subgroup differences: Chi2 = 2.98, df = 1 (P = 0.08), I2 =66%
0.01 0.1 1 10 100
Favours MDA Favours control
(1) Comer 1971 PAN: MDA (Pyr+PQ every 2 weeks for 2 years) vs. baseline data
(2) Ricosse 1959 BFA: MDA (Pyr every 2 weeks for 8 rounds) vs. baseline data
(3) Metselaar 1961 PNG: MDA (CQ+Pyr weekly for 6 rounds) +IRS vs. IRS only baseline data
(4) Archibald 1960 NGA: MDA (CQ+Pyr every 6 months for 4 rounds) + IRS vs. IRS only baseline data
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Analysis 7.4. Comparison 7 MDA versus no MDA in areas of moderate and high endemicity (Stratified by
study design; subgrouped by 8-aminoquinoline), Outcome 4 Parasitaemia Prevalence <1 month post MDA.
Review: Mass drug administration for malaria
Comparison: 7 MDA versus no MDA in areas of moderate and high endemicity (Stratified by study design; subgrouped by 8-aminoquinoline)
Outcome: 4 Parasitaemia Prevalence <1 month post MDA
Study or subgroup MDA no MDA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Uncontrolled before-and-after studies - with 8-aminoquinoline
Kligler 1931 PSE (1) 66/470 221/635 35.4 % 0.40 [ 0.31, 0.52 ]
Hii 1987 MYS (2) 17/44 25/45 25.7 % 0.70 [ 0.44, 1.10 ]
Song 2010 KHM (3) 136/777 379/679 38.8 % 0.31 [ 0.27, 0.37 ]
Subtotal (95% CI) 1291 1359 100.0 % 0.42 [ 0.29, 0.61 ]
Total events: 219 (MDA), 625 (no MDA)
Heterogeneity: Tau2 = 0.08; Chi2 = 11.53, df = 2 (P = 0.003); I2 =83%
Test for overall effect: Z = 4.59 (P < 0.00001)
2 Uncontrolled before-and-after studies - without 8-aminoquinoline
Houel 1954 MAR (4) 8/147 21/147 9.7 % 0.38 [ 0.17, 0.83 ]
Ricosse 1959 BFA (5) 103/650 315/563 40.6 % 0.28 [ 0.23, 0.34 ]
Archibald 1960 NGA (6) 14/300 23/79 14.0 % 0.16 [ 0.09, 0.30 ]
van Dijk 1961 PNG (7) 79/1280 196/1143 35.7 % 0.36 [ 0.28, 0.46 ]
Subtotal (95% CI) 2377 1932 100.0 % 0.29 [ 0.22, 0.38 ]
Total events: 204 (MDA), 555 (no MDA)
Heterogeneity: Tau2 = 0.04; Chi2 = 6.78, df = 3 (P = 0.08); I2 =56%
Test for overall effect: Z = 8.89 (P < 0.00001)
Test for subgroup differences: Chi2 = 2.39, df = 1 (P = 0.12), I2 =58%
0.001 0.01 0.1 1 10 100 1000
Favours MDA Favours control
(1) Kligler 1931 PSE: MDA (Plas+Q every 3 weeks for 3 rounds) vs. baseline data
(2) Hii 1987 MYS: MDA (SP+PQ once only) vs. baseline data
(3) Song 2010 KHM: MDA (AS+Pip once only plus PQ every 10 days for 6 months) vs. baseline data
(4) Houel 1954 MAR: MDA (Pyr once only) +IRS vs. IRS only baseline data
(5) Ricosse 1959 BFA: MDA (Pyr every 2 weeks for 8 rounds) vs. baseline data
(6) Archibald 1960 NGA: MDA (CQ+Pyr monthly for 5 rounds) + IRS vs. IRS only baseline data
(7) van Dijk 1961 PNG: MDA (CQ every 4 weeks for 11 rounds) vs. baseline data
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Analysis 7.5. Comparison 7 MDA versus no MDA in areas of moderate and high endemicity (Stratified by
study design; subgrouped by 8-aminoquinoline), Outcome 5 Parasitaemia Prevalence 1-3 months post MDA.
Review: Mass drug administration for malaria
Comparison: 7 MDA versus no MDA in areas of moderate and high endemicity (Stratified by study design; subgrouped by 8-aminoquinoline)
Outcome: 5 Parasitaemia Prevalence 1-3 months post MDA
Study or subgroup MDA no MDA Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Uncontrolled before-and-after studies - with 8-aminoquinoline
Hii 1987 MYS (1) 19/53 25/45 100.0 % 0.65 [ 0.41, 1.01 ]
Subtotal (95% CI) 53 45 100.0 % 0.65 [ 0.41, 1.01 ]
Total events: 19 (MDA), 25 (no MDA)
Heterogeneity: not applicable
Test for overall effect: Z = 1.93 (P = 0.054)
2 Uncontrolled before-and-after studies - without 8-aminoquinoline
Cavalie 1962 CMR (2) 31/466 265/413 16.1 % 0.10 [ 0.07, 0.15 ]
Cavalie 1962 CMR (3) 45/1143 162/1218 9.0 % 0.30 [ 0.21, 0.41 ]
Gaud 1953 MAR (4) 185/1527 634/1527 36.3 % 0.29 [ 0.25, 0.34 ]
Houel 1954 MAR (5) 4/147 21/147 1.2 % 0.19 [ 0.07, 0.54 ]
Jones 1954 KEN (6) 3/135 47/135 2.7 % 0.06 [ 0.02, 0.20 ]
Metselaar 1961 PNG (7) 38/2500 300/2500 17.2 % 0.13 [ 0.09, 0.18 ]
Ricosse 1959 BFA (8) 241/538 315/563 17.6 % 0.80 [ 0.71, 0.90 ]
Subtotal (95% CI) 6456 6503 100.0 % 0.32 [ 0.29, 0.34 ]
Total events: 547 (MDA), 1744 (no MDA)
Heterogeneity: Chi2 = 312.57, df = 6 (P<0.00001); I2 =98%
Test for overall effect: Z = 26.70 (P < 0.00001)
Test for subgroup differences: Chi2 = 9.56, df = 1 (P = 0.00), I2 =90%
0.01 0.1 1 10 100
Favours experimental Favours control
(1) Hii 1987 MYS: MDA (SP+PQ once only) vs. baseline data
(2) Cavalie 1962 CMR: MDA (CQ+PYR once only) vs. baseline data
(3) Cavalie 1962 CMR: MDA (CQ+Pyr every 4 months for 2 rounds) + IRS vs. IRS only baseline data
(4) Gaud 1953 MAR: MDA (AQ once only) vs. baseline data
(5) Houel 1954 MAR: MDA (Pyr once only) +IRS vs. IRS only baseline data
(6) Jones 1954 KEN: MDA (Pyr every 6 months for 3 rounds) vs. baseline data
(7) Metselaar 1961 PNG: MDA (CQ+Pyr weekly for 6 rounds) +IRS vs. IRS only baseline data
(8) Ricosse 1959 BFA: MDA (Pyr every 2 weeks for 8 rounds) vs. baseline data
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Analysis 7.6. Comparison 7 MDA versus no MDA in areas of moderate and high endemicity (Stratified by
study design; subgrouped by 8-aminoquinoline), Outcome 6 Parasitaemia Prevalence 4-6 months post MDA.
Review: Mass drug administration for malaria
Comparison: 7 MDA versus no MDA in areas of moderate and high endemicity (Stratified by study design; subgrouped by 8-aminoquinoline)
Outcome: 6 Parasitaemia Prevalence 4-6 months post MDA
Study or subgroup MDA no MDA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Uncontrolled before-and-after studies - with 8-aminoquinoline
Kligler 1931 PSE (1) 50/131 61/70 35.0 % 0.44 [ 0.35, 0.55 ]
Hii 1987 MYS (2) 12/30 25/45 28.4 % 0.72 [ 0.43, 1.20 ]
Song 2010 KHM (3) 212/1609 572/1094 36.6 % 0.25 [ 0.22, 0.29 ]
Subtotal (95% CI) 1770 1209 100.0 % 0.41 [ 0.24, 0.72 ]
Total events: 274 (MDA), 658 (no MDA)
Heterogeneity: Tau2 = 0.21; Chi2 = 28.78, df = 2 (P<0.00001); I2 =93%
Test for overall effect: Z = 3.14 (P = 0.0017)
2 Uncontrolled before-and-after studies - without 8-aminoquinoline
Archibald 1960 NGA (4) 30/125 23/79 48.8 % 0.82 [ 0.52, 1.31 ]
Cavalie 1962 CMR (5) 1130/2375 162/1218 51.2 % 3.58 [ 3.08, 4.15 ]
Subtotal (95% CI) 2500 1297 100.0 % 1.75 [ 0.41, 7.41 ]
Total events: 1160 (MDA), 185 (no MDA)
Heterogeneity: Tau2 = 1.06; Chi2 = 35.13, df = 1 (P<0.00001); I2 =97%
Test for overall effect: Z = 0.76 (P = 0.45)
Test for subgroup differences: Chi2 = 3.34, df = 1 (P = 0.07), I2 =70%
0.01 0.1 1 10 100
Favours MDA Favours control
(1) Kligler 1931 PSE: MDA (Plas+Q every 3 weeks for 3 rounds) vs. baseline data
(2) Hii 1987 MYS: MDA (SP+PQ once only) vs. baseline data
(3) Song 2010 KHM: MDA (AS+Pip once only plus PQ every 10 days for 6 months) vs. baseline data
(4) Archibald 1960 NGA: MDA (CQ+Pyr monthly for 5 rounds) + IRS vs. IRS only baseline data
(5) Cavalie 1962 CMR: MDA (CQ+Pyr once only) + IRS vs. IRS only baseline data
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Analysis 8.1. Comparison 8 MDA versus no MDA for all endemicity levels (Stratified by study design;
subgrouped by plasmodium species), Outcome 1 Parasitaemia Prevalence at baseline.
Review: Mass drug administration for malaria
Comparison: 8 MDA versus no MDA for all endemicity levels (Stratified by study design; subgrouped by plasmodium species)
Outcome: 1 Parasitaemia Prevalence at baseline
Study or subgroup MDA no MDA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Non-randomized controlled studies - falciparum
Jones 1958 KEN (1) 98/297 42/160 73.4 % 1.26 [ 0.93, 1.71 ]
Kaneko 2000 VUT (2) 34/508 24/572 26.6 % 1.60 [ 0.96, 2.65 ]
Subtotal (95% CI) 805 732 100.0 % 1.34 [ 1.03, 1.74 ]
Total events: 132 (MDA), 66 (no MDA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.63, df = 1 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 2.18 (P = 0.029)
2 Non-randomized controlled studies - vivax
Jones 1958 KEN 30/297 2/160 32.8 % 8.08 [ 1.96, 33.38 ]
Kaneko 2000 VUT 45/508 19/572 67.2 % 2.67 [ 1.58, 4.50 ]
Subtotal (95% CI) 805 732 100.0 % 3.84 [ 1.33, 11.04 ]
Total events: 75 (MDA), 21 (no MDA)
Heterogeneity: Tau2 = 0.36; Chi2 = 2.22, df = 1 (P = 0.14); I2 =55%
Test for overall effect: Z = 2.49 (P = 0.013)
Test for subgroup differences: Chi2 = 3.59, df = 1 (P = 0.06), I2 =72%
0.01 0.1 1 10 100
Favours MDA Favours control
(1) Jones 1958 KEN: MDA (Pyr every 6 months for 3 rounds) vs. no intervention
(2) Kaneko 2000 VUT: MDA (CQ+SP+PQ weekly for 9 rounds) + ITNs + larvivorous fish vs. ITNs only
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Analysis 8.2. Comparison 8 MDA versus no MDA for all endemicity levels (Stratified by study design;
subgrouped by plasmodium species), Outcome 2 Parasitaemia Prevalence during MDA.
Review: Mass drug administration for malaria
Comparison: 8 MDA versus no MDA for all endemicity levels (Stratified by study design; subgrouped by plasmodium species)
Outcome: 2 Parasitaemia Prevalence during MDA
Study or subgroup MDA no MDA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Uncontrolled before-and-after studies - falciparum
Metselaar 1961 PNG (1) 107/2500 123/2500 52.3 % 0.87 [ 0.68, 1.12 ]
Paik 1974a SLB (2) 12/462 15/99 47.7 % 0.17 [ 0.08, 0.35 ]
Subtotal (95% CI) 2962 2599 100.0 % 0.40 [ 0.08, 1.97 ]
Total events: 119 (MDA), 138 (no MDA)
Heterogeneity: Tau2 = 1.25; Chi2 = 17.15, df = 1 (P = 0.00003); I2 =94%
Test for overall effect: Z = 1.12 (P = 0.26)
2 Uncontrolled before-and-after studies - vivax
Metselaar 1961 PNG 29/2500 45/2500 77.9 % 0.64 [ 0.41, 1.02 ]
Paik 1974a SLB 15/462 7/99 22.1 % 0.46 [ 0.19, 1.10 ]
Subtotal (95% CI) 2962 2599 100.0 % 0.60 [ 0.40, 0.90 ]
Total events: 44 (MDA), 52 (no MDA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.46, df = 1 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 2.46 (P = 0.014)
Test for subgroup differences: Chi2 = 0.23, df = 1 (P = 0.63), I2 =0.0%
0.2 0.5 1 2 5
Favours MDA Favours control
(1) Metselaar 1961 PNG: MDA (CQ+Pyr weekly for 6 rounds) + IRS vs. IRS only baseline data
(2) Paik 1974a SLB: MDA (CQ+Pyr monthly for 4 rounds) + IRS vs. baseline data
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Analysis 8.3. Comparison 8 MDA versus no MDA for all endemicity levels (Stratified by study design;
subgrouped by plasmodium species), Outcome 3 Parasitaemia Prevalence <1 month post MDA.
Review: Mass drug administration for malaria
Comparison: 8 MDA versus no MDA for all endemicity levels (Stratified by study design; subgrouped by plasmodium species)
Outcome: 3 Parasitaemia Prevalence <1 month post MDA
Study or subgroup MDA no MDA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Non-randomized controlled studies - falciparum
Jones 1958 KEN (1) 2/288 52/145 100.0 % 0.02 [ 0.00, 0.08 ]
Subtotal (95% CI) 288 145 100.0 % 0.02 [ 0.00, 0.08 ]
Total events: 2 (MDA), 52 (no MDA)
Heterogeneity: not applicable
Test for overall effect: Z = 5.53 (P < 0.00001)
2 Non-randomized controlled studies - vivax
Jones 1958 KEN 0/288 5/145 100.0 % 0.05 [ 0.00, 0.82 ]
Subtotal (95% CI) 288 145 100.0 % 0.05 [ 0.00, 0.82 ]
Total events: 0 (MDA), 5 (no MDA)
Heterogeneity: not applicable
Test for overall effect: Z = 2.09 (P = 0.037)
3 Uncontrolled before-and-after studies - falciparum
van Dijk 1961 PNG (2) 11/1280 72/1143 14.0 % 0.14 [ 0.07, 0.26 ]
Paik 1974a SLB (3) 12/350 15/99 10.7 % 0.23 [ 0.11, 0.47 ]
Malaria˙Taiwan 1991 TWN (4) 0/1537 3/1502 0.7 % 0.14 [ 0.01, 2.70 ]
Song 2010 KHM (5) 71/777 251/679 74.6 % 0.25 [ 0.19, 0.32 ]
Subtotal (95% CI) 3944 3423 100.0 % 0.22 [ 0.18, 0.29 ]
Total events: 94 (MDA), 341 (no MDA)
Heterogeneity: Tau2 = 0.01; Chi2 = 3.15, df = 3 (P = 0.37); I2 =5%
Test for overall effect: Z = 12.13 (P < 0.00001)
4 Uncontrolled before-and-after studies - vivax
van Dijk 1961 PNG 65/1280 98/1143 42.8 % 0.59 [ 0.44, 0.80 ]
Paik 1974a SLB 8/350 7/99 4.0 % 0.32 [ 0.12, 0.87 ]
Malaria˙Taiwan 1991 TWN 5/1537 7/1502 3.0 % 0.70 [ 0.22, 2.19 ]
Song 2010 KHM 65/777 128/679 50.2 % 0.44 [ 0.34, 0.59 ]
Subtotal (95% CI) 3944 3423 100.0 % 0.50 [ 0.41, 0.61 ]
Total events: 143 (MDA), 240 (no MDA)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.97, df = 3 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 6.80 (P < 0.00001)
Test for subgroup differences: Chi2 = 44.15, df = 3 (P = 0.00), I2 =93%
0.001 0.01 0.1 1 10 100 1000
Favours MDA Favours control
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(1) Jones 1958 KEN: MDA (Pyr every 6 months for 3 rounds) vs. no intervention
(2) van Dijk 1961 PNG: MDA (CQ every 4 weeks for 11 rounds) vs. baseline data
(3) Paik 1974a SLB: MDA (CQ+Pyr monthly for 4 rounds) + IRS vs. baseline data
(4) Malaria˙Taiwan 1991 TWN: MDA (CQ once only) + IRS vs. IRS only baseline data
(5) Song 2010 KHM: MDA (AS+Pip once only plus PQ every 10 days for 6 months) vs. baseline data
Analysis 8.4. Comparison 8 MDA versus no MDA for all endemicity levels (Stratified by study design;
subgrouped by plasmodium species), Outcome 4 Parasitaemia Prevalence 1-3 months post MDA.
Review: Mass drug administration for malaria
Comparison: 8 MDA versus no MDA for all endemicity levels (Stratified by study design; subgrouped by plasmodium species)
Outcome: 4 Parasitaemia Prevalence 1-3 months post MDA
Study or subgroup MDA no MDA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Non-randomized controlled studies - falciparum
Jones 1958 KEN (1) 2/251 29/106 100.0 % 0.03 [ 0.01, 0.12 ]
Subtotal (95% CI) 251 106 100.0 % 0.03 [ 0.01, 0.12 ]
Total events: 2 (MDA), 29 (no MDA)
Heterogeneity: not applicable
Test for overall effect: Z = 4.90 (P < 0.00001)
2 Non-randomized controlled studies - vivax
Jones 1958 KEN 13/251 4/106 100.0 % 1.37 [ 0.46, 4.11 ]
Subtotal (95% CI) 251 106 100.0 % 1.37 [ 0.46, 4.11 ]
Total events: 13 (MDA), 4 (no MDA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.57 (P = 0.57)
3 Uncontrolled before-and-after studies - falciparum
Metselaar 1961 PNG (2) 18/2500 123/2500 51.5 % 0.15 [ 0.09, 0.24 ]
Paik 1974a SLB (3) 33/655 15/99 48.5 % 0.33 [ 0.19, 0.59 ]
Subtotal (95% CI) 3155 2599 100.0 % 0.22 [ 0.09, 0.51 ]
Total events: 51 (MDA), 138 (no MDA)
Heterogeneity: Tau2 = 0.31; Chi2 = 5.14, df = 1 (P = 0.02); I2 =81%
Test for overall effect: Z = 3.49 (P = 0.00048)
4 Uncontrolled before-and-after studies - vivax
0.01 0.1 1 10 100
Favours MDA Favours control
(Continued . . . )
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(. . . Continued)
Study or subgroup MDA no MDA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Metselaar 1961 PNG 20/2500 45/2500 69.9 % 0.44 [ 0.26, 0.75 ]
Paik 1974a SLB 29/655 7/99 30.1 % 0.63 [ 0.28, 1.39 ]
Subtotal (95% CI) 3155 2599 100.0 % 0.49 [ 0.32, 0.76 ]
Total events: 49 (MDA), 52 (no MDA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.50, df = 1 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 3.17 (P = 0.0015)
Test for subgroup differences: Chi2 = 20.83, df = 3 (P = 0.00), I2 =86%
0.01 0.1 1 10 100
Favours MDA Favours control
(1) Jones 1958 KEN: MDA (Pyr every 6 months for 3 rounds) vs. no intervention
(2) Metselaar 1961 PNG: MDA (CQ+Pyr weekly for 6 rounds) + IRS vs. IRS only baseline data
(3) Paik 1974a SLB: MDA (CQ+Pyr monthly for 4 rounds) + IRS vs. baseline data
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Analysis 8.5. Comparison 8 MDA versus no MDA for all endemicity levels (Stratified by study design;
subgrouped by plasmodium species), Outcome 5 Parasitaemia Prevalence 4-6 months post MDA.
Review: Mass drug administration for malaria
Comparison: 8 MDA versus no MDA for all endemicity levels (Stratified by study design; subgrouped by plasmodium species)
Outcome: 5 Parasitaemia Prevalence 4-6 months post MDA
Study or subgroup MDA no MDA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Non-randomized controlled studies - falciparum
Jones 1958 KEN (1) 24/262 62/148 100.0 % 0.22 [ 0.14, 0.33 ]
Subtotal (95% CI) 262 148 100.0 % 0.22 [ 0.14, 0.33 ]
Total events: 24 (MDA), 62 (no MDA)
Heterogeneity: not applicable
Test for overall effect: Z = 7.00 (P < 0.00001)
2 Non-randomized controlled studies - vivax
Jones 1958 KEN 10/262 7/148 100.0 % 0.81 [ 0.31, 2.08 ]
Subtotal (95% CI) 262 148 100.0 % 0.81 [ 0.31, 2.08 ]
Total events: 10 (MDA), 7 (no MDA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.44 (P = 0.66)
3 Uncontrolled before-and-after studies - falciparum
Paik 1974a SLB (2) 92/840 15/99 47.8 % 0.72 [ 0.44, 1.20 ]
Song 2010 KHM (3) 132/1609 393/1094 52.2 % 0.23 [ 0.19, 0.27 ]
Subtotal (95% CI) 2449 1193 100.0 % 0.40 [ 0.13, 1.23 ]
Total events: 224 (MDA), 408 (no MDA)
Heterogeneity: Tau2 = 0.63; Chi2 = 17.80, df = 1 (P = 0.00002); I2 =94%
Test for overall effect: Z = 1.61 (P = 0.11)
4 Uncontrolled before-and-after studies - vivax
Paik 1974a SLB 20/840 7/99 8.4 % 0.34 [ 0.15, 0.78 ]
Song 2010 KHM 80/1609 179/1094 91.6 % 0.30 [ 0.24, 0.39 ]
Subtotal (95% CI) 2449 1193 100.0 % 0.31 [ 0.24, 0.39 ]
Total events: 100 (MDA), 186 (no MDA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.05, df = 1 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 9.60 (P < 0.00001)
Test for subgroup differences: Chi2 = 6.60, df = 3 (P = 0.09), I2 =55%
0.01 0.1 1 10 100
Favours MDA Favours control
(1) Jones 1958 KEN: MDA (Pyr every 6 months for 3 rounds) vs. no intervention
(2) Paik 1974a SLB: MDA (CQ+Pyr monthly for 4 rounds) + IRS vs. baseline data
(3) Song 2010 KHM: MDA (AS+Pip once only plus PQ every 10 days for 6 months) vs. baseline data
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Analysis 8.6. Comparison 8 MDA versus no MDA for all endemicity levels (Stratified by study design;
subgrouped by plasmodium species), Outcome 6 Parasitaemia Prevalence >12 months post MDA.
Review: Mass drug administration for malaria
Comparison: 8 MDA versus no MDA for all endemicity levels (Stratified by study design; subgrouped by plasmodium species)
Outcome: 6 Parasitaemia Prevalence >12 months post MDA
Study or subgroup MDA no MDA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Non-randomized controlled studies - falciparum
Kaneko 2000 VUT (1) 0/691 57/640 100.0 % 0.01 [ 0.00, 0.13 ]
Subtotal (95% CI) 691 640 100.0 % 0.01 [ 0.00, 0.13 ]
Total events: 0 (MDA), 57 (no MDA)
Heterogeneity: not applicable
Test for overall effect: Z = 3.40 (P = 0.00068)
2 Non-randomized controlled studies - vivax
Kaneko 2000 VUT 7/691 18/640 100.0 % 0.36 [ 0.15, 0.86 ]
Subtotal (95% CI) 691 640 100.0 % 0.36 [ 0.15, 0.86 ]
Total events: 7 (MDA), 18 (no MDA)
Heterogeneity: not applicable
Test for overall effect: Z = 2.31 (P = 0.021)
3 Uncontrolled before-and-after studies - falciparum
Malaria˙Taiwan 1991 TWN (2) 0/2007 3/1502 1.6 % 0.11 [ 0.01, 2.07 ]
Song 2010 KHM (3) 28/1281 393/1094 98.4 % 0.06 [ 0.04, 0.09 ]
Subtotal (95% CI) 3288 2596 100.0 % 0.06 [ 0.04, 0.09 ]
Total events: 28 (MDA), 396 (no MDA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.14, df = 1 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 14.71 (P < 0.00001)
4 Uncontrolled before-and-after studies - vivax
Malaria˙Taiwan 1991 TWN 0/2007 7/1502 1.5 % 0.05 [ 0.00, 0.87 ]
Song 2010 KHM 36/1281 179/1094 98.5 % 0.17 [ 0.12, 0.24 ]
Subtotal (95% CI) 3288 2596 100.0 % 0.17 [ 0.12, 0.24 ]
Total events: 36 (MDA), 186 (no MDA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.71, df = 1 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 10.07 (P < 0.00001)
Test for subgroup differences: Chi2 = 25.82, df = 3 (P = 0.00), I2 =88%
0.001 0.01 0.1 1 10 100 1000
Favours MDA Favours control
(1) Kaneko 2000 VUT: MDA (CQ+SP+PQ weekly for 9 rounds) + ITNs + larvivorous fish vs. ITNs only
(2) Malaria˙Taiwan 1991 TWN: MDA (CQ once only) + IRS vs. IRS only baseline data
(3) Song 2010 KHM: MDA (AS+Pip once only plus PQ every 10 days for 6 months) vs. baseline data
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A D D I T I O N A L T A B L E S
Table 1. Overview of studies conducted in areas of low endemicity
Study
ID
Design Coun-
try
Year En-
demicity
MDA group Control
group/
Baseline
Drug
(dose)
Interval No. of
rounds
Popula-
tion
targeted
Cover-
age
Co-
inter-
vention
Shekalaghe
2011
CRT Tanza-
nia
2008 0%* AS (4
mg/kg/
day for 3
days)
+SP
(25 mg/
1.25 mg
on day 1)
+PQ (0.
75mg on
day 3)
- 1 1110 93% Back-
ground
ITN use
Placebo
+ Back-
ground
ITN use
Malaria
Taiwan
1991
BAS Taiwan 1955 3-4%* CQ (12
mg/kg)
- 1 1520 ND IRS IRS
CRT = Cluster-randomized trial; BAS = Uncontrolled before-and-after study; AS = Artesunate; SP = Sulfadoxine-Pyrimethamine; PQ
= Primaquine; CQ = Chloroquine; ND = Not described; IRS = Indoor Residual Spraying.
*In all ages
Table 2. Overview of studies conducted in areas of moderate endemicity
Study
ID
Design Coun-
try
Year En-
demic-
ity
MDA group Control
group/
baseline
Drug
(dose)
Interval No. of
rounds
Popula-
tion
targeted
Cover-
age
Co-
inter-
vention
Najera
1973
N-RCS Nigeria 1966-68 29%* CQ
(450
mg)
+Pyr (45
mg)
2
months
11 52,000 78-92% IRS IRS
alone
Singh
1953
N-RCS India 1952-53 22%* AQ (600
mg)
2 weeks 5 125 ND None No
inter-
vention
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Table 2. Overview of studies conducted in areas of moderate endemicity (Continued)
Jones
1958
N-RCS Kenya 1952-53 34%† Pyr (100
mg)
6
months
3 3721-
4500
ND None No
inter-
vention
Roberts
1964
N-RCS Kenya 1953 28%* Pyr (50
mg)
- 1 101,000 95% None No
inter-
vention
N-RCS Kenya 1954 22%* Pyr (50
mg)
- 1 99,000 95% None No
inter-
vention
Archibald
1960
BAS Nigeria 1958 29%† CQ
(600
mg)
+Pyr (25
mg)
1 month 5 10,000 ND IRS IRS
Cavalie
1962
BAS
Cameroon
1960-61 20%† CQ
(600
mg)
+Pyr (50
mg)
4
months
2 22,500 76-92% IRS IRS
Houel
1954
BAS Mo-
rocco
1953 14%† Pyr (100
mg)
- 1 9999 ND IRS IRS
Metse-
laar
1961
BAS New
Guinea
1958-59 13-
21%†
CQ
(450
mg)
+Pyr (50
mg)
1 week 6 2500 90% IRS IRS
Jones
1954
BAS Kenya 1952-53 35%† Pyr (100
mg)
6
months
3 3721 ND None -
van
Dijk
1961
BAS Papua
New
Guinea
1960 39%† CQ
(450
mg)
4 weeks 11 1250 97% None -
Comer
1971
BAS Panama 1965-68 17%* Pyr
(50 mg /
75 mg) +
PQ (40
mg)
2 weeks 49 1709 61-87% None -
N-RCS = Non-randomized controlled study; BAS = Uncontrolled before-and-after study; AQ = Amodiaquine; Pyr = Pyrimethamine;
CQ = Chloroquine; PQ = Primaquine; ND = Not described; IRS = Indoor Residual Spraying.
*In all ages
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†Amongst children only
Table 3. Overview of studies conducted in areas of high endemicity
Study
ID
Design Coun-
try
Year En-
demic-
ity
MDA group Control
group
Drug
(dose)
Interval No. of
rounds
Popula-
tion
targeted
Cover-
age
Co-
inter-
vention
Von Sei-
dlein
2003
CRT Gambia 1999 43%† AS (4
mg/kg/
day for 3
days)
+SP
(25 mg/
1.25 mg
on day
1)
- 1 1969 89% None Placebo
Molin-
eaux
1980
N-RCS Nigeria 1970-75 46%* SP (500
mg/25
mg)
10 weeks 9‡ 14,129 85% IRS IRS
alone
SP (500
mg/25
mg)
2-10
weeks
23‡ 1810 85% IRS IRS
alone
Escudie
1962
N-RCS Burkina
Faso
1960-61 56.1%† CQ
(600
mg)/
AQ (600
mg)
+PQ (15
mg)
1 month 8 1890 75-92% None No
inter-
vention
CQ
(600
mg)/
AQ (600
mg)
+PQ (15
mg)
2 weeks 15 2560 84-97% None No
inter-
vention
CQ
(600
mg)/
AQ (600
mg)
1 month 8 5400 81-92% IRS IRS
alone-
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Table 3. Overview of studies conducted in areas of high endemicity (Continued)
+PQ (15
mg)
CQ
(600
mg)/
AQ (600
mg)
+PQ (15
mg)
2 weeks 15 3490 82-94% IRS IRS
alone-
Schnei-
der
1961
N-RCS Burkina
Faso
1960-61 59%† CQ
(600
mg)/
AQ (600
mg)
+PQ (15
mg)
2 weeks 15 2500 90% None No
inter-
vention
Archibald
1960
BAS Nigeria 1957-59 64%† CQ
(600
mg)
+Pyr (25
mg)
6
months
4 1300 ND IRS IRS-
Cavalie
1962
BAS
Cameroon
1960-61 65%* CQ
(600
mg)
+Pyr (50
mg)
- 1 7000 100% IRS IRS
Gaud
1953
BAS Mo-
rocco
1952 42%* AQ (600
mg)
- 1 3000 ND None -
Ricosse
1959
BAS Burkina
Faso
1958-59 56%† Pyr (50
mg)
2 weeks 8 3000 82-91% None -
Song
2010
BAS Cambo-
dia
2003-06 56%† AS (125
mg/
day for 2
days) +
PIP (750
mg/
day for 2
days)
+ PQ (9
mg every
10 days)
- 1 3653 ND None -
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Table 3. Overview of studies conducted in areas of high endemicity (Continued)
Hii
1987
BAS Malaysia 1984-85 56%† SP
(1500
mg /
75 mg) +
PQ (30
mg)
- 1 148 76% None -
Kligler
1931
BAS Palestine 1930 67%† Plas
(30 mg)
+Q (900
mg)
twice
daily for
5 days
3 weeks 3 953 79% None -
CRT= Cluster-randomized trial; N-RCS = Non-randomized controlled study; BAS = Uncontrolled before-and-after study; AS =
Artesunate; SP = Sulfadoxine (or sulfalene)-Pyrimethamine; Pyr = Pyrimethamine; CQ = Chloroquine; AQ = Amodiaquine; PQ =
Primaquine; Pip = Piperaquine; Plas = Plasmochin; Q = Quinine; ND = Not described; IRS = Indoor Residual Spraying.
*In all ages
†Amongst children only
‡Estimated from the data provided
Table 4. Overview of studies comparing MDA + vector control versus no intervention
Study
ID
Design Coun-
try
Year En-
demic-
ity
MDA group Control
group/
baseline
Drug
(dose)
Interval No. of
rounds
Popula-
tion
targeted
Cover-
age
Co-
inter-
vention
Moderate Endemicity
Kaneko
2000
N-RCS Vanuatu 1991-99 29%* CQ
(600
mg) + SP
(1500
mg/
75 mg) +
PQ
(45 mg)
weeks 1,
5, and 9;
CQ
(300
mg) +
1 week 9 718 79-92% ITN +
larvivo-
rous fish
low
base-
line cov-
erage of
ITNs
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Table 4. Overview of studies comparing MDA + vector control versus no intervention (Continued)
PQ
(45 mg)
weeks 2,
3, 4, 6, 7,
and 8
Ricosse
1959
BAS Burkina
Faso
1958-59 15%† Pyr (50
mg)
2 weeks 8 5000 82-91% IRS None
De Zu-
lueta
1961
BAS Uganda 1959-60 34%† CQ
(600
mg)
+Pyr (50
mg)
3
months
4 30,384 80% IRS None
De Zu-
lueta
1964
BAS Uganda 1960 23%† CQ
(600
mg)
+Pyr (50
mg)
5
months
2 16,000 50% IRS None
Paik
1974a
BAS
Solomon
Islands
1972 28%* CQ
(600
mg)
+Pyr (50
mg)
1 month 4 ND 90% IRS None
High Endemicity
Molin-
eaux
1980
N-RCS Nigeria 1970-75 46%* SP (500
mg/25
mg)
10 weeks 9‡ 14,129 85% IRS None
SP (500
mg/25
mg)
2-10
weeks
23‡ 1810 85% IRS None
Escudie
1962
N-RCS Burkina
Faso
1960-61 56.1%† CQ
(600
mg) /
AQ (600
mg) +
PQ (15
mg)
1 month 8 5400 81-92% IRS None
CQ
(600
mg)/
2 weeks 15 3490 82-94% IRS None
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Table 4. Overview of studies comparing MDA + vector control versus no intervention (Continued)
AQ (600
mg) +
PQ (15
mg)
Schnei-
der
1961
N-RCS Burkina
Faso
1960-61 59%† AQ (600
mg) +
PQ (15
mg)
2 weeks 8 3525 ND IRS None
Metse-
laar
1961
BAS New
Guinea
1958-59 46%* CQ
(450
mg)
+Pyr (50
mg)
1 week 6 2500 90% IRS None
Hii
1987
BAS Malaysia 1984-85 46%† SP
(1500
mg /
75 mg) +
PQ (30
mg)
- 1 754 87% ITN None
N-RCS = Non-randomized controlled study; BAS = Uncontrolled before-and-after study; AQ = Amodiaquine; Pyr = Pyrimethamine;
CQ = Chloroquine; SP = Sulfadoxine (or sulfalene)-Pyrimethamine; PQ = Primaquine; ND = Not described; IRS = Indoor Residual
Spraying; ITN = Insecticide Treated Net.
*In all ages
†Amongst children only
‡Estimated from the data provided
Table 5. Overview of studies assessing parasitaemia incidence only
Study
ID
Design Coun-
try
Year Base-
line In-
cidence
MDA group Baseline
Drug
(dose)
Interval No. of
rounds
Popula-
tion
targeted
Cover-
age
Co-
inter-
vention
Garfield
1983
BAS
Nicaragua
1981-82 0.4/
1000
CQ
(500
mg/
day for 3
days) +
PQ
(15 mg/
day for 3
- 1 2,300,
000
70-80% Larval
control
None
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Table 5. Overview of studies assessing parasitaemia incidence only (Continued)
days)
Sime-
ons
1938
BAS India 1935 156/
1000
Ate (300
mg) +
Plas (60
mg)
- 1 5650 100% Larval
control
None
Gabal-
don
1959
BAS
Venezuela
1956-57 0.4/
1000
Pyr (50
mg)
1 week 24 111,995 ND IRS IRS
Kon-
drashin
1985
BAS India 1981 4/1000 CQ
(600
mg) +
PQ (45
mg)
6
months
2 51,325 85% IRS IRS
Paik
1974b
BAS
Solomon
Islands
1972-73 15/1000 CQ
(300
mg/
day for 5
days) +
PQ
(15 mg/
day for 5
days)
3
months
3 1200 90% None -
Cáceres
Garcia
2008
BAS
Venezuela
2002-07 22/1000 CQ
(25 mg/
kg over 3
days)
+PQ
(3.5 mg/
kg over 7
days)
- 1 22,941 77% None -
BAS = Uncontrolled before-and-after study; PQ = Primaquine; CQ = Chloroquine; Pyr = Pyrimethamine; Plas = Plasmochin; Ate =
Atebrin; ND = Not described; IRS = Indoor Residual Spraying.
†Amongst children only
Table 6. Summary of findings table: Mass drug administration in areas of low endemicity (≤5%)
Mass drug administration in areas of low endemicity
Patient or population: People living in malaria endemic areas
Settings: Areas with low (≤5%) endemicity
Intervention: Mass drug administration (any regimen)
Comparison: Placebo or no intervention (or baseline data in before-and-after studies)
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Table 6. Summary of findings table: Mass drug administration in areas of low endemicity (≤5%) (Continued)
Timepoint
post MDA
Outcomes Study design Illustrative comparative
risks* (95% CI)
Relative
effect
(95% CI)
No of
studies
Quality of the
evidence
(GRADE)
Assumed risk Correspond-
ing risk
Control MDA
<1 month Parasite
prevalence
Before-and-
after
50 per 10001 14 per 1000
(7 to 25)
RR 0.27
(0.14 to 0.50)
1 study ⊕©©©
very low2,3,4,5
Parasite
incidence
- - - - 0 studies −
Gametocyte
prevalence
- - - - 0 studies2 -
12 months Parasite
prevalence
Before-and-
after
50 per 10001 1 per 1000
(0 to 6)
RR 0.02
(0 to 0.12)
1 study ⊕©©©
very low
2,3,4,5
Parasite
incidence
- - - - 0 studies -
Gametocyte
prevalence
- - - - 0 studies2 -
The assumed risk has been set at 5%. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison
group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk Ratio.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change
the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to
change the estimate.
Very low quality: We are very uncertain about the estimate.
1 For illustrative purposes the control group prevalence has been set at 5%.
2 Only one cluster-randomized trial from Tanzania has evaluated MDA in a setting of low endemicity and this study recorded no
episodes of parasitaemia or gametocytaemia at baseline or throughout six months follow-up in either the control or intervention groups.
3 Downgrade by 1 for serious risk of bias: This study is uncontrolled, and so at very high risk of confounding.
4 Downgraded by 1 for serious indirectness: This singe study from Taiwan reported the effects of MDA administered as a single dose
of chloroquine (12 mg/kg). Further trials are needed from a variety of settings to have confidence in the results.
5 Compared to baseline data a large reduction in parasite prevalence was seen at 1 month and 12 months post-MDA.
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Table 7. Summary of findings table: Mass drug administration in areas of moderate endemicity (6 to 39%)
Mass drug administration in areas of moderate endemicity
Patient or population: People living in malaria endemic areas
Settings: Areas with moderate malaria endemicity (6-39%)
Intervention: Mass drug administration (any regimen)
Comparison: No intervention (or baseline data in before-and-after studies)
Timepoint
post MDA
Outcomes Study design Illustrative comparative
risks* (95% CI)
Relative
effect
(95% CI)
No of studies Quality of the
evidence
(GRADE)
Assumed risk Correspond-
ing risk
Control MDA
<1 month Parasitaemia
prevalence
Non-
randomized
250 per 1000 5 per 1000
(3 to 15)
RR 0.03
(0.01 to 0.08)
3 studies ⊕⊕⊕©
moderate
1,2,3,4
Before-and-
after
250 per 1000 73 per 1000
(43 to 120)
RR 0.29
(0.17 to 0.48)
3 studies ⊕⊕©©
low5,3,6
Parasitaemia
incidence
- - - 0 studies -
Gametocy-
taemia
prevalence
Non-
randomized
100 per 1000 28 per 1000
(10 to 82)
RR 0.28
(0.1 to 0.82)
1 study ⊕©©©
very low1,7
Before-and-
after
100 per 1000 47 per 1000
(25 to 87)
RR 0.47
(0.25 to 0.87)
3 studies ⊕⊕©©
low5,6,8
4-6 months Parasitaemia
prevalence
Non-
randomized
250 per 1000 70 per 1000
(53 to 95)
RR 0.18
(0.10 to 0.33)
2 studies ⊕⊕©©
low1,3,9
Before-and-
after
250 per 1000 438 per 1000
(103 to 1000)
RR 1.75
(0.41 to 7.41)
2 studies ⊕©©©
very low
5,10,11
Parasitaemia
incidence
- - - - 0 studies -
Gametocy-
taemia
prevalence
Non-
randomized
100 per 1000 52 per 1000
(24 to 111)
RR 0.52
(0.24 to 1.11)
1 study ⊕©©©
very low12
Before-and-
after
100 per 1000 35 per 1000
(12 to 101)
RR 0.35
(0.12 to 1.01)
1 study ⊕©©©
very low12
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Table 7. Summary of findings table: Mass drug administration in areas of moderate endemicity (6 to 39%) (Continued)
The assumed risk for parasitaemia prevalence has been set at 25%. Gametocytaemia prevalence was generally lower in the included
studies and the assumed risk has therefore been set at 10%.
The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the
intervention (and its 95% CI).
CI: Confidence interval; RR: Risk Ratio.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change
the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to
change the estimate.
Very low quality: We are very uncertain about the estimate.
1 No serious risk of bias: Although there were some differences in prevalence at baseline, these were much smaller in size than the large
effects seen post-intervention.
2 No serious indirectness: These three studies were conducted in Kenya in 1953 and 1954 (pyrimethamine administered every six
months for three rounds), and in India in 1953 (amodiaquine administered every two weeks for five rounds). A fourth study from
Nigeria in 1973 reported a similar reduction in prevalence during an ongoing MDA program. Although these studies are old, similar
effects might be expected today with effective anti-malarials.
3 No serious inconsistency: Consistent and large reductions were seen in these studies.
4 Upgraded by 1 for large effect size: Very large effects were seen consistently across both controlled and uncontrolled studies.
5 No serious risk of bias: These studies are uncontrolled, and so are at very high risk of confounding. However, as the GRADE approach
automatically downgrades non-randomized controlled studies by two levels for risk of bias we did not further downgrade.
6 No serious indirectness: These three studies were conducted between 1953 and 1961, and administered MDA as: Pyrimethamine
once only (Morocco), chloroquine plus pyrimethamine every month for five rounds (Nigeria) and chloroquine every four weeks for 11
rounds (Papua New Guinea). Although these studies are old, similar effects might be expected today with effective anti-malarials.
7 Downgraded by 1 for serious indirectness: This single trial in Kenya gave pyrimethamine every six months for three rounds. Different
regimens may have different effects and primaquine, a drug with gametocytocidal properties, was not given. One further trial from
Nigeria in the 1960s, which only reported on prevalence during an ongoing MDA programme, also administered MDA without
primaquine.
8 No serious inconsistency: Gametocyte prevalence was lower post-intervention in all four trials, however there was variation in the size
of this effect.
9 No serious indirectness: These two studies are both from Kenya in the 1950s, and both administer MDA as pyrimethamine alone.
One study continued follow-up for > 6 months when an effect was still present.
10 No serious indirectness: These two studies were conducted between 1959 and 1961, and administered MDA as: chloroquine plus
pyrimethamine every four months for two rounds (Cameroon), chloroquine plus pyrimethamine everymonth for five rounds (Nigeria).
11 Downgraded by 1 for serious inconsistency: At this time point results were mixed. One study found a higher prevalence at this time
point and one found no difference.
12 Downgraded by 1 for serious indirectness: This single trial found no substantial difference between groups at 4-6 months. Modern
trials with different regimens may have different effects. This study did not administer primaquine as part of MDA.
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Table 8. Summary of findings table: Mass drug administration in areas of high endemicity (≥40%)
Mass drug administration in areas of high endemicity
Patient or population: People living in malaria endemic areas
Settings: Areas with high malaria endemicity (≥ 40%)
Intervention: Mass drug administration (any regimen)
Comparison: No intervention (or baseline data in before-and-after studies)
Timepoint
post MDA
Outcomes Study design Illustrative comparative
risks* (95% CI)
Relative
effect
(95% CI)
No of studies Quality of the
evidence
(GRADE)
Assumed risk Correspond-
ing risk
Control MDA
< 1 month Parasitaemia
prevalence
Cluster-
randomized
500 per 1000 410 per 1000
(335 to 505)
RR 0.82
(0.67 to 1.01)
1 study ⊕⊕©©
low1,2,3
Non-
randomized
500 per 1000 85 per 1000
(50 to 140)
RR 0.17
(0.10 to 0.28)
3 studies ⊕⊕⊕©
moderate
4,5,6,7
Before-and-
after
500 per 1000 185 per 1000
(140 to 245)
RR 0.37
(0.28 to 0.49)
4 studies ⊕⊕©©
low8,9,10
Parasitaemia
incidence
Cluster-
randomized
60 per 1000 25 per 1000
(14 to 44)
RR 0.41
(0.23 to 0.73)
1 study ⊕⊕⊕©
moderate
1,2,11
Gametocy-
taemia
prevalence
Non-
randomized
100 per 1000 16 per 1000
(8 to 30)
RR 0.16
(0.08 to 0.30)
3 studies ⊕⊕⊕©
moderate
4,5,6,7
Before-and-
after
100 per 1000 38 per 1000
(13 to 108)
RR 0.38
(0.13 to 1.08)
3 studies ⊕⊕©©
low8,12
4-6 months Parasitaemia
prevalence
Cluster-
randomized
500 per 1000 580 per 1000
(465 to 720)
RR 1.16
(0.93 to 1.44)
1 study ⊕⊕⊕©
moderate
1,2,13
Non-
randomized
- - - 0 studies -
Before-and-
after
500 per 1000 205 per 1000
(120 to 360)
RR 0.41
(0.24 to 0.72)
3 studies ⊕⊕©©
low8,14
Parasitaemia
incidence
Cluster-
randomized
60 per 1000 67 per 1000
(52 to 85)
RR 1.11
(0.87 to 1.41)
1 study ⊕⊕⊕©
moderate
1,2,13
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Table 8. Summary of findings table: Mass drug administration in areas of high endemicity (≥40%) (Continued)
Gametocy-
taemia
prevalence
Cluster-
randomized
100 per 1000 107 per 1000
(62 to 185)
RR 1.07
(0.62 to 1.85)
1 study ⊕⊕©©
low1,2,3
Non-
randomized
- - - 0 studies -
Before-and-
after
100 per 1000 35 per 1000
(10 to 128)
RR 0.35
(0.10 to 1.28)
2 studies ⊕©©©
very low8,15
The assumed risk for parasitaemia prevalence has been set at 50%. Gametocytaemia prevalence was generally lower in the included
studies and the assumed risk has therefore been set at 10%. The assumed risk for parasitaemia incidence is taken from the control
group of the single trial
The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the
intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change
the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to
change the estimate.
Very low quality: We are very uncertain about the estimate.
1 No serious risk of bias: This cluster-randomized trial was at low risk of bias.
2 Downgraded by 1 for serious indirectness: This single study from the Gambia in 1999 administered MDA as AS+SP. The findings
may not be easily generalized to other settings, or to alternative MDA regimens. The first time point measured post-MDA was 1-3
months.
3 Downgraded by 1 for serious imprecision: The result was not statistically significant but the 95% CI is wide and includes important
effects.
4 No serious risk of bias: Although there was some evidence of baseline imbalance between the intervention and control areas, these
were generally of smaller magnitude than the effects seen.
5 No serious indirectness: The data presented here were measured during ongoing multiple-round MDA programmes, not at one
month post-intervention. The studies were conducted in Burkina Faso in 1961 (CQ or AQ plus PQ every two to four weeks), and
Nigeria in 1975 (SP given every two weeks or every 10 weeks). Although these studies are old, similar effects might be expected today
with effective anti-malarials.
6 No serious inconsistency: The observed effects were consistently large in all three trials.
7 Upgraded by 1 for the large effect size: Large effects seen in all trials.
8 No serious risk of bias: These studies are uncontrolled, and so are at very high risk of confounding. However, as the GRADE approach
automatically downgrades non-randomized controlled studies by two levels for risk of bias we did not further downgrade.
9 No serious indirectness: These four studies were conducted in Palestine in 1930 (plasmoquine plus quinine every three weeks for
three rounds), Burkina Faso in 1959 (pyrimethamine every two weeks), in Malaysia in 1985 (SP + PQ once only), and Cambodia in
2006 (AS + piperaquine once only plus PQ every 10 days).
10 No serious inconsistency: Three studies observed large effects, while one small study found no effect.
11 No serious imprecision: The result is statistically significant.
12 No serious indirectness: Two large studies found large effects in Burkina Faso in the 1950s (pyrimethamine every 2 weeks for 8
rounds), and Palestine in the 1930s (plasmoquine plus quinine every three weeks for three rounds). One small study from Malaysia in
the 1980s found no effect.
13 No serious imprecision: The 95% CI excludes clinically important reductions at this time point.
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14 No serious inconsistency: The two large studies from Palestine and Cambodia still demonstrated a large reduction at 4-6 months
while the small study from Malaysia found no difference
15 Downgraded by 1 for serious indirectness: Benefits beyond three months have only been demonstrated in this single study from
Cambodia. MDA was administered as artesunate plus piperaquine once only followed by primaquine every 10 days for six months.
A P P E N D I C E S
Appendix 1. Search strategy
MEDLINE+
A. Anti-Malarials
exp Antimalarials/ or exp Malaria/ or antimalarial* or anti-malarial* or ((schizonticidal* or gametocidal* or hypnozoiticidal* or drug*
or treatment) and (malaria*))
B. Mass Administration
((mass or coordinate*) adj5 (administ* or distribut* or applicat* or “use” or therap* or treatment*))
EMBASE
A. Anti-Malarials
exp antimalarial agent/ or exp malaria/ or antimalarial* or anti-malarial* or ((schizonticidal* or gametocidal* or hypnozoiticidal* or
drug* or treatment) and (malaria*))
B. Mass Administration
((mass or coordinate*) adj5 (administ* or distribut* or applicat* or “use” or therap* or treatment*))
COCHRANE LIBRARY
A. Anti-Malarials
(Must run each MeSH term separately. Ovid syntax used for recording purposes.)
exp Antimalarials/ or exp Malaria/ or antimalarial* or anti-malarial* or ((schizonticidal* or gametocidal* or hypnozoiticidal* or drug*
or treatment) and (malaria*))
B. Mass Administration
((mass or coordinate*) near/5 (administ* or distribut* or applicat* or “use” or therap* or treatment*))
CAB DIRECT
A. Anti-Malarials
ti=(antimalarial* or anti-malarial* or ((schizonticidal* or gametocidal* or hypnozoiticidal* or drug* or treatment) and (malaria*))) or
ab=(antimalarial* or anti-malarial* or ((schizonticidal* or gametocidal* or hypnozoiticidal* or drug* or treatment) and (malaria*))) or
de=“antimalarials”
B. Mass Administration
(mass) and (administ* or distribut* or applicat*)
LILACS
A. Anti-Malarials
antimalarial* or anti-malarial* or ((schizonticidal* or gametocidal* or hypnozoiticidal* or drug* or treatment) and (malaria*))
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Authors and contact person
Since the initial publication of our protocol, there have been changes in the order of authorship and in the designated contact person.
Jimee Hwang will now act as the contact person for this review, to whom correspondence about the review should be addressed. Order
of authorship has changed, with Jimee Hwang as senior author and Jacek Skarbinski listed as second author.
Study Design
Clinical illness was not assessed as an outcomemeasure, as initially planned in the original protocol. However, themethods for extracting
and analyzing all other primary and secondary outcomes followed the methods outlined in the protocol.
Adjustments for cluster randomized trials were not attempted and estimates were individually analyzed.
Methodological quality was assessed using the Cochrane Collaboration’s risk of bias tool (Higgins 2011) and suggested risk of bias
criteria for Effective Practice and Organisation of Care (EPOC) reviews. A GRADE assessment was also added.
Measures of treatment effect
Due to the few high-quality trials and the heterogeneity of our studies, funnel plots were not created to examine study effect by plotting
relative measures of treatment effect on a logarithmic scale against the standard error (and its inverse).
We did not categorize our outcomes as early outcome measures (< 6 months after MDA) versus late outcome measures (≥ 6 months
after MDA). Instead, we created smaller time intervals (eg during, within 1 month, 1-3 months, 4-6 months, 7-12 months, and >12
months post-intervention) due to the heterogeneity of our studies and early outcome measures.
Due to the small number of studies in our proposed subgroup analyses, we did not carry out analyses assessing high and moderate
quality studies only, or review the use of MDA with chloroquine/primaquine for control of P. vivax.
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